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The association between cancer and venous thromboembolism (VTE) is 
bidirectional. Starting with the observations of Bouillaud (1) and Trousseau (2), it 
was discovered that cancer patients are more prone to develop thrombosis, 
whereas thrombosis may be the harbinger of the presence of cancer. 
Epidemiological studies by Sorensen (3) and Blom (4) indicated that the incidence 
of cancer is increased among patients diagnosed with acute VTE. About 10% of 
patients with an episode of idiopathic VTE will develop cancer within a few years 
after the diagnosis (5;6). Cancer patients who developed thrombosis also have a 




Microparticles (MPs) are nanosized membrane vesicles, also named microvesicles, 
which are formed by budding of cell membranes upon activation or apoptosis and 
released into body fluids, such as blood, urine and synovial fluid. In the past, they 
have been considered to be inert cell debris (“platelet dust”) (8).  
 
MPs still bear antigens derived from their parental cells. By using specific 
antibodies it was shown that the majority of MPs detected in blood originates from 
platelets (9;10). Other blood cells such as leucocytes, erythrocytes, endothelial 
cells and also malignant cells all may shed MPs (11). MPs have been shown to 
contain DNA, RNA, and recently also miRNA (12;13).  
 
Most MPs expose the negatively charged phosphatidylserine (PS) on their 
membrane surface as a result of plasma membrane remodeling during formation 
from their parental cells (11;14;15). The exposure of PS on MPs provides a 
catalytic surface which promotes the assembly of procoagulant proteins and 
stimulates coagulation reactions (16;17). The PS content of MPs may vary 
according to their cellular origin, the mechanism by which they have been formed, 
and several pre-analytical conditions (18;19). 
 
The presence of MPs in the blood of healthy persons is well documented, and 
elevated numbers of specific subsets of MPs have been reported in vascular 
disorders, cancer, and auto-immune diseases (11;16;20). In recent years, there 
has been a growing interest to study the role of MPs in physiology and pathology. 
However, individual studies use a wide variation of pre-analytical and analytical 




Procoagulant microparticles in cancer-associated thrombosis 
 
Several studies have been conducted to identify the mechanism underlying the 
association between cancer and thrombosis (23-25). In various studies, an 
association between (active) tissue factor (TF)-bearing MPs and thrombosis in 
cancer patients has been found. This suggests that perhaps the release of MPs 
bearing TF by tumor cells and host cells into the blood may trigger thrombosis 
(9;26-28). TF has a major role in the initiation of blood coagulation. TF is found 
predominantly in the adventitial and much less in the medial layers surrounding 
blood vessels. Fibroblasts, adipocytes, and pericytes have also been shown to 
constitutively express TF. Normally, TF is not expressed by cells within the 
vasculature. However, after in vitro or in vivo stimulation by various agonists 
smooth muscle cells, endothelial cells, and peripheral blood mononuclear cells 
(monocytes and neutrophils) can express TF. TF binds to coagulation factor 
VII/VIIa (fVII/VIIa) to form a bimolecular complex that functions as the primary 
initiator of blood coagulation in vivo. In the presence of calcium ions (Ca2+) and 
negatively charged phospholipids (PL), the TF/fVIIa complex activates fX into fXa 
which subsequently leads to the formation of thrombin and insoluble fibrin. 
Thrombin also activates platelets which together with fibrin form a stable clot (29). 
 
One of the processes of tumor metastasis is the invasion of tumour cells through 
the vessel wall into the blood. This invasion of tumour cells causes vascular 
damage which triggers the expression of TF on cells within the vasculature leading 
to exposure of TF to the blood (30). The presence of a tumour may also elicit a 
host response that leads to induction of TF expression in monocytes and possibly 
endothelial cells and to the shedding of MPs bearing TF (31). In addition, some 
tumour cells express TF themselves (32) and these cells may shed MPs bearing 
TF (33;34). Figure 1 illustrates this hypothetical explanation of the role of MPs 
bearing TF in cancer-associated thrombosis. 
 
Figure 1. Hypothesis of the role of MPs bearing TF in cancer-associated thrombosis 
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Not all TF antigen is able to initiate the coagulation process (35;36). TF with 
reduced procoagulant activity has been referred to as encrypted. To date, little is 
known about the encryption status of cell- or MP-bound TF in vivo. Interestingly, in 
the cohorts studied by Tesselaar et al (9), cancer patients with elevated MP-
associated TF activity and poor prognosis also had a small fraction of MUC-1-
positive MP in their pool of blood MP suggesting tumour MPs bearing active TF as 
a link between cancer and thrombosis. In addition to its procoagulant activity, TF 
has cell signaling properties. Formation of the TF/fVIIa complex may activate signal 
transduction pathways via de proteolytic cleavage of protein-activated receptor 2 
(PAR2) promoting tumor growth and tumor angiogenesis (31;37). 
 
Measurement of microparticles 
 
The choice of anticoagulant used for blood collection, the centrifugation speeds 
used for the preparation of plasma and the isolation of MPs, and the storage of 
blood and plasma samples are important pre-analytical variables which all may 
affect the outcome of MP measurements. Blood can be collected in sodium citrate, 
ethylenediaminetetraacetic acid (EDTA), and citrate theophylline adenosine 
dipyridamole (CTAD) anticoagulants, but more information is needed on the 
relative stability of MPs in these anticoagulants (38). After blood withdrawal, blood 
should be immediately centrifuged to isolate plasma (39). The centrifugation speed 
applied should remove platelets from plasma to avoid cellular activation of platelets 
leading to inadvertent production of platelet MPs (PMPs). A direct measurement of 
MPs in fresh plasma is preferred to reduce MP loss and to preserve MP 
characteristics (21). When frozen-thawed plasma is used, especially PMP and 
annexin V-positive MP counts should be interpreted with caution (39-41). For 
certain MP assays (e.g. fluorescence or electron microscopy, proteomic analysis 
and some functional MP assays), MPs are isolated from plasma to reduce the 
plasma protein content and to increase the MP concentration. Nevertheless, 
isolation procedures include multiple washing steps and will inevitably cause loss 
of some MPs. Most importantly, it is not known which centrifugation force is optimal 
to pellet plasma MPs (42). 
 
Different analytical methods and combinations of these have been used to 
measure the number, concentration, and functional properties of MPs. Flow 
cytometry, capture-based assays, and functional assays are commonly used 
methods to measure MPs.  
 
Since flow cytometry uses laser light which typically excites at a wavelength of 488 
nm and MPs vary in size below 1 µm in diameter, using flow cytometry the 
enumeration of MPs with a size of less than 0.5 µm is inaccurate (43;44). To 
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standardize PMP measurements by flow cytomety in multi-centre studies, the ISTH 
SSC Working Group on Vascular Biology proposed the use of calibrated beads 
with sizes of 0.5, 0.9 and 3 µm (Megamix beads) to adjust the instrument settings 
and increase the resolution of the flow cytometer (45). Recently, a new generation 
of flow cytometers has been developed (e.g. Gallios from Beckman Coulter, Influx 
from Becton Dickinson, and Apogee A50 from Apogee Flow System) which seem 
to have improved scatter performances in terms of resolution and background as 
they can detect and resolve beads with sizes between 0.3 and 0.5 µm (46). 
However, plastic beads remain an imperfect model for size calibration of MPs. The 
scattering intensity of MPs depends on the characteristics of MPs such as shape, 
refractive index, and absorption which are different from those of the calibration 
beads (44). 
 
Flow cytometry allows fast enumeration of total MPs by using annexin V. This 
method is based on the assumption that all blood MPs carry PS on their 
membrane. However, not all MPs expose PS. For example, in vitro stimulation of 
endothelial cells by TNF-α generated MPs with low PS exposure (47), platelets 
treated with thrombin receptor-activating peptide (TRAP) generated both PS-
positive and -negative MPs (48), and a human monocytic cell line (THP-1) 
stimulated with soluble P-selectin-Ig chimera (P-sel-Ig) generated more PS-
negative MPs (~60%) than PS-positive MPs (49). Furthermore, the binding of 
annexin V to MPs is influenced by the calcium concentration and the membrane 
PS content (50). Therefore, the use of other fluorescent dyes or proteins (e.g. 
calcein AM, lactadherin, SYTO13) might increase the accuracy of enumeration of 
total MPs (46). 
 
Specific antibodies conjugated with different fluorochromes are used in flow 
cytometry measurements to identify and accurately count subsets of MPs. A list of 
antibodies to distinguish MPs derived from platelets, leucocytes, erythrocytes, and 
endothelial cells can be found in the publication of the Forum “Measuring 
circulating cell derived microparticles” (21) and some recent reviews (11;22). 
Additionally, MPs derived from malignant cells have been detected by the use of 
antibodies such as MUC1 for breast and pancreatic cancer cells (9;25), FasL for 
melanoma cells (51), EGFRvIII for glioblastoma cells (52), and CXCR-4 for 
leukemic cells (53). 
 
Recently, quantum dots, nanocrystals of inorganic semiconductors with a diameter 
of 2–8 nm (200–10000 atoms), have opened new possibilities for antibody labelling 
(54;55). Quantum dots have significant advantages over common fluorochromes 
(for example, fluoroscein, phycoerythrin or allophycocyanin), such as brighter 
fluorescence and resistance to photobleaching (54). Additionally, quantum dots 
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have relatively narrow emission spectra giving less spectral overlap in standard 
multicolor immunophenotyping by flow cytometry (55). In the near future, the use of 
quantum dots-labeled specific antibodies may improve the sensitivity of flow 
cytometry detection of MP subsets (44).  
 
Capture-based assays for MP measurement rely on an antibody or annexin V 
which specifically binds a subset of MPs from plasma. Captured MPs can then be 
quantified/characterized by using a second probe (e.g., peroxidase conjugated-
antibody) (56) or by the measurement of the concentration of negatively charged 
phospholipids supporting prothrombinase activity (57;58). These capture-based 
assays enable a high-throughput measurement of subsets of MPs but do not 
provide direct enumeration of total MPs in plasma. Other disadvantages are 
interference by soluble antigens and lack of information on the size distribution of 
MPs (59).  
 
The measurement of functional properties of plasma MP is limited at the moment to 
the measurement of MP-associated TF activity. Such assays are based on the fVII-
dependent fXa generation in isolated MPs (9;27). The TF activity of MP (MP-TF 
activity) is defined as the fVII dependent and anti-TF sensitive formation of fXa. 
The assay provides information on MPs bearing active TF. A commercial two-stage 
chromogenic assay (Actichrome® TF from American Diagnostica) has also been 
used to measure TF activity in plasma (58;60). However, the observed fXa 
generation was found to be independent of exogenously added fVIIa and/or TF, 
and not inhibited by anti-fVIIa (61). Although the measurement of MP-associated 
TF activity provides information on MPs bearing active TF, it still fails to identify the 
cellular origin(s) of these MPs. 
 
Aims of this thesis 
 
MPs have important physiological and pathological roles in blood coagulation, 
inflammation and tumor progression (11;16). In recent years MPs also have been 
recognized to participate in important biological processes (15), such as in 
signaling and in the horizontal transfer of their membrane and/or cargo molecules, 
which are enriched in specific proteins and mRNAs. However, studies of MPs have 
been hampered by the lack of methods for the sensitive detection and accurate 
quantification of MPs. Furthermore, there is no method available to asses the origin 
of MPs bearing active TF in plasma. Thus, one of the aims in this thesis was to 
develop a new methodology for the sensitive detection and accurate quantification 
of MPs (MP subsets). Preferentially, such a method would also allow the 
determination of the size distribution of these MPs in their native state. In addition, 
efforts have been made to develop a method for analyzing subsets of MPs bearing 
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active TF. Finally, TF activity was measured in MPs isolated from plasma of 
multiple myeloma patients and its possible association with the development of 
VTE was investigated. 
 
Outline of this thesis 
 
Chapter 2 is a literature based review of pre-analytical and analytical issues in the 
analysis of blood microparticles. This review discusses pre-analytical variables 
related to plasma and MP preparation which may affect the outcome of MP 
measurements. In addition, several analytical issues in commonly used MP assays 
and some novel approaches for the detection and characterization of MPs are 
briefly discussed. 
 
In Chapter 3 atomic force microscopy (AFM) is proposed as a new methodology for 
MP measurement.  The use of AFM operated in fluid tapping mode is compared 
with the widely used conventional flow cytometry to quantify the number of CD41-
positive MPs isolated from fresh plasma and to determine their size distribution. 
Finally, it was investigated whether this new methodology also can be used to 
detect MPs bearing TF antigen (Chapter 4).  
 
To prevent loss of MPs during the isolation procedure, it would be preferable to use 
blood plasma directly for the MP measurements. Therefore, the use of microfluidics 
in combination with AFM was explored for the direct detection, quantification, and 
size determination of CD41-positive MPs in plasma. Results of this study are 
reported in Chapter 5.  
 
Although conventional transmission electron microscopy (TEM) has been used in 
the past to study the morphology and membrane composition of MPs, this method 
requires steps such as dehydration, chemical fixation, and staining of specimens 
which all may affect MP morphology. This method is also not suitable for direct 
detection of MPs in plasma. For that reason, the use of cryo-TEM for visualization 
of submicron particles (MPs and exosomes) directly in plasma was studied. 
Chapter 6 deals with the results of cryo-TEM imaging of platelet-rich, platelet-poor, 
and platelet-free plasma isolated from citrate and EDTA anticoagulated-blood. 
Results are compared with images of submicron particles isolated from plasma and 
in the supernatant of thrombin activated-isolated platelets.  
 
Up till now the cellular origin of MPs bearing active TF in blood is unknown. 
Chapter 7 presents the development of an immuno-magnetic beads method to 
directly capture/deplete selected subsets of MPs from plasma. By using 
biotinylated antibody and streptavidin coated magnetic beads, CD41- and CD14-
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positive MPs were captured from plasma. Fractions containing captured and 
depleted CD41-/CD14-positive MPs were analysed for MP-associated TF activity. 
 
Multiple myeloma (MM) is one of the malignancies associated with an increased 
risk of VTE complications. Chapter 8 reports the results of MP-TF activity 
measurements in patients with newly diagnosed MM before and after 
chemotherapy and discusses whether MP-TF activity levels found in these patients 
are associated with VTE.  
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Pre-analytical and analytical issues in 
the analysis of blood microparticles 
 
Yuana Yuana, Rogier M. Bertina and Susanne Osanto 
 






Results of plasma microparticles (MPs) measurements reported in the literature 
vary widely. This is clearly not only related to the lack of well-standardized MP 
assays, but also to variations in pre-analytical conditions. In this review we will 
discuss the pre-analytical variables related to plasma and MP preparation which 
may affect MP analysis. Additionally we will address several analytical issues in 
commonly used MP assays and briefly discuss some novel approaches for the 
detection and characterization of MPs.  
 
Ideally MP measurements should be performed in plasma, freshly prepared directly 
after blood withdrawal. As platelet contamination seems to be one of the major pre-
analytical problems in processing plasma for MP measurement, the use of platelet-
free plasma may be preferred. When frozen-thawed plasma is used, especially 
PMP and annexinV-positive MP counts should be interpreted with caution.  
 
When flow cytometry is chosen as a method for quantification of MPs, some 
analytical conditions should be standardized, e.g. settings of the flow cytometer, 
quality of the antibodies, and use of counting beads. Fluorescence-nanoparticle 
tracking analysis and atomic force microscopy can accurately count nanosized 
MPs, but unfortunately the operational procedures of both methods are still time 
consuming and they give no information on the functional properties of MPs. The 
MP-TF activity assay provides information on MPs carrying active TF, regardless of 
their parental origin.  
 
Ultimately, standardisation of pre-analytical procedures and the introduction of 
reliable and rapid methods for the measurement of MPs are urgently needed to 
facilitate their use as biomarker in the pathophysiology of diseases. 




Since Wolf in 1967 (1) showed that platelet shedding results in the formation of 
‘platelet-dust’, the shedding of microparticles (MPs) in blood has been recognized 
as a regulated process during cell activation and early apoptosis (2;3). MPs formed 
by membrane vesiculation of cells are generally heterogeneous in size (<1 µm). 
They differ from exosomes with respect to their origin, protein content, and size 
distribution. Exosomes originate from multivesicular bodies and are usually more 
homogeneous and smaller in size (<0.1 µm) (4-7). However, there is no consensus 
on the precise cut off in the size distributions of these two populations. This is not 
only due to limitations of the methods used for the characterization of these 
nanoparticles, but also by pre-analytical variables like anticoagulant, centrifugation, 
and storage. 
 
The large majority of MPs detected in blood originates from platelets, but other 
blood cells such as leucocytes, erythrocytes, endothelial cells and even malignant 
cells also may shed MPs. These MPs still bear antigens of their parental cells so 
that their origin can be determined by using specific antibodies against these 
antigens (4;8). Furthermore, blood MPs may carry the negatively charged 
phosphatidylserine (PS) on their surface as a result of plasma membrane 
remodeling during their formation from their parental cells (2;4;5). The exposure of 
PS on MPs provides a catalytic surface which promotes the assembly of 
procoagulant proteins and stimulates coagulation reactions (2;9-11). The PS 
content of MPs may vary according to their cellular origin, the mechanism by which 
they have been formed and several pre-analytical conditions (9-14).  
 
The presence of MPs in the blood of healthy persons is well documented and 
elevated numbers of specific subsets of MPs have been reported in vascular 
disorders, cancer, and auto-immune diseases. Therefore, there is a growing 
interest to study the role of MPs in physiology and pathology (for recent reviews 
see (4;9;12-16)). However, individual studies use a wide variation of pre-analytical 
and analytical procedures, which all may affect the outcome of the MP 
measurement (17) (Table 1). Therefore, the Vascular Biology group of the 
Scientific and Standardization Committee (SSC) of the International Society on 
Thrombosis and Haemostasis (ISTH) decided during their meeting in 2003, to 
address issues related to the detection, measurement, function, and clinical 
significance of membrane MPs derived from blood and vascular cells.  
 
At present, standardization of pre-analytical and analytical methods for the 
measurement of MPs remains a challenge. In this review we will discuss the pre-
analytical variables related to plasma and MP preparation which may affect the 
Chapter 2 
 22 
characterization and enumeration of MPs. In addition we will address several 
analytical issues in commonly used MP assays and briefly discuss some novel 
approaches for the detection and characterization of MPs. Finally, we will make 







Needles ranging from 19 to 22 Gauge (G) are commonly used for venepuncture in 
haemostasis laboratories (18). Prolonged placement of a tourniquet is avoided 
during venepuncture (19). Theoretically, when a small-diameter needle (high G 
number) is connected to an evacuated tube, the vacuum force applied to the blood 
is large. Such shear stress and excessive pressure on the vein during blood 
withdrawal might cause in vitro haemolysis (20) and possibly formation of 
erythrocyte MPs (ErMPs) (21). A system using a small-diameter butterfly needle is 
commonly used on small children and patients with difficult venous access (22). 
This system reduces the blood flow and consequently increases the risk of platelet 
activation (18). During blood collection, the first 3-7.5 mL of blood is discarded to 
avoid the effects of the vascular damage caused by the venepuncture (23;24).  
 
Several anticoagulants are used to collect blood for MP analysis (Table 1). It is 
important to consider how these anticoagulants may help to limit platelet activation 
during blood collection and plasma preparation, because platelet activation will 
result in release of alpha and dense granules and platelet MPs (PMPs) (25-27). 
Sodium citrate with a concentration of 0.105 or 0.129 mol/L (3.2% or 3.8%) is the 
most widely used anticoagulant (8). Other anticoagulants that have been used are 
Acid-Citrate-Dextrose (ACD) (28-30), ethylenediaminetetraacetic acid (EDTA) 
(8;31-33), a strong chelator of calcium ions, and heparin (34-36), which will 
preserve extracellular calcium. However, blood collected in heparin gave 
significantly higher levels of annexin V-positive MPs than blood collected in sodium 
citrate (37). Connor et al (38) reported that the number of annexin V-positive MP 
and the concentration of procoagulant phospholipid increased more strongly over a 
60 min period following blood collection in sodium citrate-anticoagulated samples 
than in EDTA-anticoagulated samples. They suggested that when blood is not 
immediately processed, MP measurement should be performed on EDTA-
anticoagulated samples. Use of citrate theophylline adenosine dipyridamole 
(CTAD) has been shown to inhibit in vitro platelet activation by increasing the 
cytosolic AMP concentration without affecting platelet function (18;25;39). During a 
period of 3 hours after blood collection PMPs counts increased 2-fold in plasma 
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from citrated blood but were relatively stable in plasma isolated from CTAD-blood 
(40). Unfortunately, there is no study which directly compares the effects of citrate, 




Platelets need to be removed from the plasma in order to avoid cellular activation 
leading to inadvertent production of MPs. For this purpose, a proper centrifugal 
speed should be applied for plasma preparation. According to the Clinical and 
Laboratory Standards Institute (CLSI) (41), plasma with a platelet count less than 
10x109/L is obtained by centrifuging the blood at 1,500g for 15 minutes at room 
temperature (RT). To obtain platelet-poor plasma (PPP) CLSI recommends re-
centrifuging the plasma for another 10 minutes at 1,500g. We observed that PPP 
isolated by centrifuging blood once at 1,550g for 20 minutes still contained 
2.8x109/L platelets. However, when the same blood sample was used to isolate 
PPP by performing a two-step centrifugation, each at 2,000g for 10 minutes, there 
were only 6.1x108/L platelets present in the plasma. 
 
Platelet-free plasma (PFP) can be isolated by a centrifugation using 1,500g for 20 
minutes followed by a high speed centrifugation at 13,000g for 2 minutes (8). Some 
studies (23;42;43) where flow cytometry was used to measure MPs, indicate that 
MP counts are lower in PFP than in PPP. The reason is still unclear. Probably, the 
last centrifugation step used in the preparation of PFP is vigorous and depletes 
platelets and also some MPs.  
 
Cold activation of citrated blood samples has been reported to result in falsely 
elevated levels of (activated) factor VII (FVII) and factor VIII (FVIII) (44;44). 
Therefore, the temperature is generally kept at RT (20-25°C) for centrifuging 
citrated blood (8). However, the effect of centrifugation temperature on MPs has 
not yet been thoroughly investigated.  
 
Furthermore, during centrifugation the use of breaks should be avoided as much as 
possible and plasma should be carefully collected without disturbing the platelet 




Ideally, plasma is prepared immediately after blood collection. To avoid changes in 
MP number and characteristics the use of freshly isolated plasma is recommended 
for MP measurements (8). However, the logistic of blood sampling, transport time 
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to the in-house laboratory or even to laboratories elsewhere are all variables which 
are difficult to control and keep uniform across different centres.  
 
According to CLSI guidelines (41) storage of uncentrifuged blood on ice is not 
recommended because of the possibility of cold activation of FVII and FVIII, loss of 
von Willebrand Factor (vWF), and platelet disruption (45). During storage blood 
samples should be maintained at room temperature while mechanical agitation is 
avoided (46).  
 
In multi-centre studies and prospective trials it is often inevitable to freeze and 
store the plasma samples before performing the assay. However, validated 
protocols are not yet available for freezing and thawing of plasma to be used for 
MP analysis (47). In some publications it is described that plasma is first snap 
frozen in liquid nitrogen before it is stored at -80°C (23;47-50) while others directly 
freeze the plasma directly at -80°C (51-53).  
 
Frozen-thawed PPP prepared by single centrifugation at 2,000g for 30 minutes 
contained 10-fold more PMPs counted by flow cytometry than fresh PPP (54). 
Conversely, PMP and annexin V-positive counts were not increased in frozen-
thawed PFP prepared by  a two-step centrifugation procedure (1,500g for 20 
minutes and 13,000g for 2 minutes) (48). Probably some platelets present in PPP 
are fragmented during freezing and thawing leading to an increase in the number 
of PMPs and annexin V-positive MPs. Weber et al reported in an abstract that 
methods applied for cryopreservation of MPs, even by using established chemicals 
for cell cryo-conservation such as DMSO, trehalose, and paraformaldehyde, could 
not prevent the 10-fold increase in the number of annexin V-positive MPs caused 
by freezing and thawing (43).  
 
However, most studies which investigated the effect of storage on MPs used flow 
cytometry for the measurement of MPs. A conventional flow cytometer uses a 488-
nm laser and as MPs are heterogeneous and can have sizes below 488 nm, the 
sizing and identification of MPs is not accurate ((55), see also section ‘Flow 




Direct measurement of MPs in plasma is preferred to prevent loss of MPs during 
the isolation procedure and to preserve their morphology (51). For this purpose, 
flow cytometry and capture-based assays can be employed (31;32;51-53;56;57). 
Other methods require a MP isolation step prior to the MP measurements, such as 
fluorescence or electron microscopy, proteomic analysis and some functional MP 
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assays (29;34;49;58;59). In the next section these analytical methods will be 
discussed.  
 
The advantages of using isolated MPs are less interference of plasma proteins and 
an increase in MP concentration. On the other hand, isolation procedures will 
cause inevitably loss of some MPs, especially when multiple washing steps are 
included. Most importantly, it is not known which centrifugation speed is optimal to 
pellet (all) plasma MPs. 
 
Table 2 compares the results of several studies using different centrifugation 
protocols to prepare plasma and MPs for the measurement of PMPs by flow 
cytometry. Results are those obtained for citrated blood of healthy subjects. It 
seems that when fresh plasma is used, more PMPs can be detected directly in 
plasma than in the isolated MP fraction. Furthermore, the number of PMPs is about 
3-10-fold higher in MPs isolated from frozen-thawed PPP than in MPs isolated from 
fresh PPP, especially when single-centrifuged PPP has been used. 
   
Recommendations 
 
During blood collection, it is necessary to prevent ex vivo activation of blood 
leading to inadvertent production of ErMPs or PMPs. Therefore, blood should be 
withdrawn by using a large diameter needle, for example a 21-G needle, and a 
tourniquet is only applied for locating the vein. In general, sodium citrate, EDTA, 
and CTAD anticoagulants can be used for blood collection. However, more 
information is needed on the relative stability of MP in blood collected in these 
anticoagulants.  
 
After blood withdrawal, blood should be immediately centrifuged to isolate plasma. 
The centrifugation speed applied is crucial for the removal of platelets from plasma. 
Because PPP still contains some platelets, use of PFP may be preferred. However, 
it should be considered that some MPs might be lost during the high-speed 
centrifugation step. MPs measurements should be performed preferably directly in 
fresh plasma to reduce MP loss and to preserve MP characteristics. When frozen-
thawed plasma is used for MP measurements, especially PMP and annexin V-
positive MP counts should be interpreted with caution.  
 
Ultimately, it is important to set up guidelines for preparing samples for MP 
measurements which include the choice of anticoagulant used for blood collection, 











Analytical methods for MP measurements 
 




Flow cytometry is commonly used for the measurement of MPs. It is fast and 
allows both the enumeration of MPs and the assessment of their cellular origin 
(4;8). MPs pass a laser in a flowing sample stream and are counted by flow 
cytometer. The enumeration of MPs is based on the light that is scattered by each 
MP in forward direction (roughly proportional to their size) and in side direction 
(dependent on to granularity and structural complexity). However, the laser used by 
the flow cytometer excites at 488 nm. As MPs are heterogeneous and can have 
sizes below 488 nm, this wavelength is not suitable as a trigger or discriminator for 
MP detection (55;58;60).  
 
To provide the concentration or absolute count of MPs in a sample, counting beads 
of a known concentration are used. These are calibrated microsphere-
polypropylene/latex beads (mean diameter 7-9 or ~10 µm) that are brightly 
fluorescent across a wide range of excitation and emission wavelengths. When 
they are used as internal standard, the beads are added to each sample before the 
flow cytometry measurement. When used as external standard, the counting beads 
are processed as a sample at the same flow cytometry settings/conditions used for 
the samples. The flow cytometer counts the number of beads and/or MPs in the 
sample until the acquisition time is reached. With these numbers, the concentration 
of MPs in plasma can be calculated (50;51;58;61). As to the flow cytometry 
settings, the MP population is defined by using size calibration beads. Beads of 1 
µm diameter are used to define the upper limit of the MP population and to 
discriminate the MP population from platelets (34;40). Another possibility is to use 
a mixture of fluorescent beads with diameters of 0.5, 0.9, and 3 µm (Megamix 
beads) to cover the MP (0.5 and 0.9 µm) and platelet populations (0.9 and 3 µm) 
ranges (51;62). However, as the refractive index of the plastic beads is different 
than that of MPs, also these beads remain an imperfect model for defining the cut-
off of MP population.   
 
The cellular origin of MP can be assessed by staining MPs with fluorescently 
labelled antibodies. In a flow cytometer, the fluorescent light passes a series of 
filters and appropriate fluorescence detectors allowing the simultaneous detection 
of more than two antigens on one MP (63). The correlation of the fluorescence 
signal to the light scatter of all measured events is used to identify and count a 
certain subset of MPs. The downside of this approach is that the fluorescence 
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signal depends on the specificity and affinity of the antibody to the target antigen 
and on the number of antigens present on the MP surface. 
 
Although not all MPs expose PS (34;61;64-67), fluorescently labelled annexin V is 
commonly used to measure the total number of MPs with flow cytometry. The 
binding of annexin V to MPs is influenced by the calcium concentration and the 
membrane PS content (64;68). Consequently, the concentration of calcium in the 
buffer should be titrated for optimal staining of MPs in citrate- and EDTA-
anticoagulated plasma samples. Staining with lactadherin, a milk-derived protein 
that also binds PS, has been shown to give similar results as obtained with annexin 
V staining (69). Lactadherin has been claimed to be more sensitive to small 
changes in PS expression than annexin V (66) and it detects PS-positive MPs in a 
calcium-free environment, such as citrate- or EDTA-anticoagulated plasma 
samples. Other markers such as bio-maleimide, phalloidin, and calcein 
acetoxymethyl ester (calcein AM) have been recently used to improve the detection 
of MPs. The staining with bio-maleimide, a thiol-reactive probe with spectral 
characteristics very similar to fluorescein, was found to give similar results as 
staining with annexin V (70). Staining with phalloidin and calcein AM seems to be 
useful to avoid false positive counts related to platelet or other cellular fragments. 
Phalloidin, a cyclic peptide which binds f-actin with high affinity, only stains platelet 
fragments discriminating these from PMPs (54). Calcein AM, a non-fluorescent 
marker that becomes fluorescent upon cleavage by cytosolic esterases only stains 
intact MP/cells and is not reactive with cellular fragments (65;71;72)  
 
Flow cytometry uses fluorescently labelled specific antibodies to identify the cellular 
origin of MPs. These antibodies can distinguish MPs derived from platelets, 
leucocytes, erythrocytes, and endothelial cells. A list of such antibodies can be 
found in the publication of the Forum “Measuring circulating cell derived 
microparticles” (8) and some recent reviews (4;73;74). In addition, there are 
antibodies that have been used for the detection of MPs derived from malignant 
cells such as MUC1 for breast and pancreatic cancer cells (49;75), FasL for 
melanoma cells (76), EGFRvIII for glioblastoma cells (77), and CXCR-4 for 
leukemic cells (78).   
 
The results of flow cytometry measurements depend on the type of instrument, 
instrument settings, and resolution. Recently, the ISTH SSC Working Group on 
Vascular Biology proposed the use of calibrated beads with sizes of 0.5, 0.9 and 3 
µm (Megamix beads) to adjust the instrument setting and increase the resolution of 
the flow cytometer. The primary goal was to standardize the enumeration of PMPs 
>0.5 µm by using flow cytometry (51). Forty laboratories from 14 countries 
participated in the study. Firstly, these laboratories had to establish the resolution 
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and the level of background noise of their cytometers and to set the window of MP 
analysis by using the same batch of Megamix beads. Secondly, to define the inter-
instrument reproducibility they received the same frozen PFP with three different 
concentrations of PMPs and used the same batch of phycoerythrin-labelled anti-
CD41/IgG1 and fluorescein isothiocyanate-labelled annexin V from BioCytex 
(Marseille, France) for PMP staining. Several types of flow cytometer were used by 
these laboratories, such as FACSCalibur, FACSCanto II, and LSRII (all from 
Becton Dickinson) and EPICS XL, Gallios and FC500 (all from Beckman Coulter). 
The results of this study have been reported recently (62). Among 59 registered 
instruments from 40 laboratories, 49 were tested and 33 (67%) from 29 
laboratories were qualified for subsequent analysis of PMP samples indicating that 
the strategy of using calibrated megamix beads is useful for the standardisation of 
PMP measurements by flow cytomety in multi-centre studies. 
 
The enumeration of MPs by flow cytometer will not only be influenced by the 
analytical factors (e.g. laser, antibody, type of instrument, instrument calibration), 
but also on factors related to the sample preparation and storage (see Table 2). 
Especially the presence of residual platelets, storage of the blood/plasma, 
freezing/thawing of the plasma and centrifugation can influence MP counts.  
 
Electron and fluorescence confocal laser scan microscopy  
 
Electron microscopy (EM) can be used to study the morphology and membrane 
composition of MPs. In addition information on the antigenic composition of 
isolated MPs can be obtained by using immunogold-labelled antibodies (34;65;79). 
Heijnen et al (79) firstly reported that there were two types of membrane particles 
released by platelets after stimulation with thrombin receptor agonist peptide 
(TRAP). They concluded that the larger particles (diameters of 0.1-1 µm) were MPs 
because these particles were positively stained by immunogold-labelled antibodies 
against annexin V, GPIb, Pecam-1, integrins αIIb-β3, and two tetraspanins, Peta-3 
and CD9. In contrast, from the smaller particles (diameters of 40-100 nm and 
defined as exosomes) less than 30% were stained by these antibodies, while about 
50% were stained by gold labelled anti-CD63. Aras et al (34) performed EM 
imaging of MPs (diameters of 0.1-0.5 µm) isolated from PFP of a volunteer 
receiving endotoxin and showed that MPs have vesicular structures, but no cellular 
organelles. Interestingly, some of these MPs expressed CD14 and/or TF antigen 
as shown by immunogold labelling. By using EM, Bernimoulin et al. (65) 
demonstrated that MPs derived from THP-1 cells contain cytoskeletal proteins 
organized into a complex cytoskeletal network. As to the enumeration of MPs, EM 
can be used to make a rough estimate of the relative number of MPs in 
preparations subjected to flow cytometric analysis (54;80).  
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EM operational procedures require a vacuum environment and dehydration of the 
sample. These conditions may affect particle/MP morphology and are also not 
suitable for direct detection of MPs in plasma. The standard diameter of EM grids, 
3.05 mm, can only hold a small sample volume (~2-4 µL). The sample material 
used to perform a conventional on-grid negative staining by using uranyl acetate 
preferably contains 0.1 to 1.0 mg protein/mL in aqueous solution (81). Therefore, 
plasma MPs need to be isolated and concentrated by centrifugation. In addition, 
EM produces a two-dimensional image of a sample, which gives an inaccurate 
estimation of the MP size. 
 
Prior to detection by confocal laser microscopy, MPs are stained with fluorescently 
labelled antibodies to enable the identification of subsets of MPs based on their 
antigen expression. Confocal laser microscopy has been used by Dale et al (82) to 
characterize PMPs. These PMPs were 0.3–0.5 µm in diameter and positive for 
glycoprotein IIb/IIIa, glycoprotein Ib, CD9, and PS, but negative for fibrinogen and 
thrombospondin. Interestingly, confocal laser microscopy also can be used to 
identify fusion particles. For instance, Tesselaar et al (49) used fluorescence 
confocal laser microscopy to demonstrate that part of the MUC1-positive MPs 
isolated from the plasma of a metastatic breast carcinoma patient, co-expressed 
the platelet specific antigen, CD61. The fluorescence intensity profiles of these 
MPs corresponded with a MP diameter of approximately 0.15-0.2 µm. However, 
this estimation of MP diameter was based on a two-dimensional image and 
therefore inaccurate. Unfortunately it is not possible to use this method directly in 
plasma because of the high background caused by the interference of plasma 
proteins. 
 
Like other optical methods that are based on the detection of a fluorescence signal, 
the results obtained by confocal laser microscopy also depend on the specificity 
and affinity of the antibody to the target antigen and on the density of the antigens 
on the MP surface.  
 
EM and fluorescence confocal laser scan microscopy give information on 
morphological features of MPs (e.g. size, membrane structure, cytoskeleton). The 
operation of both methods requires several hours and they are not suitable for 
direct detection and quantification of MPs in plasma. However, they are useful for 




For capture-based assays, wells are coated with a probe (antibody or annexin V) 
that specifically binds a subset of MPs from plasma. Captured MPs can then be 
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quantified/characterized by using a second probe (e.g., peroxidase conjugated-
antibody) (31;32) or by using a functional property of the captured microparticles 
(e.g. their procoagulant activity) (53;56;57;83). At present there is limited 
experience with this type of approach, while there are still many questions related 
to the kinetics of MP capture. Nevertheless, we will briefly describe some of the 
test designs that have been proposed in the literature. A clear advantage of these 
assays is that they will allow the measurement of MPs directly in plasma.   
 
Nomura et al (32) and Ueba et al (31) described a method to measure the number 
of PMPs in EDTA-ACD PPP. Wells were coated with a monoclonal antibody 
against glycoprotein CD42a, while anti-CD42b, conjugated to a peroxidase, was 
used as secondary antibody.  The concentration of PMPs is reported as U/mL 
where one U/mL is defined as the number of PMPs obtained from 24,000 
solubilised platelets/mL.  
 
Aupeix et al (84) first reported the use of annexin V-coated wells for the 
quantification of procoagulant MPs. The immobilized annexin V captures PS 
containing MPs from recalcified PFP. The procoagulant surface of these MPs is 
then quantified by measuring the prothrombinase activity after adding excess FXa-
FVa. A direct relationship exists between the procoagulant phospholipid 
concentration and the amount of thrombin generated. Hugel et al (8) described this 
assay in detail in a publication of the Forum “Measuring circulating cell derived 
microparticles”. Liposomes of known concentration containing 33% PS/67% PC 
(mol/mol) were used as reference material. The MP concentration is reported as 
nM PS equivalent.  
 
Meanwhile two commercially available variants of this assay are available 
(Actichrome® MP activity from American Diagnostica, Connecticut, USA and 
Zymuphen MP activity from Hyphen Biomed, Neuville-sur-Oise, France). These 
assays use a washed and lysed platelet concentrate as calibrator. Results are 
reported as nM PS. 
 
Annexin V captures PS containing MPs in the presence of calcium ions. Therefore, 
the free calcium concentration in (diluted) plasma is an important determinant, 
which may influence the capture efficiency. As PFP is used for these 
measurement, the type of anticoagulant (EDTA, 3.2% citrate, 3.8% citrate) used for 
blood collection may influence the test result. The need to recalcify the plasma also 
raises the possibility of activation of the clotting system. This should be prevented 
by adding specific inhibitors to the (diluted) plasma. A final analytical issue is that 
the calculation of the MP concentration in plasma is based on comparison with a 
calibrator which does not have the same characteristics/behaviour as plasma MPs. 
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A limitation of this approach is the need to use fresh plasma, because freezing 
thawing will result in an increase in the number of annexin V-positive MPs (43;47) 
 
Instead of biotinylated annexin V, biotinylated antibodies (e.g. anti-CD42b for 
platelets, anti-CD31 and anti-CD105 for endothelial cells, anti-CD3 and/or CD4 for 
T lymphocytes and anti-CD11a for leucocytes) have been used to capture specific 
subsets of MPs and then measure the prothrombinase activity as in the annexin V 
capture-based assay (8;83). As a control, irrelevant IgG is used for capturing MPs. 
The MP concentration in this antibody capture-based assay is expressed in nM PS 
as in the annexin V capture-based assays. A problem with the interpretation of the 
results of these tests is that part of the captured MPs might not express PS and 
that the specificity of the antibodies is broader than generally assumed (e.g., anti 
CD31 and anti CD105). 
 
Aras et al (34) described the use of an immunoglobulin M monocolonal mouse anti 
human fibroblast surface protein (1B10) to capture MPs from PFP. Captured MPs 
were analysed for the presence of active TF using a two-step chromogenic assay. 
The TF-dependent FXa generation (pM/hour) was determined after subtracting the 
amount of FXa generated in the presence of polyclonal anti-human TF antibody 
prior to addition of FVIIa and FX. The 1B10 antibody apparently recognizes 
antigens on the surface of monocytes, granulocytes, endothelial cells, smooth 
muscle cells and fibroblasts, but not on platelets and epithelial cells. Consequently, 
MPs originating from platelets and epithelial cells are most likely not measured in 
this assay.   
 
These capture-based assays enable a high-throughput measurement of subsets of 
MPs but will give no information on the size and total number of these MPs in 
plasma. Specific problems related to the antibody capture-based assays are not 
only the eventual presence of soluble antigen together with MP bound-antigen 
(42), but also the specificity and affinity of the antibody for the target antigen, and 
the amount of antibody coated on the well. Together they will determine the 
number of MPs captured in the assay.  
 
Apart from the analytical factors that influence the capture-based assays, pre-
analytical steps such as blood collection, plasma isolation and sample storage are 
also important. Although frozen-thawed plasma is frequently used in capture-based 
assays, there is not much information on how freezing and thawing of plasma will 




Functional assays on isolated MPs 
 
The analysis of certain functional properties of MPs can be achieved by separating 
MPs from the plasma proteins. An example of this is the measurement of TF 
activity in isolated MPs. The isolated MPs are supplemented with excess FVII(a) 
and FX in the presence of calcium, after which the formation of FXa is measured 
with a specific chromogenic substrate using either a one-stage (49;85) or two-stage 
approach (86;87). The TF activity of MP (MP-TF activity) is defined as the FVII 
dependent and anti-TF sensitive formation of FXa. MP-TF activity and has been 
expressed as fM Xa/min (no external calibrator) or as pg/mL (using relipidated 
recombinant human TF as a calibrator). The one-stage assay uses excess 
negatively charged phospholipids in the assay (49;85;88), while the users of the 
two-stage assay do not add phospholipids. In our own experience the presence of 
these phospholipids does not importantly affects the TF activity of isolated MPs. 
Interestingly no difference in MP-TF activity was observed between MPs isolated 
from fresh plasma and MPs isolated from frozen thawed plasma (49). A 
commercial two-stage chromogenic assay (Actichrome® TF, American 
Diagnostica, CT, USA) has also been used to quantify TF activity in the isolated 
MP fraction. Although this assay has also been used to measure TF activity in 
plasma (57;89), the observed FXa generation was found to be independent of 
exogenously added FVIIa and/or TF, and not inhibited by anti-FVIIa (90). 
 
One limitation of all available TF-dependent FXa generation assays is the lack of 
an accepted standard for TF. For this reason, a working group on TF 
standardization in cancer was presented by the SSC at ISTH 2005. This group 
aimed and proposed to compare measurement of TF with a variety of methods in 
different laboratories and to improve intra- and inter-laboratory reproducibility by 
developing standardized protocols, appropriate reagents, and reference materials.  
 




Mass spectrometry (MS)-based proteomic analysis provides an opportunity to 
characterize the protein composition of MPs. Generally this method requires 
extraction, separation, trypsin digestion, MS analysis, and identification of proteins. 
Cell-surface antigens are generally of high molecular weight and hydrophobic 
(91;92). Therefore, an ionic/non-ionic detergent (e.g. sodium dodecyl sulfate, Triton 
X-100, NP-40) or a high-pH solvent (sodium carbonate pH 11) is used for the 
extraction of the membrane proteins prior to the gel separation and MS analysis 
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(92;93). Finally, each MS spectrum is used to search the protein database for 
matched peptides (91;94). 
  
Proteomic analysis has been used by several groups to investigate the protein 
content of PMPs (29;30). For instance, PMPs isolated from the supernatant of ADP 
stimulated-platelets contained membrane surface proteins derived from platelets 
(GPIIIa, GPIIb, and P-selectin), chemokine ligand 4 (CXCL4), pro-platelet basic 
protein (CXCL7), and RANTES (CCL5). Proteins from the alpha granules 
(fibrinogen, vWF, FV and FXIII, thrombospondin, and protein S) were also found 
(30). In a different study (29), several proteins were detected in MPs isolated from 
plasma that were not found in PMPs isolated from the supernatant of ADP 
stimulated-platelets. These included proteins associated with apoptosis (CD5-like 
antigen, galectin 3-binding protein, and several complement components), iron 
transport (transferrin, transferrin receptor, haptoglobin), immune response 
(immunoglobulin J and Kappa chains), and blood coagulation (protein S and FVII). 
Some of these might represent contamination of the MP with plasma proteins. 
 
The supernatant of TRAP-induced platelets contains mainly proteins from alpha 
granules (28). Some proteins potentially involved in angiogenesis, such as platelet-
derived endothelial cells growth factor (PD-ECGF), angiopoietin-1, and galectin-3 
binding protein are also found in this fraction. Importantly, four different isoforms of 
protein disulfide isomerase (PDIA3, P4HB, PDIA4 and PDIA6) were found, proteins 
that have been identified as critical mediators of wound healing (95) and assist in 
the de-encryption of an inactive form of TF into its active form (96;97). Recently, 
the presence of PDI on the surface of PMPs was also reported (98). 
 
Proteomic analysis allows identification of various proteins in a complex mixture. 
However, quantification of proteins is difficult. The contamination of MPs with 
abundant plasma proteins like albumin and immunoglobulins might affect the 
results of proteomic analysis (94).  
 
Impedance-based flow cytometry 
 
Unlike the conventional flow cytometer, impedance-based flow cytometry is based 
on the Coulter principle to detect changes in electrical impedance produced by 
particles in suspension. These changes can be measured as a voltage pulse or a 
current pulse. The pulse height is proportional to the volume of the sensed particles 
(99). For MP measurement, this system is calibrated using fluorescent polystyrene 
microspheres of uniform size. Subsequently, MPs can be detected directly in PPP 




Zwicker et al. (75) have compared the measurement of PMPs, calibrated 
microspheres (0.78 µm), and platelets in frozen-thawed PPP, both by impedance- 
and light scatter-based flow cytometry. The size of platelets and PMPs is poorly 
characterized by the light-scatter based flow cytometry and both populations 
overlap with the 0.78 µm-microspheres. Conversely, the impedance-based flow 
cytometer could resolve the populations of PMPs, calibrated microspheres, and 
platelets. The same group (75) used impedance-based flow cytometry to measure 
the number of TF-bearing MPs in PPP of pancreatic cancer patients and found 3 to 
4 orders of magnitude more MPs than previously reported by Tesselaar et al (49) 
who used light scatter-based flow cytometry. This might confirm that light scattering 
is not suitable for the enumeration of TF-bearing MPs. Impedance-based flow 
cytometry is presently used to quantify TF bearing MPs in the MicroTEC study, a 
randomized, multi-centre trial to evaluate the benefit of primary thrombophylaxis in 
cancer patients with high levels of TF bearing MPs (100).   
 
In impedance-based flow cytometry, the size detection limit of the measurement 
depends on the diameter of the flow cell. Postmarket installation of smaller flow 
cells with diameters of 25 and 40 µm is required to analyze particles between 0.3 
and 1.0 µm in diameter (75). Thus, MPs below 0.3 µm in diameter might not be 
detected by using these flow cells. Using fluorescently labelled antibody, the size 
distribution of MPs can theoretically be determined from the amplitude of the 
fluorescent signal under the assumption that the signal is either proportional to the 
volume or the surface of the particles (in the case of surface labeling). In addition 
the size distribution is calculated assuming a spherical shape. In the case of 
fluorescent labeling one generally assumes that the labeling efficiency is 
independent of the particle shape and (surface) composition.  
      
Dynamic light scattering (DLS) and Nanoparticle tracking analysis (NTA) 
 
Dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA) measure 
Brownian motion of MPs in liquid suspension and from this movement the particle 
size can be calculated using the Stokes-Einstein equation (101). NTA measures 
the movement of each particle through image tracking analysis, whereas DLS 
measures all particles at the same time and produces an average particle size.  
 
Two DLS systems, the Zetasizer Nano S (Malvern Instruments Ltd, 
Worcestershire, UK) and the N5 Submicron Particle Size Analyser (Beckman 
Coulter, CA, USA) were used to examine the size distribution of MPs in frozen-
thawed plasma (102). It was found that MPs with sizes ranging from 50-1000 nm 
could be detected by the N5 instrument utilizing a 30.1° angle of measurement, 
whereas the Zetasizer detected some particles considerably larger than those 
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identified by the N5. The main disadvantage of DLS for measuring MPs is that it 
performs best in studying monodisperse particles while cell-derived MPs are clearly 
polydisperse. This makes that the size distribution of MPs measured by DLS is 
biased towards the presence of small numbers of large particles or contaminants 
as they scatter light more intensely than the smaller particles. The Zetasizer Nano 
S uses the back scattered light to increase the sensitivity of the method, while the 
N5 system can use up to 6 different scattering angles. The scattering angles of 
both instruments do not overlap. 
 
This problem seems not to occur with the NTA approach because a microscope 
and a CCD camera track and visualize the individual particles by using particle 
tracking image analysis software. Harrison, et al. (103) used an NTA system, 
known as Nanosight LM10 (Nanosight, Amesbury, UK) to measure MP 
distributions in isolated MPs and in PPP diluted in PBS (1:40-1:60). They found 
that MPs have a polydisperse distribution up to 1,000 nm, but with a predominant 
population from lower than 50 nm to above 300 nm. They estimated that PPP 
contains ~200-260x109 MPs/L which is 1,000-fold higher than previous estimates 
based on using flow cytometry.  
 
As mentioned before, NTA can accurately size particles in a sample, but 
unfortunately the presence of a few larger particles will reduce the number of small 
particles detected by the software.  This has been demonstrated by Filipe et al 
(104) by mixing 60-nm/100-nm beads in a 4:1 ratio. The NTA analysis of this 
mixture showed two distinct size populations, but it detected more 100-nm beads 
than 60-nm beads due to the masking effect of the larger beads over the smaller 
beads.   
 
For MP measurements the NTA approach has some disadvantages when 
compared to the DLS approach. The operation of NTA is not yet as user friendly as 
that of DLS. This is due to the fact that several parameters need to be adjusted 
carefully by a skilled operator prior to the NTA measurement. These parameters 
include the settings for the video capture and analysis, which are essential to 
obtain accurate and reproducible measurement results. As the Brownian motion of 
a particle in a solution depends on the viscosity and temperature of the solution, 
these parameters should also be defined prior to MP measurement in (diluted) 
plasma.  
 
NTA and DLS may be unable to differentiate MPs from other particles present in 
plasma like (lipids/lipoproteins). Recently, Nanosight has launched a fluorescence-
NTA, the NS500. This instrument enables the detection of individual quantum dots, 
fluorescent nanoparticles with a diameter of 2-10 nm, with minimal background 
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interference of other particles in the solution. This will hopefully enable the 
detection of specific subsets of MPs, for example by using quantum dot-labelled 
antibodies. 
 
Atomic force microscopy 
 
Scanning probe microscopy, especially atomic force microscopy (AFM), has 
opened new perspectives in biomedical research for the investigation of 
(bio)particles (105). AFM probes the surface of a sample with an ultra-sharp tip, a 
couple of microns long and often less than 100 Å in diameter. The tip is located at 
the free end of a cantilever which is 100-200 µm long. The interaction force 
between the tip and the sample depends on their distance. A detector, often with 
the use of a laser beam, measures the cantilever deflection when the tip moves 
across the sample or when the sample is moved under the tip. The measured 
cantilever deflections allow a computer to generate a three dimensional (3D)-
surface topography (x, y and z dimensions) (106). The detection is so sensitive that 
forces can be detected as small as a few picoNewton. The advantage of employing 
AFM in the study of MP is that AFM can be operated in fluid tapping mode. The 
AFM tip is oscillated in liquid to create intermittent contact with the sample surface 
allowing the preservation of sample properties in their physiological state (Figure 
1). A flat surface is needed for MP attachment, in order to distinguish individual 
MPs from the roughness of the supporting surface. Muscovite mica is a commonly 
used surface for AFM imaging because this non conductive mineral consists of 
layers which can be easily cleaved to produce clean and atomically flat surfaces 
(107). After cleaving, the mica surface can be modified to covalently attach a 
protein or antibody.   
 
Recently, Yuana et al (58) have used AFM operated in fluid tapping mode for the 
sensitive detection of a defined subset of MPs isolated from double-centrifuged 
PPP. Using AFM and mica-coupled anti-CD41 1,000-fold more CD41-positive MPs 
were detected than by using conventional flow cytometry. These MPs have sizes 
ranging between 10-475 nm with a peak at 67.5 nm which is clearly below the 
detection limit of conventional flow cytometry. After freezing and thawing a 
decrease in the number of CD41-positive MPs was found by AFM, but the size 
distribution of these MPs remained the same. AFM also was employed to 
investigate the formation of PMPs by Siedlecki et al. (108). PMPs were generated 
by using surface-activated and thrombin-stimulated platelets deposited on glass 
and were found to have a similar size distribution as reported by Yuana et al (58). 
Siedlecki’s group also showed that PMPs are clustered in close proximity to 
adherent platelets and localized in the platelet periphery and in some cases 
appeared to originate from platelet pseudopodia.   
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Baran et al (109) used AFM to detect MPs from frozen-thawed PFP isolated from 
EDTA blood of gastric cancer patients. AFM detected MPs mainly with sizes 
around 10 nm. This result was confirmed by using other techniques such as 
transmission EM and DLS. However, they did not operate AFM in fluid, so the 
characteristic of MPs might have changed. 
 
AFM can be operated in fluid to detect MPs with a minimal force, thereby 
preserving their natural state, but it also enables the detection of the individual MP 
and simultaneously measures the 3D-size of MPs. Furthermore, the numbers of 
MPs attached to the surface can be quantified by using image processing software. 
When a specific antibody is used to coat a surface, a specific subset of MPs can be 
captured (58). However, as MPs need to be isolated from plasma and concentrated 
prior to AFM measurement, the isolation step might influence the morphology and 
the number of MPs. At present, the detection of MPs by AFM is low-throughput 
(typically 2 hours per sample). Therefore, modifications that will allow faster 
detection of specific populations of MPs in plasma will be essential.  
 
  
Figure 1. A scheme showing AFM operated in 
tapping mode to detect MPs attached on anti-
CD41 coated mica surface. This mica surface 
was first modified with ethanolamine as 





Results of plasma MP measurements reported in the literature vary widely. This is 
clearly not only related to the lack of well-standardized high-throughput MP assays, 
but also to variations in pre-analytical conditions. Some examples of these 
variations are listed in Table 1. Therefore, standardisation of both pre-analytical 
procedures and assay protocols is urgently needed.  
 
When flow cytometry is chosen as a method for quantification of MPs, some 
analytical conditions should be standardized. Before measurement of the samples, 
the setting of the flow cytometer should be adjusted by using calibrated size 
standard beads, for example Megamix beads, to define the threshold (>0.5 µm and 
<0.9 µm) of MP detection. Counting beads should be used to measure the 
concentration or absolute count of MPs in a sample. For the characterization and 
enumeration of subsets of MPs the choice of antibody for labelling and capturing 
MPs is crucial. The antibody should be specific and have a high affinity for the 
target antigen.  
 
Since not all plasma MPs expose annexin V and the percentage of annexin V-
positive MPs can differ importantly depending on preanalytical conditions, the total 
number of MPs should not only be determined by binding of annexin V to MPs. In 
flow cytometry measurements and annexin V-capture assays binding of annexin V 
to MPs is influenced by the calcium concentration and the membrane PS content. 
Thus, it is important to find/develop a marker for direct detection of total number of 
MPs in a calcium-free environment.  
 
Fluorescence-NTA and AFM can accurately count the nanosized MPs, but 
unfortunately both do not give information on the functional properties of MPs. 
Before employed in the clinic these methods need to be further validated. Similar 
like other methods which rely on the use of an antibody for the detection of MPs, 
specific and high affinity antibodies are required for the fluorescence-NTA and 
AFM.   
   
Remaining Issues 
 
Ideally MP measurements should be performed in plasma, freshly prepared directly 
after blood withdrawal. Platelet contamination seems to be one of the major pre-
analytical problems in processing plasma for MP measurement. Platelets might be 
activated and/or fragmented resulting in an increase in the number of PMPs. 
Therefore, the choice of the anticoagulant used for blood collection and the 
centrifugation speed used for plasma preparation is critical. Freezing/thawing of 
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PPP unfortunately results in changes in the number of PMPs and in the number of 
PS-exposing MPs. There is therefore a great need for internationally accepted 
recommendations for the preparation and storage of plasma for MP measurements 
and for the isolation of MP from plasma. In addition, standardization of protocols, 
including the use of appropriate reagents and reference materials, is needed to 
improve intra- and inter-laboratory reproducibility in MP measurements.  
 
At this moment we still have very limited information on what type of MPs (e.g. 
origin, protein content, and morphology) play a role in the development and 
progression of vascular disorders, cancer, and auto-immuno diseases. This is 
mostly due to the limitations of the methodology presently used for the enumeration 
of specific subsets of plasma MP. Some new methods (Impedance-based flow 
cytometry, DLS, NTA, and AFM) have been developed in the past years that might 
enable the accurate measurement of these nanosized MPs, but unfortunately 
these methods do not give information on the functional properties of MPs. 
Moreover, at this moment these methods are impractical for use in the clinic as 
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Background: Microparticles (MPs) are small vesicles released from cells of 
different origin, bearing surface antigens from parental cells. Elevated numbers of 
blood MPs have been reported in (cardio)vascular disorders and cancer. Most of 
these MPs are derived from platelets.  
 
Objectives: To investigate whether atomic force microscopy (AFM) can be used to 
detect platelet-derived MPs and to define their size distribution.  
 
Methods: Blood MPs isolated from seven blood donors and three cancer patients 
were immobilized on a modified mica surface coated with an antibody against 
CD41 prior to AFM imaging. AFM was performed in liquid-tapping mode to detect 
CD41-positive MPs. In parallel, numbers of CD41-positive MPs were measured 
using flow cytometry. Mouse IgG1 isotype control was used as a negative control.  
 
Results: AFM topography measurements of the number of CD41-positive MPs 
were reproducible (coefficient of variation = 16%). Assuming a spherical shape of 
unbound MPs, the calculated diameter of CD41-positive MPs (dsph) ranged from 
10 to 475 nm (mean: 67.5 ± 26.5 nm) and from 5 to 204 nm (mean: 51.4 ± 14.9 
nm) in blood donors and cancer patients, respectively. Numbers of CD41-positive 
MPs were 1,000-fold higher than those measured by flow cytometry (3-702 x 109/L 
plasma vs. 11-626 x 106/L plasma). After filtration of isolated MPs through a 0.22-
µm filter, CD41-positive MPs were still detectable in the filtrate by AFM (mean 
dsph: 37.2 ± 11.6 nm), but not by flow cytometry.  
 
Conclusions: AFM provides a novel method for the sensitive detection of defined 
subsets of MPs in the nanosize range, far below the lower limit of what can be 
measured by conventional flow cytometry. 




Microparticles (MPs) or microvesicles are small cellular fragments (vesicles) that 
were initially considered to be ‘cell dust’, but were later shown to be released from 
cells upon activation and apoptosis (1,2). The majority of MPs found in blood 
plasma are platelet-derived MPs (PMPs), as defined by the presence of CD41 and 
CD61 on their surface (3,4). Several studies point to a role of blood MPs in 
processes such as angiogenesis, cancer, and thrombosis (4-7).  
 
The precise mechanism by which MPs are released has not yet been elucidated; 
however, an increase in cytosolic calcium concentration appears to be necessary 
to trigger vesicle release (8). Some specific enzymes (floppase and scramblase) 
are thought to assist in remodeling the plasma membrane by inducing the 
translocation of anionic phospholipids, such as phosphatidylserine (PS), from the 
inner membrane to the outer membrane (9). This event is followed by MP release 
and cytoskeletal degradation by calcium-dependent proteolysis (10).  
 
In recent years, blood MPs have increasingly received attention as potential 
biomarkers in the diagnosis and prognosis of disease. However, such studies have 
been hampered by the lack of accurate methods for the detection and 
quantification of MPs. Different methods and combinations of methods have been 
used, including enzyme-linked immunosorbent assays (ELISAs), capturing MPs 
with immobilized annexin V or cell-specific antibodies (7,11), and flow cytometry 
(4,5,12). The advantage of ELISAs is that these can be easily developed into user-
friendly diagnostic/screening assays for analysis of large numbers of samples. 
Captured MPs are quantified via measurement of the concentration of negatively 
charged phospholipids supporting prothrombinase activity. The drawback of using 
this method is that MPs do need to expose accessible PS on their surfaces, and 
that the method does not give information on the number of MPs (12). Other 
disadvantages of ELISAs are interference by soluble antigens and lack of 
information on size distribution. An advantage of flow cytometry is that it can be 
used for the simultaneous detection of two or more antigens on MPs by using 
antibodies conjugated with different chromophores. However, the laser light 
employed in flow cytometers, which excites at a wavelength of 488 nm, makes the 
measurement of the smaller MPs by flow cytometry unreliable (13). Standardization 
of PMP detection with flow cytometry in the size range 500-1,000 nm by using 
calibrated beads was recently proposed (14).  
 
Scanning probe microscopy, especially atomic force microscopy (AFM), has 
opened new perspectives in biomedical research for the investigation of 
(bio)particles (15). With AFM, high-resolution topography imaging of particles can 
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be obtained with a resolution down to the subnanometer range. Moreover, the 
ability of AFM to image biological samples in aqueous fluids enables the 
preservation of sample properties in their physiological state (16,17). We chose 
AFM as a method for the detection of CD41-positive MPs. Muscovite mica, a non-
conducting layered mineral that can easily be cleaved and has an atomically flat 
surface (18), was modified and used to immobilize anti-CD41 antibody. This 
modified mica was then used for capturing MPs. AFM in fluid/liquid tapping mode, 
where the probe is oscillated in liquid to create intermittent contact with the sample 
surface, was used to detect the MPs. We report that AFM detects 1,000-fold more 
CD41-positive MPs than flow cytometry, and that the size of the majority of these 
MPs is below the detection limit of conventional flow cytometry. We propose AFM 
as a suitable method for studying the size, antigenic properties and numbers of 
defined subsets of MPs. 
 
Materials and methods 
 
Blood collection and plasma preparation 
 
After giving their informed consent, seven blood donors were sampled between 
08.00 h and 10.00 h. Venous blood was drawn by using a 21-gauge needle (BD 
Vacutainer; Becton Dickinson, San Jose, CA, USA) and minimal stasis. After 
discarding of the first 4 mL of blood, blood was collected in a 1/10 volume of 
sodium citrate (3.2%, 0.105 M) using a 4.5-mL BD Vacutainer tube (Becton 
Dickinson). Within 10-15 minutes of withdrawal, blood was centrifuged at 2,000g 
for 10 minutes at 20°C, without brake. Plasma was carefully collected and 
centrifuged again at 2,000g for 10 minutes at 20°C, without brake, to obtain 
platelet-poor plasma (PPP). PPP was aliquoted in 250-µL portions. For the 
isolation of MPs from fresh PPP, PPP was directly subjected to the next 
centrifugation steps. Otherwise, PPP was snap frozen in liquid N2 and stored at - 
80°C until used for MP isolation. In addition, blood was collected from three 
patients with cancer (metastatic colorectal, pancreatic and renal cell carcinoma) 
after informed consent had been obtained. 
 
Isolation of MPs 
 
For AFM measurement, 750 µL of PPP was pooled and centrifuged at 18,890g and 
20°C for 30 minutes, with minimum brake. The supernatant was removed carefully, 
except for 25 µL containing the MP pellet. This pellet was resuspended in 1 mL of 
Hepes buffer [10 mM Hepes (Merck, Darmstad, Germany), 137 mM NaCl (Merck), 
4 mM KCl (Merck), 0.1 mM Pefabloc SC (Fluka, Munich, Germany), pH 7.4], 
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vortexed, and centrifuged as before. The supernatant was removed, leaving a 
volume of 25 µL containing the MP pellet. This 25 µL was vortexed and then used 
for AFM.  
 
For flow cytometry, 250 µL of PPP was centrifuged at 18,890 g and 20°C for 30 
minutes, with minimum brake, and the supernatant was then carefully removed, 
leaving a volume of 25 µL containing the pellet. To wash the MPs, 225 µL of Hepes 
buffer was added, and this mixture was then centrifuged again at 18,890g and 
20°C for 30 minutes, with minimum brake. The supernatant (225 µL) was removed, 
and the residual 25 µL was diluted to 100 µL with Hepes buffer. This MP 
preparation was directly used for staining with antibodies.  
 
Modification of mica for immobilization of mouse anti-human CD41 antibody 
 
The surface of mica was modified as follows. A solution was made containing 55% 
(w/v) ethanolamine (Sigma Aldrich, Munich, Germany) in dimethylsulfoxide 
(DMSO) (99.7% purity; Biosolve BV, Dordrecht, the Netherlands). Molecular sieve 
beads (0.3 nm; Sigma Aldrich) were added to adsorb the water formed later during 
the amine reaction on the mica surface. This solution was heated at 70°C until the 
ethanolamine was completely dissolved. Next, freshly cleaved muscovite mica 
sheets (Electron Microscopy Sciences, Hatfield, PA, USA), with a diameter of 10 
mm, were incubated overnight in the ethanolamine solution.  
 
Subsequently, mica sheets were rinsed twice in DMSO (99.7% purity, 70 °C) and 
twice in absolute ethanol (Biosolve BV) at room temperature (RT). These mica 
sheets were dried under N2. At this point, the amine-modified mica can be used 
immediately for the next modification step or stored in a desiccator for up to several 
weeks. Prior to protein coupling, the modified mica was incubated for 3 hours with 
1 mg/mL EGTA (Sigma Aldrich) in chloroform (Merck) containing 0.5% (v/v) 
triethylamine (Merck). The mica sheets were then washed in chloroform, dried 
under N2, and glued onto a steel disk (diameter of 12 mm) with a silicon-based glue 
(Rhodia Silicon, Leverkusen, Germany). Fifty microliters of mouse anti-human 
CD41 antibody clone P2 (Beckman Coulter, Fullerton, CA, USA) (0.01 mg/mL) was 
applied to the modified mica and incubated for 30 minutes at RT. Excess of anti-
CD41 was removed by washing with Hepes buffer. As a negative control, mouse 




AFM analysis of CD41-positive microparticles 
 
Twenty microliters of the MP fraction was applied to the anti-CD41-coated mica 
surface and incubated for 30 minutes to allow the binding of MPs to anti-CD41. To 
remove unbound MPs, the mica was washed twice with Hepes buffer. During the 
incubation step and before imaging, the mica surface was kept in a closed 
container. 
 
Before use, the AFM glass fluid cell (Veeco, New York, NY, USA) was sonicated 
for 5 minutes in sodium dodecylsulfate (Serva Electrophoresis, Heidelberg, 
Germany), rinsed with distilled water, and allowed to dry under N2. A 
microcantilever silicon tip (Olympus, Tokyo, Japan), with a spring constant of 2 N/m 
and 70-kHz resonant frequency, was attached to the fluid cell. After mounting of 
the steel disk containing the sample on the piezoelectric scanner of the atomic 
force microscope, 80 µL of imaging buffer containing 20 mM Tris (Roche, Basel, 
Switzerland) and 150 mM KCl (pH 7.4) was added. The fluid cell with the cantilever 
attached was then seated against the sample. An atomic force microscope (Veeco) 
operated in fluid-tapping mode was used to scan the topography of the mica and 
attached MPs, thus providing three dimensional images of the MPs. With an 
imaging rate of 1.5 Hz, the surface was scanned at different positions to obtain four 
to 10 images with a scan size of 100 µm2 per image. Images were captured and 
recorded using NANOSCOPE software version 5.30r2 (Veeco). 
 
AFM data were analyzed using SPMEDIATOR version 6.1 (courtesy of S. J. T. van 
Noort, Leiden University, Leiden, the Netherlands) that evaluates the center of 
mass of particles in comparison with the surface background. This software 
automatically calculates the volume (V) and height (z) of MPs. From the MP 
volume, the MP diameter ( 3 6V/π=sphd ) was calculated, assuming a spherical 
shape for the MP when not bound to the mica. 
 
To calculate the number of CD41-positive MPs/L PPP detected by AFM, the 
following formula was used: (106/750) x (25/20) x (78.5 x 106/100) x NAFM, in which 
750 (µL) is the original volume of PPP used for MP isolation, 25 (µL) is the volume 
of MP suspension, 20 (µL) is the volume of the MP suspension applied to the mica 
surface, 78.5 x 106 (µm2) is the surface area of the mica, 100 (µm2) is the surface 
area of an AFM image, and NAFM is the mean of the total number of CD41-positive 
MPs per image after correction for the number of MPs found on IgG1 control-
coated mica.  
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Flow cytometry analysis of CD41-positive MPs 
 
Flow cytometry analysis was performed using a FACS Calibur flow cytometer with 
CELLQUEST PRO software (Becton Dickinson). The FACS Calibur used can 
detect polystyrene beads of 0.2, 0.5 and 1 µm (Fluka) if they are analyzed 
separately, but is unable to resolve these particles when they are analyzed as a 
mixture (data not shown).  
 
Five microliters of the MP fraction was incubated with 5 µL of phycoerythrin (PE)-
labeled mouse anti-human CD41 clone P2 (1:100 dilution) (Beckman Coulter) in 40 
µL of Hepes buffer for 30 minutes at RT in the dark. Then, 200 µL of Hepes buffer 
was added, and the MP suspension was centrifuged at 18,890g and 20°C for 30 
minutes, with minimum brake. The supernatant was removed carefully, and the 
residual 50 µL was diluted to 350 µL with Hepes buffer. As negative control, mouse 
IgG1 PE clone X40 (Becton Dickinson) was used at the same concentration as the 
anti-CD41 antibody. For counting absolute numbers of CD41-positiveMPs per liter, 
we used flow cytometry absolute count standard beads with a mean diameter of 
7.58 µm per bead and a known concentration (Cbeads) (Bang Laboratories, Fishers, 
IN, USA) as an external standard. Two hundred microliters of these beads (Vbeads) 
was mixed with Hepes buffer to a volume of 600 µL (Vtot) and then measured in 
triplicate (Nbeads). For measurement of counting beads as well as MPs, the flow 
cytometer was programmed to count events in 1 minute. To calculate the volume 
(Z) measured by flow cytometry, the following formula was used: Vtot/Vbeads x 
(Nbeads/Cbeads). The amount of CD41-positive MPs/L PPP detected by flow 
cytometry was calculated as (350/Z) x (100/5) x 106/250 x NFACS, in which 350 (µL) 
is the total volume of MPs before analysis, 100 (µL) is the total volume of the 
original MP suspension, 5 (µL) is the volume of MPs used for antibody labeling, 
250 (µL) is the original volume of PPP used for MP isolation, and NFACS is the mean 
number of CD41-positive events counted by flow cytometry, after correction for 




Statistical evaluation was performed using SPSS 14.0. Correlation of the amount of 
MPs in PPP measured by AFM and flow cytometry was tested with the Pearson 








The surface of cleaved mica scanned with an atomic force microscope operated in 
fluid-tapping mode was flat, with an apparent height of ~ 0.1 nm (Figure 1A). After 
modification of this surface, the surface topography was still nearly flat, with a 
measured height of ~ 0.2 nm (Figure 1B). Following the immobilization of mouse 
anti-human CD41 antibody on the modified mica, an apparent height of 2.3 ± 1.17 
nm of the anti-CD41 antibody was detected (Figure 1C). As a negative control, a 
mouse IgG1 isotype control was immobilized on the modified mica, and from the 
surface topography scan, an apparent height of 2.3 ± 1.50 nm was determined 
(Figure 1D). The number of anti-CD41 and IgG1 molecules on the surface (100 
µm2) was~ 2,000/100 µm2 and, on the basis of the surface topography scan, they 




Figure 1. Atomic force microscopy image showing the three-dimensional surface topography of mica 
(A), modified mica (B), anti-CD41 antibody-coated mica (C), and IgG1 isotype control-coated mica (D). 
Inserts show the results of the height analysis (z) of the surfaces. 
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Imaging with AFM demonstrated specific binding of MPs isolated from fresh PPP to 
anti-CD41-coated mica. The three-dimensional AFM topography showed that there 
were particles, defined as MPs, attached to the anti-CD41-coated mica, whereas 
these were virtually absent on the IgG1 isotype control-coated mica (Figure 2A, B). 
The IgG1 isotype control was used to control for non-specific MPs binding to the 




Figure 2. Three-dimensional atomic force microscopy topography of (A) CD41-positive microparticles 
(MPs) and (B) isotype control (IgG1)-coated mica. The scale bar in these images is 1 µm. The dashed 
box on the surface (A) was scanned (1 µm2) and analyzed with NANOSCOPE software by positioning 
cross-sectional line on two MPs (C; #1 and #2). A histogram of this line presents the MP peak with its 




Using NANOSCOPE software version 5.30r2, the diameter and height of MPs in 
surface topography scans were analyzed. In Figure 2C, a cross-sectional line was 
positioned on two MPs (#1 and #2). Figure 2D shows the histogram of this line. 
The values of the edge-to-edge diameter, dflat, of surface-bound MPs were about 
10-fold higher than the z-values (for #1 dflat/z = 125.0 nm/12.9 nm; for #2, 146.5 
nm/14.7 nm), indicating that bound MPs were flat. Considering the physiological 
state of unbound MPs, and to facilitate future comparisons with, for example, 
transmission electron microscopy images, we chose to analyze MPs in terms of 
their volume. Additionally, a volume measurement is more easily automated and 
more accurate, because it does not depend on the direction in which the 
crosssection is made. MP volume is measured by summing the volume of each 
pixel in the AFM image (using SPMEDIATOR version 6.1), and from this volume 
the effective diameter, dsph, of the MP is calculated. The effective diameters, dsph, 
for MPs #1 and #2 were 49.2 and 54.0 nm, respectively. This result shows that dsph 
of these MPs was approximately two-fold smaller than dflat. In the remainder of this 
article, all diameters will be given as effective diameter, dsph, unless stated 
otherwise. 
 
Variation of the incubation time of MPs with the anti-CD41-coated mica (2, 15, 30, 
and 45 minutes) showed that the total number and size distribution of specifically 
attached MPs had reached a plateau after 15 minutes (for a particular MP 
preparation, 323 counts per 100 µm2). 
 
Figure 3A shows that the MPs attached to the anti-CD41-coated mica had dsph 
values ranging from 10 to 475 nm (mean: ~ 50 nm). When isolated platelets were 
stimulated with thrombin (0.5 U/mL), CD41-positive MPs with a similar dsph (mean: 
44.1 ± 13.7 nm) were found. 
 
To investigate the relationship between MP concentration and number of CD41-
positive MPs detected by AFM, different dilutions of MPs isolated from PPP were 
incubated with anti-CD41-coated mica and imaged by AFM. A linear relationship 
was obtained between the number of CD41-positive MPs per 100 µm2 mica and 
the MP concentration (100% = undiluted MPs) (Figure 3B). At saturation, the 
CD41-coated mica can bind about 500 MPs per 100 µm2. This value was 
confirmed in several separate experiments. For AFM analysis, samples need to be 
sufficiently diluted to give a response in the linear part of the dose-response curve. 
 
To determine the reproducibility of the measurements, MPs were isolated from 
frozen-thawed PPP on three consecutive days, and analyzed by AFM for the 
presence of CD41-positive MPs. The between-assay variation for MP isolation and 
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AFM measurement (including mica modification) was 16% (mean 528 x 109 CD41-
positive MPs/L; standard deviation 83 x 109 CD41-positive MPs/L). 
 
To investigate the effect of freezing and thawing on the number and size 
distribution of CD41-positive MPs measured by AFM, MPs were isolated from PPP 
of three donors before and after freezing-thawing. For two donors, there was no 
significant difference in size distribution of the CD41-positive MPs before and after 
freezing-thawing, although the number of CD41-positive MPs decreased (two-fold 
and seven-fold, respectively) after freezing-thawing. For one donor, we found a 
two-fold increase in number and a slight shift in the effective diameter (dsph) of the 
CD41-positive MPs in MPs isolated after freezing and thawing of the PPP (from 50-
250 nm to 10-200 nm). 
 
 
Figure 3. Atomic force microscopy (AFM) detection of CD41-positive microparticles (MPs) isolated from 
fresh platelet-poor plasma. (A) Size distribution (dsph) and counts of MPs per 100 µm
2 surface area and 
(B) relationship between the MP concentration in the sample and the number of CD41-positive MPs 






The CD41-positive MPs were quantified by flow cytometry, using a known 
concentration of counting beads as external standard in the measurement. The 
singlet population of these beads could be detected as shown in the forward 
scatter plot of Figure 4A. By counting the number of beads, the volume used for the 
measurement could be calculated. The mean volume analyzed by flow cytometry 
was 80 ± 4 µL. 
 
MPs were characterized by their CD41 expression (Figure 4B, C). The number of 
CD41-positiveMPs was calculated after correction for the number of MPs staining 
with the IgG1 isotype (negative control). The reproducibility of MP measurement 
with flow cytometry was assessed on three consecutive days by one single 
operator performing the CD41-positive MP measurement in triplicate. For these 
experiments, MPs were isolated from aliquots of frozen PPP. The variation in the 
number of CD41-positive MPs was 10% (mean 389 x 106 MPs/L; SD 41 x 106 
MPs/L). 
 
The effect of freezing and thawing on the number of CD41-positive MPs measured 
by flow cytometry was also assessed. Flow cytometric analysis of MPs isolated 
from PPP of four donors before and after thawing revealed that, depending on the 
donor, two-fold to 10-fold more CD41-positive MPs were detected in the MP 





Figure 4. Flow cytometry plots representing the measurement of the absolute count beads (A), the 
detection of CD41-positive microparticles (B), and IgG1 isotype control (C). PE, phycoerythrin.
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AFM vs. flow cytometry 
 
AFM seems to be able to detect nanosized MPs (Figs 2 and 3). To confirm this, 
isolated MPs were passed through a 0.22-µm filter (Puradisc 30; Whatman 
Nederland BV., ‘s-hertogenbosch, the Netherlands). Subsequently, the MPs 
isolated from the filtrate were used for AFM and flow cytometry measurements. 
Figure 5 shows that AFM could still detect CD41-positive MPs in the filtrate, with 
sizes ranging from 10 to 120 nm (mean dsph 37.2 ± 11.6 nm), whereas flow 




Figure 5. Analysis of isolated microparticles (MPs) after filtration through a 0.22-µm filter by atomic force 
microscopy (AFM) (A, B) and by flow cytometry (C-E). AFM still detects CD41-positive MPs (A), 
whereas MPs are hardly found on IgG1-coated mica (B). Flow cytometry fails to detect CD41-positive 
MPs with sizes below 0.22 µm (D). Controls were Hepes buffer only (C) and MPs labeled with IgG1 
isotype control (E). PE, phycoerythrin. 
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MPs were isolated from fresh PPP of seven donors (MPs 1-7). From one donor, 
PPP for MP isolation was obtained on three different days (MPs 1a, 1b and 1c). All 
nine MP preparations were analyzed simultaneously by AFM and flow cytometry 
for numbers and size distribution of CD41-positive MPs (Table 1). 
 
Depending on the MP preparation, four to 10 images of 100 µm2 were scanned. 
About 255 CD41-positive MPs were detected by AFM per 100 µm2 of anti-CD41-
coated mica surface, whereas about 48 MPs per 100 µm2 attached non-specifically 
to IgG1 isotype control-coated mica. We found that the number of CD41-positive 
MPs detected by AFM (3-702 x 109 L/PPP) was about 1,000-fold higher than the 
number of CD41-positive MPs detected by flow cytometry (11-291 x 106/L PPP). In 
all seven donors, the size of the CD41-positive MPs calculated from AFM images 
ranged from 10 to 475 nm (mean dsph 67.5 ± 26.5 nm). On the IgG1 isotype control-
coated mica, particles were found ranging in size from 10 to 200 nm, with the 
majority of MPs having a dsph of 53.8 ± 13.4 nm. The diameters of particles 
detected on anti-CD41 antibody-coated mica and on IgG1 isotype control coated 
mica were not significantly different (P = 0.07). 
 
The interindividual variation in the number of CD41-positive MPs was quite high: 
75% for AFM measurements, and 86% for flow cytometry measurements (n = 
7).There was only a weak correlation between the numbers of CD41-positive MPs 
detected with AFM and with flow cytometry (r = 0.17, P > 0.05). 
 
MPs isolated from the blood of three cancer patients were used to measure the 
number of CD41-positive MPs simultaneously by AFM and flow cytometry (Table 
1). MPs were isolated from fresh plasma and analyzed by AFM in three different 
dilutions, both on CD41-coated mica and on IgG1-coated mica. For all three 
patients, the number of CD41-positive MPs per 100 µm2 was linearly related to the 
concentration of MPs (R2 > 0.95). AFM detected 83-333 x 109 CD41-positive 
MPs/L PPP, whereas flow cytometry detected 98-626 x 106 CD41-positive MPs/L 





In this study, we report a method for the detection of CD41-positive MPs with 
AFM.We found that the number of CD41-positive MPs detected by AFM was about 
1,000-fold higher than the number detected by flow cytometry. Mica modification, 
and detection of CD41-positive MPs on anti-CD41-coated mica with AFM, resulted 
in reproducible numbers of CD41-positive MPs (coefficient of variation = 16%). 





The high interindividual variation in the number of CD41-positive MPs isolated 
fromfresh PPP (75% for AFM and 86% for flow cytometry) mainly reflects biological 
variation. 
 
Immobilization of mouse anti-human CD41 antibody and of mouse IgG1 isotype as 
a control on modified mica was successful. There was a linear relationship 
between the MP concentration in the sample and the number of CD41-positive 
MPs detected by AFM up to about 500 CD41-positive MPs per 100 µm2. Binding of 
MPs to anti-CD41-coated mica seemed to be specific, as we found many fewer 
MPs bound to IgG1 isotype control-coated mica (see Table 1). The particles bound 
to IgG1 isotype control-coated mica had a similar size. We do not know what these 
objects were. Theoretically, they could be non-specifically bound MPs, (aggregates 
of) plasma proteins still present in the MP preparation, or even contaminants from 
the environment. However, the last of these is not likely, because buffer controls 
were negative (Figure 1C, D). 
 
Guidelines have currently been developed to standardize CD41-positive MP 
counting by FACS [14]. We have compared the results obtained with our settings 
on the FACS Calibur with those obtained with an LSRII calibrated following the 
SSC guidelines. No significant difference in the number of CD41-positive MPs was 
obtained with the two methods (our setting = 105 x 106 CD41-positive MPs/L PPP 
vs. SSC proposed setting = 109 x 106 CD41-positive MPs/L PPP).  
 
Filtration of isolated MPs through a 0.22-µm filter confirmed that AFM detects 
nanosized CD41-positive MPs (mean dsph 37.2 ± 11.6 nm), whereas flow cytometry 
does not. This is not due to the flow cytometry settings used, as CD41-positive 
MPs were detected in the non-filtered MP preparations tested (see Table 1 and 
Figure 4). 
 
Our results showed that AFM detected 1000-fold higher numbers of CD41-positive 
MPs than flow cytometry did in all MP preparations. Furthermore, the number of 
CD41-positive MPs detected by AFM correlated only weakly with those detected by 
flow cytometry (r = 0.17, P > 0.05). A similar observation by Zwicker (19) showed 
that the number of tissue factor-bearing MPs measured by light scatter flow 
cytometry was 10,000-fold less than what was observed with the use of an 
impedance-based flow cytometer. Apparently, conventional flow cytometry is not 
suitable for the detection of nanosized MPs. 
 
The diameter of CD41-positiveMPs isolated from fresh PPP ranged from 10 to 475 
nm, with the majority clustering at an effective diameter, dsph, of 67.5 ± 26.5 nm. 
Atomic force microscopy: a novel approach 
 65 
The height of MPs bound to mica (z = 17.4 ± 8.6 nm) was approximately 10-fold 
smaller than their edge-to-edge diameter, dflat, indicating that these MPs were flat, 
which may be related to the process of binding to the antibody-coated mica 
surface. Interestingly, Harrison et al. (20) recently reported, in an abstract, similar 
numbers (~200-260 x 109/L) and size distributions (< 50 to> 300 nm) of MPs in 
plasma, determined with the dynamic light scattering Nanosight LM10 system. 
 
Siedlecki et al. (21) reported that PMPs generated from thrombin-stimulated 
platelets deposited on glass and measured by AFM had an edge-to-edge diameter 
of 125 ± 22 nm and a height of 4.1 ± 1.6 nm. We also generated PMPs by 
stimulating isolated platelets with thrombin. Similar to Siedlecki’s results, AFM 
analysis showed that these contained CD41-positive MPs with an edge-to-edge 
diameter of 125.3 ± 11.7 nm and a height of 4.3 ± 1.9 nm. The effective diameter 
of these MPs was 44.1 ± 13.7 nm (range 4-189 nm), corresponding to the effective 
diameter observed for CD41-positive MPs from fresh PPP. 
 
There is no generally accepted protocol for the isolation of MPs from plasma (12). 
In this study, fresh PPP was used for isolation of MPs to overcome artefacts of the 
freeze-thawing procedure (11). We observed that, after freezing and thawing, a 
decrease in the number of CD41-positive MPs was found by AFM, whereas an 
increase in the number of MPs was found by flow cytometry. We do not have a 
satisfactory explanation for this observation, and further investigations will be 
needed. 
 
Recently, the question has been raised (22) of whether MP preparations might 
contain exosomes, which are secreted microvesicles formerly present in large 
multivesicular endosomes. Exosomes have diameters ranging from 30 to 90 nm 
(23), whereas the effective diameters of the CD41-positive MPs detected by AFM 
ranged from 10 to 475 nm. Further experiments, which are beyond the scope of the 
present study, using exosome-specific antibodies such as anti-CD63 and anti-
CD81 (23,24), and density-gradient differential ultracentrifugation, are needed to 
investigate whether a proportion of the MPs isolated from PPP consists of 
exosomes. 
 
In the present study, we demonstrated that AFM is a suitable method for the 
sensitive and reproducible detection of CD41-positive MPs, and that their plasma 
concentration is 1,000-fold higher than measured by conventional flow cytometry. 
The present AFM method has also its disadvantages, particularly in dealing with 
large cohorts of plasma samples, as the procedure from blood withdrawal until the 
AFM measurement and analysis is labour-intensive. Therefore, we are working on 
modifications that will allow the detection of specific populations of MPs directly in 
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TF associated with cell-derived vesicles (MPs) in blood has been shown to be 
involved in (cardio) vascular disorders, inflammation, and cancer. However, such 
studies have been hampered by the lack of methods for the sensitive detection and 
accurate quantification of MPs. In a previous study, our group demonstrated that 
atomic force microscopy (AFM) can be used to sensitively detect and accurately 
quantify a specific subset of MPs.  
 
In the current study, we investigated whether TF-bearing MPs could be captured 
on mica coated with anti-TF antibody and sensitively be detected by AFM operated 
in fluid tapping mode. MPs derived from the supernatant of MDA-MB231 cells 
stimulated with calcium ionophore were used as an experimental model. We 
showed that FITC-labelled anti-TF monoclonal antibody (MoAb) evenly coated the 
surface of modified mica. This coated surface captured TF-positive MPs which 
have diameters (dsph) ranging from 6-296 nm (median: 40.4 nm; mean: 46.4 ± 26.0 
nm). These MPs were virtually absent on the mica surface coated with FITC-
labelled mouse IgG1 isotype control MoAb. Numbers of TF-positive MPs were 
2,000-fold higher than those measured by flow cytometry (8 x 106 per µL 
supernatant vs. 4 x 103 per µL supernatant). 
 
In conclusion, AFM provides a sensitive detection of TF-positive MPs. We propose 




       




The role of tissue factor (TF) as the major player in initiation of blood coagulation 
has been known for more than 100 years (1). TF is a 47 kDa transmembrane 
glycoprotein consisting of 263 amino acids: 219 amino acids on the extracellular 
domain, 23 amino acids on the transmembrane domain, and 21 amino acids on the 
cytoplasmic tail.  
 
TF is normally not expressed by cells within the vasculature; rather, it is found 
predominantly in the adventitial and much less within the medial layers around 
blood vessels (2). Later, fibroblasts, adipocytes (3) and pericytes (4) were also 
shown to constitutively express TF. Smooth muscle cells, endothelial cells, and 
peripheral blood mononuclear cells (e.g. monocytes, neutrophils) do not express 
TF constitutively, but TF expression can be induced in these cells in vitro and in 
vivo by various agonists (5;6). Most of the TF antigen in plasma is encrypted and 
not biologically active (7;8). In 1999 Giessen et al (9) demonstrated the presence of 
TF antigen and activity on monocytes, neutrophils, and cell-derived vesicles (also 
named ‘blood-borne TF’) in blood and plasma of healthy volunteers.  In the mouse 
model TF-bearing vesicles have been shown to bind to the developing thrombus 
and play a role in the propagation of the fibrin clot (10;11). These vesicles, later 
known as microparticles (MPs) based on their submicron diameter, express protein 
surface antigens from the parent cells from which they are derived (12;13). 
 
In recent years, blood MPs have increasingly received attention as potential 
biomarkers in the diagnosis and prognosis of disease (12-14). However, such 
studies have been hampered by the lack of methods for the sensitive detection and 
accurate quantification of MPs and also by variations in pre-analytical conditions 
related to plasma and MPs preparation (15;16).  
 
New methods to provide sensitive detection of MPs have been proposed (17). By 
using an impedance-based flow cytometer, Zwicker et al (18) characterized TF-
bearing MPs in plasma of cancer patients. Harrison et al (19) used a nanoparticle 
tracking analysis to measure MPs size distribution and quantify MPs in isolated 
MPs fraction and platelet-poor plasma (PPP). Our group (20) has chosen atomic 
force microscopy (AFM) operated in fluid tapping mode to analyse a defined subset 
of MPs (platelet MPs) in the MPs isolated from PPP. We demonstrated that AFM 
detects 1,000-fold more CD41-positive MPs than conventional flow cytometry, a 
commonly used method for MPs detection, and that the size of the majority of 
these MPs (mean dsph: 67.5 ± 26.5 nm) is well below the detection limit of 




In the current study, we investigated whether TF-bearing MPs could be captured 
on mica coated with anti-TF antibody and detected by AFM operated in fluid 
tapping mode. The number of TF-bearing MPs in plasma of healthy subject is low 
(18;21). Therefore, as an experimental model we used TF-bearing MPs isolated 
from the supernatant of cultured breast carcinoma cells (MDA-MB-231), which 
constitutively express TF, and were stimulated with calcium ionophore. 
 
Assuming a spherical shape of unbound MPs, we found that the calculated 
diameter (dsph) of TF-positive MPs ranged from 6-296 nm (median: 40.4 nm; mean: 
46.4 ± 26.0 nm) in the supernatant of MDA-MB231 cells stimulated with calcium 
ionophore. These MPs were barely found attached on IgG1 isotype control-coated 
mica. We propose AFM as a suitable method for the detection and analysis of TF-
positive MPs.  
 




Breast carcinoma cell line, MDA-MB-231, was cultured in DMEM (Invitrogen, 
Breda, The Netherlands) with 10% fetal bovine serum (Invitrogen), 1% L-glutamine 
(Lonza, Cologne, Germany) and 1% Penicillin/Streptomycin (Invitrogen) at 37ºC in 
an incubator with humidified atmosphere under 5% CO2. Cells at 80% confluence 
were subcultured twice a week. 
 
Generation and isolation of microparticles 
 
Cells grown at 80% confluence in a T75 flask (Greiner Bio One, Alphen a/d Rijn, 
The Netherlands) were used for the experiment. To stimulate cells with calcium 
ionophore (A23187, VWR International, Amsterdam, The Netherlands), the culture 
medium was removed from the cells and cells were washed twice with Hank's 
buffered salt solution (HBSS) without CaCl2 (Sigma-Aldrich Chemie, Zwijndrecht, 
The Netherlands). Next, 10 mL of Dulbecco's modified eagle medium (DMEM) 
containing 10 µM calcium ionophore was added to the cells. Cells were placed at 
37°C in the incubator for 30 minutes.  
 
After stimulation, the culture medium was collected and centrifuged for 20 minutes 
at 2,000g, at room temperature (RT) without brake to remove dead cells and 
debris. The supernatant was collected, aliquoted in 1 mL-portions and centrifuged 
for 30 minutes at 18,890g at RT with minimum brake. The supernatant was 
discarded except for the 25 µL containing the MPs pellet. The MPs pellets isolated 
from 3 mL supernatant were pooled, resuspended in 1 mL Hepes buffer [10 mM 
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Hepes (Merck, Darmstad, Germany), 137 mM NaCl (Merck), 4 mM KCl (Merck), 
0.1 mM Pefabloc SC (Fluka, Munich, Germany), pH 7.4], and centrifuged for 30 
minutes at 18,890g at RT with minimum brake. The supernatant was discarded 
except for the 25 µL containing the MPs pellet. These preparations were used 
immediately or snap-frozen in liquid nitrogen and stored at –80ºC. 
 
Flow cytometry analysis of TF-positive microparticles  
 
Flow cytometry analysis was performed using a FACS Calibur flow cytometer with 
CELLQUEST PRO software (Becton Dickinson, CA, USA). Five µL of MPs fraction 
was incubated with 5 µL of fluorescein (FITC)-labelled mouse anti-human TF 
monoclonal antibody (MoAb) (clone CLB/TF-5, Sanquin, Amsterdam, The 
Netherlands) and 5 µL of allophycocyanin (APC)-labelled annexin V (Caltag 
Laboratories,CA, USA) in 35 µL of Hepes buffer containing 2.5 mM CaCl2 (Sigma 
Aldrich) for 30 minutes, in the dark, at RT. Anti-human TF-FITC MoAb was 20 
times diluted, whereas annexin V-APC was 300 times diluted in the final mixture. 
As negative controls, FITC-labelled mouse IgG1 isotype control MoAb (clone X40, 
Becton Dickinson) was used at the same concentration as FITC-labelled anti-TF 
MoAb. As a control of annexin V staining, Hepes buffer without CaCl2 was used.  
 
Before flow cytometry measurement, the labelled MPs were diluted with 300 µL of 
Hepes-citrate buffer. For counting absolute numbers of MPs per µL supernatant, 
200 µL of flow cytometry absolute count standard beads (Bang Laboratories, IN, 
USA) was mixed with Hepes buffer to a volume of 600 µL and then measured in 
triplicate. For measurement of counting beads as well as MPs, the flow cytometer 
was programmed to count events in 1 minute. 
 
Modification of mica for immobilization of mouse anti-human TF antibody 
 
The surface of mica was modified as described by Yuana et al (20). Fifty µL of 
FITC-labelled mouse anti-human TF MoAb (clone CLB/TF-5, Sanquin) (0.1 mg/mL) 
was applied onto the modified mica and incubated for 30 minutes at RT. Excess of 
FITC-labelled anti-human TF MoAb was removed by washing with Hepes buffer. 
As a negative control, FITC-labelled mouse IgG1 isotype control MoAb (clone X40, 
Becton Dickinson) was used at the same concentration of 0.1 mg/mL. 
 
AFM analysis of TF-positive microparticles 
 
Frozen MPs isolated from the supernatant of MDA-MB231 cells stimulated with 
calcium ionophore were quickly thawed at 37ºC, diluted 2 times with Hepes buffer, 
and used immediately for AFM measurement. Twenty µL of the MPs fraction was 
Chapter 4 
 74 
applied to the FITC labelled-anti-human TF and IgG1 isotype control-coated mica 
surfaces and incubated for 30 minutes. To remove unbound MPs, the mica was 
washed twice with Hepes buffer. During the incubation step and before imaging, 
the mica surface was kept in a closed container. AFM imaging, image analysis, and 
calculation of diameter of MPs were performed as described by Yuana et al (20). 
For each sample, the mica surface was scanned at different positions to obtain 10 
images with a scan size of 100 µm2.  
 




Using flow cytometry we compared the number of MPs and the expression of TF 
and annexin V on MPs in fresh and frozen-thawed MPs fractions isolated from the 
supernatant of MDA-MB231 stimulated with calcium ionophore. MPs detected in 
fresh and frozen-thawed fractions expressed both TF and annexin V (Table 1). We 
observed about a 2-fold decrease in the total number of MPs, TF-positive MPs, and 
annexin V-positive MPs after one freeze-thaw cycle. In contrast to what is observed 
in plasma, depending on the centrifugation speed used for plasma isolation, some 
groups observed an increase in the number of platelet MPs and annexin V-positive 
MPs caused by freezing and thawing the plasma (22-24).  
 
Table 1. Flow cytometry analysis of MPs from fresh and frozen-thawed MP fractions isolated from 
supernatant of MDA-MB231 cells stimulated with calcium ionophore. 
    
Fresh Frozen-thawed 






Total MPs 1,1725  7,479  
TF-positive MPs 10,293 88 4,076 55 
Annexin V-positive MPs 8,794 75 3,416 46 
TF and annexin V-positive 
MPs 
5,870 50 3,248 43 
 
In fresh and frozen-thawed MPs fractions, flow cyotmetry measured the total number of MPs, TF and 
annexin V-positive MPs per µL supernatant of MDA-MB231 cells after stimulation with 10 µM calcium 
ionophore for 30 minutes and also the percentage of TF- and annexin V-positive MPs. Experiments 
were performed in duplicate. 
 




Before antibody was immobilized to the modified mica surface, we first scanned the 
surfaces of the cleaved mica and the modified mica by AFM. The surface 
topography of cleaved mica was flat (height (z): ~0.1 nm) and after modification, 
the mica surface was still flat, with an apparent height of less than 0.5 nm (Figure 
1A).  
     
Immobilization of the anti-human TF MoAb on the modified mica surface should be 
optimal and evenly distributed over the surface. In our previous study (20), we 
found that for immobilizing the anti-human CD41 MoAb a concentration of 0.01 
mg/mL was needed for the optimal capture of CD41-positive MPs on the mica 
surface (100 µm2). Therefore, we tested different concentrations of unlabelled 
mouse anti-human TF MoAb (clone CLB/TF-5, Sanquin), 0.01, 0.02, 0.1, and 0.2 
mg/mL, to coat the modified mica surface. It appeared that at 0.01 and 0.02 mg/mL 
anti-human TF the antibody did not distribute homogenously on the mica surface 
(100 µm2). There were also small protein aggregates found and the number of 
these aggregates increased with increasing concentration of anti-TF (0.1 and 0.2 
mg/mL) used. Apparently this particular anti TF was not suitable for the production 
of homogeneously coated mica surfaces.   
 
Subsequently we compared the unlabelled anti-human TF MoAb with the FITC-
labelled anti-human TF MoAb from the same manufacturer. Similar to our previous 
observation, unlabelled anti-human TF MoAb (0.1 mg/mL) formed aggregates on 
the mica surface (Figure 1B). The surface topography of aggregates was 20 nm 
(Figure 1B, z1), whereas that of a single molecule of anti-TF was 5 nm (Figure 1B, 
z2). In contrast, FITC-labelled anti-human TF MoAb (0.1 mg/mL) coated the mica 
surface evenly without any aggregates and has an apparent height of 4.9 nm 
(Figure 1C). As a negative control, FITC-labelled mouse IgG1 isotype control MoAb 
(0.1 mg/mL) was immobilized on the modified mica (Figure 1D, z= 1 nm). Possibly, 
the FITC molecules attached to the anti-TF IgG create a spacer between anti-TF 






Figure. 1. AFM images showing the three-dimensional surface topography of (A) modified mica, (B) 
unlabelled anti-TF MoAb-coated mica (0.1 mg/mL), (C) FITC-labelled anti-TF MoAb-coated mica (0.1 
mg/mL), and (D) FITC-labelled IgG1 isotype control MoAb-coated mica (0.1 mg/mL). Inserts show the 
results of the height analysis (z) of the surfaces. 
 
Atomic force microscopy detection of tissue factor- bearing microparticles 
 77 
After the mica surface was coated with FITC-labelled anti-human TF MoAb, frozen-
thawed MPs were applied. FACS analysis showed that about 50% of the MPs in 
the frozen-thawed fraction still express TF (Table 1). As expected, three-
dimensional AFM topography also showed that there were MPs captured on the 
mica surface coated with FITC-labelled anti-human TF MoAb (Figure 2A), whereas 
these were virtually absent on the mica surface coated with FITC-labelled mouse 




Figure 2. Three-dimensional AFM topography of MPs bound to (A) FITC-labelled anti-TF coated mica 
and (B) FITC-labelled isotype control (IgG1)-coated mica. The scale bar in these images is 1 µm. 
 
The size of the TF-positive MPs calculated from the AFM images ranged from 6 to 
296 nm (median dsph:  40.4 nm; mean dsph: 46.4 ± 26.0 nm) (Figure 3). About 113 
TF-positive MPs were detected by AFM per 100 µm2 of FITC-labelled anti-TF-
coated mica surface, whereas about 11 MPs per 100 µm2 attached non-specifically 
to FITC-labelled IgG1 isotype control-coated mica (Figure 3). After correction for 
the number of MPs found on FITC-labelled-IgG1 control-coated mica, the total 
number of TF-positive MPs detected by AFM is 8 x 106 per µL supernatant. This 
number is 2,000-fold higher than the number of TF-positive MPs from the same 
MPs preparation detected by flow cytometry (4 x 103 per µL supernatant, Table 1). 
Interestingly, we previously reported that AFM detects 1,000-fold more CD41-




Figure 3. Size distribution (dsph) and counts of TF-positive MPs per 100 µm




The results of this study show that FITC-labelled mouse anti-human TF MoAb at a 
concentration of 0.1 mg/mL coated the modified mica surface homogenously. This 
coated surface could capture TF-positive MPs isolated from the supernatant of 
MDA-MB231 stimulated with calcium ionophore. AFM operated in fluid tapping 
mode sensitively detected MPs with sizes ranging from 6 to 296 nm (median dsph: 
40.4 nm; mean dsph 46.4 ± 26.0 nm). There were only about 11 MPs captured on 
the mica surface coated with FITC-labelled mouse IgG1 isotype control MoAb. 
Numbers of TF-positive MPs were 2,000-fold higher than those measured by flow 
cytometry (8 x 106 per µL supernatant vs. 4 x 103 per µL supernatant). In this study, 
we frozen-thawed MPs isolated from cell culture supernatant for the AFM 
measurement. However, when a precise quantification of the number of TF-positive 
MPs in the sample is needed, AFM measurement on freshly prepared samples is 
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Microparticles, also known as microvesicles, found in blood plasma, urine, and 
most other body fluids, may serve as valuable biomarkers of diseases such as 
cardiovascular diseases, systemic inflammatory disease, thrombosis, and cancer. 
Unfortunately, the detection and quantification of microparticles are hampered by 
the microscopic size of these particles and their relatively low abundance in blood 
plasma.  
 
The use of a combination of microfluidics and atomic force microscopy to detect 
microparticles in blood plasma circumvents both problems. In this study, capture of 
a specific subset of microparticles directly from blood plasma on antibody-coated 
mica surface is demonstrated. The described method excludes isolation and 
washing steps to prepare microparticles, improves the detection sensitivity, and 
yields the size distribution of the captured particles.  
 
The majority of the captured particles have a size ranging from 30 to 90 nm, which 
is in good agreement with prior results obtained with microparticles immediately 
isolated from fresh plasma. Furthermore, the qualitative shape of the size 
distribution of microparticles is shown not to be affected by high-speed 
centrifugation or the use of the microfluidic circuit, demonstrating the relative stable 
nature of microparticles ex vivo. 
 




Blood microparticles (MPs), also known as microvesicles, are small particles shed 
from the surface of many cells upon stimulation or apoptosis (1). For a long time 
they were considered as platelet dust (2), but now they have been recognized to 
participate in important biological processes (3). Examples of such processes are 
surface-membrane traffic and the horizontal transfer of protein and RNAs among 
neighboring cells, which are necessary for rapid phenotype adjustments in a variety 
of conditions (3). In addition, blood MPs have important physiological and 
pathological roles in blood coagulation, inflammation and tumor progression (4;5).  
 
Flow cytometry (FCM) and capture-based assays are commonly used methods to 
measure the number of MPs, define their origin based on membrane antigen 
expression, and asses their procoagulant features (6-8). However, these methods 
have their drawbacks. FCM employs laser light which excites at 488 nm, while MPs 
may have sizes far below this wavelength (9). Yuana et al. (10) reported the 
presence of MPs bearing CD41 antigen in plasma with sizes ranging between 10-
475 nm using atomic force microscopy (AFM). They also found that the MP 
numbers detected by AFM are 1,000-fold higher than those detected by FCM. 
Although capture-based assays using annexin V or MP-specific antibodies allow 
high throughput assessment of procoagulant features of MPs (11-13), these assays 
give no information on the size and total number of MPs in plasma.  
 
Electron microscopy (EM) has been used for detection of MPs (14-16), but this 
method only provides semi-quantitative information on MPs. Furthermore, sample 
dehydration and vacuum procedures required in EM might affect the characteristics 
of MPs. Recently, a promising method, nanoparticle tracking analysis (NTA), has 
been applied to count MPs in plasma (17). This method uses a CCD camera 
system that allows simultaneous tracking of multiple particles. In the future NTA 
may be able to detect, count, and size antibody-labeled MPs efficiently, thus 
allowing the detection of subsets of MPs. 
 
Not only is the analytical measurement of MPs a challenge, but also there is no 
golden standard yet to prepare MPs (18). Many studies have isolated MPs from 
platelet free or platelet poor plasma by applying high speed centrifugation or even 
ultracentrifugation (19;20). To prevent loss and phenotypic changes of MPs during 
the isolation procedure, using blood plasma directly for MP measurement would be 
preferable (21). Furthermore, the time between blood withdrawal and the actual MP 
test should be as short as possible to avoid activation of cells and coagulation 




We propose a method to detect MPs directly in blood plasma by using a 
microfluidic flow cell and performing subsequent analysis using AFM in liquid-
tapping mode. Laminar flow patterns within the flow cell ensure complete fluid 
turnover in a controlled manner. The flow cell allows experimentation with very 
small sample volumes. In this study, a detachable flow cell was developed to 
enable direct contact between the fluid in the microfluidic channel and the surface. 
Diluted plasma was flown through the microfluidic channel with a controlled 
pressure driven laminar flow and made to be directly in contact with anti-CD41 
antibody-coated mica. MPs exposing CD41 antigen were captured on this surface 
and subsequently imaged by AFM. We employed the AFM method for MP 
detection previously used in the study of Yuana et al. (10).  
 
Clotting of the plasma and clogging of the microfluidic channel pose a potential 
problem within such small volumes and with such a sensitive detection method as 
AFM.  These problems have been solved by diluting plasma with either citrate or 
EDTA-enriched Hepes buffer and coating the microfluidics channels and the tubing 
of the microfluidics system. We demonstrated that this method increases the 
sensitivity of detecting specific MPs in a sample 100 to 1,000-fold. In conclusion, 
the application of a flow cell allows the AFM measurement of a specific subset of 
MPs directly in blood plasma.  
 
Materials and Methods  
 
Blood collection and plasma preparation 
 
After giving their informed consent, venous blood of three healthy volunteers is 
collected by using a 21-gauge needle (BD Vacutainer, San Jose, CA) with minimal 
stasis. Except for the first four ml, the blood is collected either in 1/10 volume of 
sodium citrate (3.2%, 0.105 M) or in K2 EDTA (3.6 mg) using 4.5 mL BD Vacutainer 
tubes (Becton Dickinson, San Jose, CA). Within 10-15 minutes after withdrawal, 
the collected blood is centrifuged at 2,000g for 10 minutes at 20°C, without brake. 
The supernatant plasma is carefully collected and centrifuged again at 2,000g for 
10 minutes, 20°C, without brake, to obtain platelet  poor plasma (PPP). PPP was 
aliquotted in 250 µL portions, snap frozen in liquid N2, and stored at -80°C until 
used. Before used, PPP is quickly frozen-thawed at 37°C. Unless stated otherwise 




For MP isolation, 750 µL of frozen-thawed citrate PPP is centrifuged at 18,890g 
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and 20°C for 30 minutes, with minimum brake. The su pernatant is removed 
carefully, except for 25 µL containing the MP pellet. This pellet is resuspended in 1 
mL of Hepes buffer [10 mM Hepes (Merck, Darmstad, Germany), 137 mM NaCl 
(Merck), 4 mM KCl (Merck), 0.1 mM Pefabloc SC (Fluka, Munich, Germany), pH 
7.4], vortexed, and centrifuged as before. The supernatant is removed, leaving a 
volume of 25 µL containing the MP pellet. Subsequently, this 25 µL is carefully 
diluted with 725 µL of Hepes buffer to reconstitute to the original plasma volume 
(750 µL)   before use in the experiment.  
 
Flow cell: mold fabrication 
 
A flow cell mold is fabricated from brass. This brass is milled so that ridges with 
dimensions of 10 mm x 300 µm x 100 µm are created that shape the liquid 
channels during polymerization. The top surface of the ridges is polished to allow 
viewing through the channel from bottom to top after molding. At the end of the 
ridges, small holes are drilled and small pins are inserted with a diameter of 1 mm 
and a height of about 1 mm. 
 
Flow cell: fabrication 
 
Polydimethylsiloxane (PDMS) flow cells are fabricated using a Sylgard 184 kit 
(Dow Corning, UK). Silicone primer and catalyst are mixed in a 10:1 ratio by weight 
and this mixture is placed in a vacuum chamber for 1 hour to remove air bubbles 
trapped during mixing. Next, the mixture is slowly poured into the mold and then 
the mold is carefully closed with a glass plate. The mold containing the polymer 
solution is placed in an oven at 70°C for 1 hour. Afterwards, the glass slide with the 
PDMS flow cell is released from the mold and covered with a clean glass slide to 
keep the chip channel area dust-free. The polymerized flow cell is shown in Figure 
1A. 
 
Flow cell: setup 
 
The complete microfluidic setup is shown in Figure 1B. To prepare the flow cell 
setup, a mica surface (1) is placed on a metal support disc (2). The metal support 
disc is placed onto the bottom plate of the holder device (4), in a small cavity that 
closely fits the metal disc. The PDMS flow cell (3) is placed onto the top plate with 
the open microfluidic channels facing down. Two pins, situated in the holder top 
plate (5) align the flow cell (see the two holes next to the channels in Figure 1A) 
with respect to the mica surface and the holes for the glass capillaries (7) (TSP 
Fused Silica Tubing, ID/OD 150/375 micrometer, deactivated with DPTMDS, from 
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BGB Analytik Vertrieb, Germany). Then the top and bottom plate are pressed onto 
each other with four screws (6). Using microscopic inspection the screw pressure is 
carefully adjusted. The glass capillary tubes are beveled to 45 degrees before use, 
using a mechanical grinder (Michael Deckel S0) with a disc containing diamond 
dust. After careful rinsing with water, to remove remaining grinding dust, the glass 
capillary tubes are gently forced into the PDMS flow cell, and guided through 




Figure 1. Flow cell setup 
(A) Open PDMS flow cell. (B) Microfluidic flow cell setup with schematic side view. The holder system 
(4,5,6) is used to press the PDMS chip (3) onto the mica surface (1). The glass capillary tubes (7) are 
guided through holes in the holder top plate (5) to reach the connection chambers in the chip (3). The 
metal disc (2) is used as a support for the mica surface. In the photo (C), the middle channel is 
connected and filled with a dark blue solution; the glass capillary tubes are bent towards the side using 
scotch tape. The blue solution and scotch tape are for illustration purposes and are not used in 
experiments. 
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Mica Surface preparation for attachment of anti-human CD41 monoclonal 
antibody 
 
The surface of mica (Electron Microscopy Sciences, Washington) for MP 
attachment is prepared as described before (10) with a slight modification.  Freshly 
cleaved mica disks (diameter 12 mm) are overnight immersed in DMSO containing 
55% (w/v) ethanolamine at 70°C. Subsequently, the m ica surfaces are rinsed twice 
with dry DMSO at 70°C and then with HPLC grade ethanol to remove the DMSO. 
Next, the mica surfaces are put for 10 minutes into 30 mL phosphate buffered 
potassium (PBK) (10.2 g KCl, 0.97 g K2H2PO4 and 5.71 g K2HPO4 per L) (pH 7.4) 
previously saturated with EGTA by adding 100 mg EGTA. The surfaces are then 
rinsed with Hepes buffer, before 20 µL of 0.05 mg/mL (in Hepes buffer) mouse anti-
human CD41 antibody clone P2 (Beckman Coulter, Fullerton, CA) is applied to the 
surface and incubated for 3 hours. Excess anti-CD41 is removed by washing with 
Hepes buffer. Anti-CD41 antibody coated-mica surfaces are stored in Hepes buffer 
until used. As a negative control, mouse IgG1 pure clone X40 (Becton Dickinson, 
San Jose, CA) is used (0.05 mg/mL in Hepes buffer).  The IgG1 isotype control 
antibody is allowed to incubate for 3 hours on the functionalized mica surfaces. All 
chemicals are purchased from Sigma Aldrich (Munich, Germany) unless otherwise 
indicated.   
 
Prior to the attachment of MPs antibody-coated mica surfaces were inspected by 
using AFM to ensure that the number of false spots and holes in the antibody 
coating was minimized. 
 
Attachment of microparticles without using microfluidics 
 
PPP (100 µL EDTA plasma) is dropped onto the mica surface coated with IgG1 
isotype control and anti-CD41 antibody (“drop method”). To check the saturation of 
MPs on the anti-CD41-coated surface, PPP is incubated on the surfaces for 2, 30, 
and 60 minutes. Similar to what was found by Yuana et al (10), 30 minutes 
incubation seemed to be sufficient. On anti-IgG1-coated surface PPP was 
incubated for 60 minutes to match the long exposure time on the anti-CD41 
surface. The surfaces are carefully rinsed with Hepes buffer and then scanned by 
AFM to determine the number of MPs captured on CD41- and IgG1 isotype control- 
coated mica surfaces. 
 
Attachment of microparticles using microfluidic flow cell 
 
The open microfluidic flow cell (PDMS) is attached to a mica surface as described 
above. A 1 mL-syringe (Becton Dickinson, San Jose, CA, USA) is connected to a 
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Harvard Apparatus PicoPlus (Harvard apparatus, Holliston, MA, USA) syringe 
pump and set at a constant flow speed of 0.01 mL/minute. The syringe is 
connected to the glass capillary tubes using Luer-Lock Adapters and One-Piece 
Fittings from LabSmith (Livermore, CA, USA). The glass capillary tubes are gently 
forced into the microfluidic chip using the beveled end. 
 
The channels of the flow cell are rinsed with 50 µl EGTA-enriched Hepes buffer (5 
mM EGTA, 10 mM Hepes, 137 mM NaCl, 4 mM KCl, 0.1 mM Pefabloc® SC, pH 
7.4) buffer for about 5 minutes. Hundred fifty µL of either EDTA plasma diluted with 
EDTA-enriched Hepes buffer (20 mM EDTA (Sigma Aldrich), 10mM Hepes, 137 
mM NaCl, 4 mM KCl, 0.1 mM Pefabloc® SC, pH 7.4) or isolated MPs diluted with 
Hepes buffer is allowed to flow through the channel in the flow cell for about 15 
minutes total flow time. The channel is then rinsed with 50 µL Hepes buffer (~5 
minutes flow time). Before removal from the flow cell, the back of the mica is 
carefully marked to indicate the location of the channel in the AFM. Subsequently, 
the flow cell is removed and the coated surface with the attached MPs is rinsed 
with Hepes buffer and stored in Hepes buffer until imaged by AFM. All steps are 




AFM imaging is performed with a Digital Instruments Multi-mode AFM (Veeco, New 
York, NY, USA) using the E scanner. Olympus cantilevers (Olympus, Tokyo, Japan) 
with force constant of 2 N/m and a resonant frequency of 70 kHz are used. The 
liquid cell tip holder (Veeco) is rinsed with ethanol and milli-Q water between each 
sample to prevent contamination. Each image was scanned at 10 x 10 µm and 10 
images are taken at a variety of locations on the surface. For each particle, the 
sum of pixel heights multiplied by the pixel area is used to estimate a volume and 




Generally, glass, polymer or similar materials are used with microfluidics. However, 
the AFM cantilever must have physical access to the top of the sample and AFM 
requires an atomically flat background to give the best image of the sample. Mica is 
preferred surface material because it has distinct atomically flat layers that can be 
easily separated for cleaning and functionalization. As PDMS binds strongly to 
mica, the mica surface can be pealed away when the PDMS is removed, ruining 
the sample. In our study, the mica surface is functionalized with antibodies to 
produce a hydrophilic mica surface that cannot bind to the PDMS flow cell. Anti 
human-CD41 antibody was used to coat the functionalized mica to capture platelet 
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MPs (PMPs) bearing CD41 surface antigen. PMPs constitute 80-95% of blood MPs 
detected by FCM (22;23). The IgG1 isotype control is used as a control for 
nonspecific binding of MPs on anti-CD41-coated surface. A schematic overview of 
the experiment is given in Figure 2. The microfluidic setup used in Figure 2B is 
constructed from a PDMS flowcell (Figure 1B), attached to the mica surface by a 
removable holder system (Figure 1B,C) so that the flow cell can be removed from 




Figure  2. Schematic overview of experiments 
Collected blood plasma is centrifuged twice to acquire PPP. In some experiments blood plasma proteins 
are removed by use of high-speed centrifugation (A). Using an antibody coated mica surface, a fresh 
PDMS chip and a holder system a microfluidic setup is build, and the PPP is run over a small surface 
area (B). Finally, mica surface is removed and imaged using AFM, followed by automated image 
analysis (C). 
 
Application of microfluidic system to count MPs in plasma 
 
With microfluidics many more MPs in the plasma sample will have a chance to 
interact with the antibody-coated mica surface by flowing an equal volume of 
plasma over a very small active surface area in the confined volume of the 
microfluidic channel. To examine this we applied the microfluidic system and 
compared it with the drop method to count MPs in plasma obtained from two 
healthy donors. For the microfluidic system two samples were prepared: the first 
sample consists of MPs isolated from citrate PPP, reconstituted to the original 
plasma volume, and subsequently diluted 5 times with Hepes buffer; the second 
sample is EDTA PPP diluted 5 times with EDTA-enriched Hepes buffer. For the 
drop method undiluted EDTA plasma is used.  
 
In all samples processed by the microfluidic system, the AFM detected MPs 
attached on anti-CD41-coated mica surface (Table 1). The attachment of these 
MPs was specific because there were at least two times less particles found 
attached on the IgG1-coated surface compared to those on the anti-CD41-coated 
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surface (Table 1). This also confirms that these MPs bear CD41 surface antigen 
(CD41-positive MPs). Using image quantification software we found in the samples 
processed by microfluidic system that there is no significant difference in the 
number of MPs attached on anti-CD41-coated surface (218, 276, 203, and 240 
MPs/100 µm2). Strikingly, there were hardly any MPs captured on anti-CD41 
coated-surface by using the drop method, even after one hour incubation of plasma 
on the surface (3 MPs/100 µm2 anti-CD41-coated surface and 3 MPs/100 µm2 
IgG1-coated surface, Table 1). 
 
Table 1. Comparison of microfluidic method and drop method to count CD41-positive MPs.  
 
Number of particles attached 
on anti-CD41-coated mica 
Number of particles attached 
on IgG1 isotype control-
coated mica Samples  
Mean SEM Mean SEM 
Reconstituted isolated-MPs D1 218 51 82 22 
Reconstituted isolated-MPs D2 276 50 1.7 0.6 
EDTA plasma D1 203 80 70 19 
EDTA plasma D2 240 40 1.8 0.04 
EDTA plasma drop D1 0.15 0.09 2 0.55 
EDTA plasma drop D2 3 1.5 3 1.0 
 
For the microfluidic method MPs isolated from citrate PPP and diluted EDTA PPP of two healthy donors, 
D1 and D2, were used. Isolated MPs were reconstituted to the original plasma volume and 
subsequently five-fold diluted in Hepes buffer (Reconstituted isolated-MPs D1/D2). EDTA PPP was 
diluted five-fold with EDTA-enriched Hepes buffer (EDTA plasma D1/D2). For the drop method undiluted 
EDTA PPP from the same healthy donors was used (EDTA plasma drop D1/D2). 
 
It has been reported in the literature (24;25) that when EDTA is used as 
anticoagulant for blood collection, the CD41/CD61 complex on the plasma 
membrane of platelets may loose their affinity for anti-CD41 and CD61 antibodies. 
To check this we have used FCM to measure the binding of anti-CD61 and anti-
CD41 antibodies to platelet MPs in citrate- and EDTA-anticoagulated blood plasma. 
We found that the numbers of CD41/CD61-positive MPs in citrate and EDTA 
plasma are not significantly different (Figure 3). 
 
Despite the fact that macroscopic clotting could be prevented by diluting EDTA 
PPP with EDTA-enriched Hepes buffer, we noticed in preliminary experiments that 
there still was some clotting in the small confinements of the microfluidic channel. 




Figure 3. Comparison of CD41/CD61-positive MPs in citrate and EDTA plasma. 
EDTA and citrate PPP were isolated from blood of a healthy volunteer. EDTA and citrate PPP are 
assayed fresh, after storage for 2 hours at room temperature (RT), after frozen-thawed at 37°C, and 
after frozen-thawed at 37°C and stored for 2 hours at RT. These PPP samples were directly stained by 
using PE-labeled anti-CD41 and FITC-labeled anti-CD61. The number of CD61/CD41-positive MPs was 
measured by FCM. All experiments were performed in duplicate. 
 
In some studies it has been shown that unmodified PDMS is not compatible with 
some of the blood/plasma components and may initiate activation of the clotting 
system (26;27). Platelets adhere more strongly to the surface of unmodified PDMS 
than to the modified PDMS (28). Moreover, unmodified PDMS is hydrophobic and 
this might induce clotting when plasma is introduced in the microfluidic channel 
(29;30).  To prevent this clotting in the microfluidic channels, a solution of EGTA-
enriched Hepes buffer was flowed through the channel before application of the 
plasma. EGTA is also known as a strong chelator of calcium ions, but it is not 
known to the authors whether the EGTA also can physically be adsorbed on the 
PDMS, acting to prevent clotting on the surface of the channel, or if EGTA performs 
its anti-clotting action in some other way. 
 
Analysis of AFM images 
 
The AFM images provide a unique challenge for image processing. As images are 
generated by scanning line after line, each neighboring line scan can have a 
different offset, slope or parabolic background (Figure 4A,E). This background must 
be dealt with for the accurate determination of neighboring scan lines to calculate 
the heights and volumes of the MPs correctly. The most commonly used 
techniques involve performing linear regression on the fast scan line and then 
subtracting the background estimate from each line. This technique is frequently 
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foiled by small, high features on the surface, such as MPs. To overcome this 
difficulty, a special technique is developed in our lab. First, a standard linear 
regression subtraction is performed (Figure 4B,F). Second, Labview IMAQ is used 
to find all the particles (Figure 4C,G). Third, the regions containing the particles are 
then removed from the background subtraction input and the linear regression 
subtraction is performed again to provide a much flatter surface (Figure 4D,H). 
While this is a computationally expensive task, it provides the high precision 
background subtraction for the needed accurate determination of the particle 
volumes. 
 
Particle counting is performed by using the Labview IMAQ library to determine the 
location of the particles. The Imaq Count Objects 2 VI is first used to filter and 
obtain a list of possible particles. This software uses a threshold to make a binary 
image, and then uses the watershed method to count the particles. Particles that 
touch the boundaries will not be counted. Additionally, all holes within the particles 
are automatically filled. The lower limit of height, width, and breadth of the particles 
is set to separate them from the background. For counting, the particle must at 
least 3 nm high and occupies at least 3 pixels. The particle must be larger than 1 
pixel in width or breadth. By setting this limit constant selection rules can be 
applied throughout a large dataset of AFM images. 
 
As can be deduced from Figure 4 the height is smaller than the width in detected 
MP profiles, the MPs appear disc shaped after binding to the surface. Using the 
disc radius and height, the particle volume is estimated and converted into an 
effective diameter assuming that MP have a spherical shape in solution (10). This 
procedure ignores the effects of tip flattening. It seems that this does not have a 
major effect on the final calculated volume of the particles (results not shown), and 
only a small systematic error exists in the volume calculations from the tip 
broadening effect. The size distribution of the example image is shown in Figure 4I. 
 
Size distribution graphs are made to further analyze possible differences between 
MPs captured from diluted isolated MPs and from diluted EDTA plasma, to see if 
high-speed centrifugation has an effect on the particle size. No significant 
differences in the number and size distribution of CD41-positive MPs was observed 
before and after high-speed centrifugation (Table 2, Figure 5). As mentioned 
before, we do not need to concentrate particles using high-speed centrifugation; 
however the clotting probability is strongly reduced by removal of blood plasma 
proteins. Therefore we use purified MPs, reconstituted to the original volume for all 
further experiments. 
 




Figure 4. AFM image quantification  
Original AFM image, intensity represent height, see scale bar on the right side (A). This image is 
flattened using the standard linear regression background subtraction (B). White squares show all the 
particles that are found on the image from image A (C). The background is subtracted, corrected for the 
shadowed regions, and the particles are correctly sized (D). The bottom row (E,F,G,H) shows an 
enlarged region of (A,B,C,D) respectively, scale is 500 nm. The measured particles are indicated with 




Table 2. Statistics obtained from comparing distributions of isolated MPs against plasma MPs (see also 
Figure 5). 
 






Number of processed images 8 9 
Number of particles 1992 527 
Mean* 58 63 
Median* 52 50 
Standard deviation* 23 43 
Range* 223 367 
Min* 26 23 
Max* 249 390 





Figure 5. Distributions of the effective diameter of CD41-positive MPs. 
Black bars show the size distribution of particles captured from MPs isolated from frozen-thawed citrate 
PPP. Grey bars show sizes of particles captured from frozen-thawed EDTA PPP diluted five-fold with 
EDTA-enriched Hepes buffer. All counts are normalized so the sum of the probabilities is 1.  
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Relationship between MP concentration and number of MPs captured on anti-
CD41-coated surface 
 
Prior to measuring the concentration of MPs in a sample, the dynamic range 
should first be established. Therefore we used MPs isolated from frozen-thawed 
citrate PPP of a healthy volunteer. Isolated MPs are first reconstituted with Hepes 
buffer to reach the original plasma volume before isolation (100%) and 
subsequently diluted 2 to 40-fold. These diluted MP fractions are run through the 
microfluidics system to measure the number of captured CD41-positive MPs. 
Figure 6A shows that only at sufficiently low concentrations (<10%) there is a linear 
relationship between the MP concentration and the number of particles attached on 
the anti-CD41-coated surface. Probably because of unspecified binding in the 
microfluidics circuit the line does not cross the origin (0,0). At higher concentrations 
(>10%) the number of MPs captured to the anti-CD41-coated surface reaches a 
maximum of ~250 particles/100 µm2. This number of captured MPs is very similar 
to those reported in Table 1 for the reconstituted isolated MP fraction and EDTA 
plasma which are diluted 5 times before processing with the microfluidic system.  
 
The AFM images show that, typically, the particles are not uniformly distributed on 
the surface (Figure 4A). As a result, the standard error of the mean is quite large 
(Figure 6A). The linear range is rather small, and it may be difficult to find a suitable 
working range when samples differ as strongly in particle counts as mentioned 
before (10). Interestingly, it is found that the size distribution does not differ 
significantly between different images (Figure 6B), and different dilutions (Figure 
6C, Table 3) of the same sample, with the exception of the highest dilution. This 
sets microfluidic capture combined with AFM imaging as the first method able to 




We report on a novel method to identify and characterize a specific subset of MPs 
directly in plasma. To enable the measurement of MPs directly in plasma, we have 
developed a method that combines a microfluidic system and AFM detection. 
Microfluidic channels allow blood plasma to flow over a small surface of antibody 
coated mica, resulting in a high enough surface concentration of specifically bound 
MPs to detect and quantify using AFM. A much higher number of MPs is captured 
from (diluted) plasma on antibody-coated mica than without, using this microfluidic 
method (plasma drop system). Further optimization of the method is required for 






Figure 6. Relationship between the MP concentration in the sample and the number of CD41-positive 
MPs detected by AFM. 
MPs isolated from frozen-thawed citrate PPP are diluted from 50% to 2.5% (100% is undiluted 
reconstituted-isolated MPs) in Hepes buffer and run through the microfluidics device. These 
experiments were done on two different days using the same plasma pool of one healthy volunteer and 
the particles were counted from images of 100 µm2 (A). The size distribution from a single dilution 
(3.8%) is based on three images of 100 µm2 (B). A normalized size distribution of all dilutions averages 
is weighted equally (C). Scale bars represent the standard error of the mean.  
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Table 3. Statistics obtained from the dilution experiment of Figure 6A 
 
Percent Reconstituted MPs 2.6% 3.2% 3.8% 9.1% 29% 50% 80% 
Dilution 75 60 50 20 5 2 1 
Number of processed images 5 7 3 9 1 5 5 
Number of particles 98 339 196 1766 186 1270 373 
Mean* 30 49 46 54 50 45 51 
Median* 29 42 42 46 46 40 41 
Standard deviation* 12 27 15 28 20 17 34 
Range* 68 192 87 301 152 160 283 
Min* 8 26 27 26 26 25 23 
Max* 76 218 114 327 177 185 306 
*Values based on calculated particle diameter in nanometer 
 
For the first time it is demonstrated that the size distribution of CD41-positive MPs 
is robust against high-speed centrifugation and dilution. However, to prevent 
clotting to occur, the use of MPs isolated by means of high-speed centrifugation is 
advised. 
 
Yuana et al (10) have shown that MPs isolated from fresh citrate PPP have 
calculated, spherical like diameters (dsph) of ~50 nm (range 10-475 nm). Using 
microfluidics we found that MPs isolated from frozen-thawed citrate PPP and 
frozen-thawed EDTA PPP have a similar calculated diameter (dsph) of ~45 nm. 
Software has been developed to automate the measurement and counting of MPs. 
This results in much more consistent results and provides faster data analysis. By 
comparing the results from previous experiments by Yuana et al (10) to the new 
automated quantification of the same dataset we observed that the size distribution 
was similar to those reported earlier (data not shown). 
 
There are advantages and disadvantages in using the microfluidic system and AFM 
to measure MPs. In this study we found that about 10 µL of plasma is enough to 
count significant number of MPs and determine their size distribution. Furthermore, 
the microfluidic system allows the measurement of MPs directly in plasma thus 
reducing time between venepuncture and MP measurement and also preventing 
MP loss because of washing steps in the isolation procedure. However, the 
preparation of mica (modification and coating) typically takes two days. In 20% of 
all cases we also dealt with leakage from microfluidic channels during plasma 
injection. AFM scanning of the surface is also time-consuming. It takes at least an 
hour finding a right surface to position the AFM tip and scanning 10 images of 100 
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µm2 at different locations on the surface.   
 
Therefore, when this present method will be used as a diagnostic tool, the 
throughput needs to be increased by developing high speed AFM and automated 
sample handling. Additionally, if fluorescent labeling can be implemented efficiently, 
the number of particles captured should allow optical detection of these particles by 
means of fluorescence imaging. With the AFM technique being used for calibration, 
it should be possible to fluorescently tag the MPs to provide optical quantification of 




In this study, it is demonstrated that by using a removable microfluidic circuit, 
CD41-positive MPs can be captured directly from diluted blood plasma, and 
detected by AFM. Quantification of MPs is automated to allow consistent and fast 
quantification. Use of the microfluidic system increases the sensitivity of MP 
detection considerably, leading to a higher surface concentration of attached MPs, 
reducing the AFM scanning time. Direct use of plasma as opposed to isolated MPs 
shortens the pre-processing time and enables the detection of MPs in a more 
natural state. Ten µL EDTA plasma is sufficient to quantify the number and 
determine the size distribution and shape of CD41-positive MPs using microfluidics 
and AFM. 
 
In future experiments the characterization of MPs from other origins (endothelial 
cells, monocytes, tumor cells, etc) by using antigen-specific monoclonal antibodies 
will be addressed. This will help in monitoring subsets of MPs that may play a 
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There is increasing interest in measuring submicron particles (microparticles, 
exosomes) in plasma as disease biomarkers. Often these particles need to be 
isolated from plasma before the actual measurements can be performed. There is 
little information on the structure of these particles in plasma and how these 
structures may be influenced by isolation procedures. 
 
We used cryo-electron microscopy (cryo-EM) to visualize and determine the size 
distributions of submicron particles in plasma. Freshly prepared plasma was 
directly applied on the electron microscope specimen support (grid) and vitrified by 
rapid cryo immobilization to enable observation of biological structures in their 
native state (in plasma).  
 
In citrate platelet-rich plasma platelets were slightly activated as shown by budding 
of vesicles from the membrane, although clearly less than in samples of thrombin-
activated platelets. Platelets in EDTA platelet-rich plasma were less activated than 
in citrate platelet-rich plasma. In EDTA and citrate plasma (platelet-rich, platelet-
poor, and platelet-free plasma) most particles have no apparent lipid bilayer and an 
electron dense appearance. Most likely these represent lipoprotein particles. A 
fraction of the total number of particles observed had a discernable lipid bilayer and 
could be identified as lipid vesicles. Both types of particles have about the same 
size distribution (median: 30 nm; range: 25-260 nm). Most likely the lipid vesicles 
represent microparticles and exosomes. In thrombin-activated platelets similar lipid 
vesicles were observed. Isolated microparticles were shown to contain 
predominantly lipid vesicles. 
 
In conclusion, cryo-EM proved to be a useful method to perform structural studies 
and determine the morphology and size distributions of submicron particles in 
plasma. A combination of cryo-EM and (e.g. antibody-gold or fluorescent) labelling 
of the different types of submicron particles in plasma will enable a further 
characterization of the variations in size and morphology. 




Microparticles (MPs) are submicron particles that are formed by budding of cell 
membranes upon activation or apoptosis and are released into body fluids, such as 
blood, urine and synovial fluid. MPs are present in the blood of healthy subjects. 
Elevated concentrations of plasma MPs have been associated with the 
manifestation and development of disease (1-4).  
 
To date, there is only limited information on the morphology, composition and size 
distribution of plasma MPs because of the limitations of the analytical methods 
used and the largely unknown influence of pre-analytical variables such as blood 
collection, plasma and MP preparation and storage (5). Recently, the application of 
novel analytical tools like atomic force microscopy (AFM) and dynamic light 
scattering indicated that the large majority of plasma MPs have a size much 
smaller than previously reported using flow cytometry (6-8). Conventional 
transmission electron microscopy (TEM) has been used to study the morphology of 
MPs (9-13). However, for the investigation of the morphology of MP in their native 
state (in plasma), conventional TEM has significant shortcomings since the sample 
preparation steps and imaging techniques in conventional TEM require 
dehydration, chemical fixation, and/or staining of specimens.  
  
Cryo-electron microscopy (cryo-EM) on vitrified aqueous suspensions and cells 
has been shown to enable the observation of biological structures in their native 
state (14;15). Vitrification is a cryo fixation method to preserve biological 
specimens to atomic resolution while water is transformed into a glass-like state 
without the formation of ice crystals. Cryo-EM does not use staining or chemical 
fixation procedures and samples are directly applied onto an EM grid and vitrified. 
 
Despite increasing interest in the measurement of plasma MPs as biomarker for 
certain diseases, most pre-analytical parameters are not well standardized (5). 
Blood collection, plasma and MP preparation and storage all may affect the 
outcome of the MP measurements. Plasma is usually prepared from blood 
collected in 1/10 volume of sodium citrate (0.105 or 0.129 mol/L). The choice of this 
anticoagulant is based on international guidelines which are widely followed in 
routine haematology testing (16), but might be less optimal for MP measurements. 
Furthermore, the whole procedure from blood collection until plasma preparation 
should be rapid, but gentle to avoid in vitro activation of blood cells and in particular 
platelets. To prepare platelet-poor/free plasma, blood has to be subjected to 
(multiple) centrifugation steps. The centrifugal force applied is crucial for the 
removal of blood cells and platelets, but at the same time this force should not 
trigger inadvertent formation of MPs. Preferably, MPs are directly measured in 
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fresh plasma to maintain the characteristics and morphology of MPs in their native 
state (17;18).   
 
In the current study cryo-EM imaging has been used to determine the size and 
morphology of submicron particles and to estimate their numbers in fresh plasma 
samples. Since platelet activation during sample processing may lead to 
inadvertent formation of platelet microparticles (PMPs) and release of alpha and 
dense granules, and since it has been reported that most plasma MPs are derived 
from platelets (19-21), we studied platelets and submicron particles in citrate- and 
EDTA-anticoagulated plasma, and in isolated platelet and MP preparations. We 
observed that platelets in citrate platelet-rich plasma are more activated than in 
EDTA platelet-rich plasma, although not as much as in samples of thrombin-
activated platelets. In citrate platelet-poor plasma various types of submicron 
particles and cellular debris like microtubules and actin filaments were found, 
whereas in EDTA platelet-poor plasma there was less variation in the types of 
particles.  
 
Most of the submicron particles found in plasma of healthy volunteers are spherical 
electron dense particles with a size ranging from at least 25 nm to a few hundred 
nanometers resembling lipoprotein particles. In the same plasma samples only a 
few lipid vesicles were found. Based on their morphology and structure such lipid 
vesicles could be microparticles and exosomes. Similar lipid vesicles could be 
found in samples of thrombin-activated isolated platelets. 
 
Materials and Methods 
 
Blood collection and plasma isolation 
  
Venous blood was collected after fasting for more than 12 hours from three healthy 
volunteers (one female and two males, 34, 38 and 57 years old), who gave 
informed consent to donate blood. Blood was drawn using a 21-G needle. The first 
five mL of blood were discarded. The next 4.5 mL were collected into a five-mL 
sodium citrate (0.105 mol/L) vacutainer tube, after which the next ten mL were 
collected into K2EDTA (1.8 mg EDTA/mL blood) vacutainer tubes. The needles and 
blood collection tubes were purchased from BD Biosciences, USA. Plasma was 
prepared within 30 minutes (min) after blood collection.  
  
Three types of plasma were prepared: platelet-rich plasma (PRP), platelet-poor 
plasma (PPP), and platelet-free plasma (PFP). Blood was centrifuged at 160g, 
20°C for 13 min without brake to obtain PRP. For PPP preparation, blood was 
centrifuged twice at 2,000g, 20°C for 10 min without brake. PFP was prepared by 
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centrifuging the blood first at 1,500g, 20°C for 15 min and then at 13,000g, 20°C for 
2 min, without brake (18). During aspiration of supernatant plasma, about 700 µL 
plasma was left above the white blood cell layer to avoid contamination of the 
plasma with white cells and platelets. All plasma samples were vitrified within two 
hours after blood collection for cryo-EM analysis. The scheme of plasma 
preparation is depicted in Figure 1. 
 
 
Figure 1. Scheme of the procedures used for blood collection and isolation of plasma, platelets, and 




MPs were isolated from 750 µL of fresh citrated or EDTA PPP by centrifugation at 
18,890g, 20°C for 30 min. The supernatant (725 µL) was removed without 
disturbing the pellet. Next, this pellet was resuspended in 1 mL Hepes buffer (10 
mM Hepes, 137 mM NaCl, 4 mM KCl (all from Merck, Germany), 0.1 mM Pefabloc 
SC (Fluka, Germany), pH 7.4) and centrifuged again at 18,890g, 20°C for 30 min. 
Finally, the supernatant was removed leaving an undisturbed pellet in 25 µL of 
solution. The pellet (isolated MPs) was carefully resuspended and processed for 




Thrombin activation of washed platelets 
  
Citrated venous blood of the healthy female volunteer was centrifuged at 160g for 
13 min at 20°C, without brake. One mL of PRP was collected and centrifuged at 
300g for 10 min at 20°C, without brake. The supernatant was discarded leaving an 
undisturbed platelet pellet in 25 µL of solution. The platelet suspension was 
reconstituted to 1 mL by adding Hepes buffer and again centrifuged at 300g for 10 
min at 20°C, without brake. After removing the supernatant, the platelet suspension 
was reconstituted with 1 mL Hepes buffer. This platelet suspension  was 
supplemented with thrombin (Kordia, Leiden, The Netherlands) at a final 
concentration of 0.5 U/mL, incubated for 10 min, and directly applied on the grid 
and vitrified for cryo-EM analysis (Figure 1, scheme of platelet isolation and 
stimulation). 
 
Lipoprotein isolation  
 
Very low density lipoproteins (VLDL; d < 1.006 g/mL), low density lipoproteins 
(LDL; 1.019 < d < 1.063 g/mL), high density lipoproteins (1.063 < d < 1.21 g/mL) 
and lipoprotein-deficient plasma (LPDP; d > 1.21 g/mL) were isolated from 3.5 mL 





Samples were applied on a 300 mesh EM grid with lacey carbon and were vitrified 
using a Vitrobot Mark IV (FEI Company, The Netherlands) at room temperature 
and 100% humidity. Excess sample was removed by blotting once between 1 and 
2 seconds with filter paper. The blotted grids were plunged into liquid ethane that 
was kept in equilibrium with solid ethane. After vitrification the grid was stored 
under liquid nitrogen until further use. Grids were mounted in a Gatan 626 cryo-
holder for cryo-EM imaging. 
  
Two dimensional data collection was performed on a Tecnai 12 electron 
microscope (FEI Company, The Netherlands) operated at 120 keV. Images were 
recorded on a 4k x 4k Eagle camera (FEI Company, The Netherlands). Images 
were recorded at 13,000x magnification at 8 micron under focus. For large scale 
automatic data collection we used custom written software that was able to collect 
100 images in 15 min. In each experiment 1,000 non-overlapping images (in total 
~3,000 micron2) were recorded. 
 
Cryo-electron microscopy of submicron particles in plasma 
 107 
Cryo-EM was performed on a Tecnai 20 FEG (FEI Company, The Netherlands) 
operated at 200 keV. Images were recorded on a 2k x 2k camera mounted behind 
a GIF energy filter operated at a slit width of 20 eV. Cryo-electron tomograms were 
recorded from ±60° at a defocus of -50 micron and a  magnification of 3,600x 




Isolated MPs versus plasma MPs 
 
Citrate-anticoagulated blood is most frequently used to prepare plasma for MP 
measurements (directly in plasma or after isolation of MP). Our first investigations 
of the morphology of MPs with cryo-EM were performed with citrate PPP. This 
citrate PPP was either directly used for the measurement or first subjected to high-
speed centrifugation for the isolation of MPs (see Figure 1). In the isolated MP 
fraction, various types of particles were found (Figure 2). Most of the particles had 
a round shape (Figure 2A and B) and were either electron lucent empty structures 
with a clear lipid bilayer (further referred to as “lipid vesicles”) (Figure 2A, D, G and 
I) or electron dense structures with diverse morphology (Figure 2B, C, E and F). 
Surprisingly also actin (Figure 2H) and small microtubules (data not shown) were 
observed. Similar results were obtained for MPs isolated from EDTA plasma, 
although the number of particles seemed to be slightly lower than in samples 
isolated from citrate plasma.  
 
In citrate and EDTA PPP particles were more uniform in type and less variable in 
shape. Most particles were vesicular structures with a round shape resembling 
particles found in the isolated MP fraction (see Figure 2A and 2B), with diameters 
between 25 and 300 nm. Smaller particles, below 25 nm were also present but 
more difficult to detect unambiguously because of limited contrast due to the 
technique of cryo-EM and the relative large amount of proteins present in plasma. 
The size distribution of the isolated MPs was in the same range as observed for 




Cryo-EM images of thrombin-activated platelets showed that the outer membrane 
of activated platelets is often not observable anymore. Instead, multiple membrane 
vesicles are observed at the peripheral zone of the platelets, in what seems 
vesiculation of the platelet membrane (Figure 3A and D). Importantly, platelet 
granules, mitochondria and membrane vesicles were observed in the near vicinity 
of the platelet (Figure 3D). When platelets were not activated with thrombin, their 
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plasma membrane was smooth and its content remained inside the plasma 
membrane, while no vesicles were observed in the surrounding of these platelets. 
 
Figure 2. Cryo-EM images of MPs isolated from fresh citrated PPP. In the isolated MP fraction (MPs 
were 25x concentrated compared with citrated platelet-poor plasma) many different particles were 
observed by cryo-EM imaging: (A) most frequently observed were round empty particles with a clear 
lipid bilayer, (B) filled spherical structures without an apparent lipid membrane resembling VLDL, (C) 
Large dark vesicles, (D) small  light vesicles with rough surfaces, (E) dark vesicles, (F) dark structures 
with no apparent border, (G) multilamellar vesicles, (H) actin filaments, (I) elongated lipid structures. 
Bars are 200 nm. 
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Platelets in citrate and EDTA plasma 
  
We investigated whether the anticoagulants sodium citrate and EDTA influence the 
morphology of platelets in PRP. Figure 3B, C, E and F show the morphology of 
platelets as observed in citrate and EDTA PRP, respectively. Platelets seemed to 
be slightly activated in citrate plasma, but to a lesser extent than in samples of 
thrombin-activated platelets. Platelets in citrate PRP (Figure 3B and E) showed 
membrane processes, the presence of small vesicles, and membrane-associated 
lipid structures but their outer membrane was still observable, unlike in thrombin 
activated platelets. Platelets in EDTA PRP (Figure 3C and F), showed less 
pronounced activity of the plasma membrane and were largely devoid of budding 
vesicles or lipid structures. The morphology of platelets in EDTA PRP was similar 
to that of non-activated isolated platelets. 
  
 
Figure 3. Cryo-EM images of (activated) platelets. Cryo-EM imaging shows the morphology of thrombin 
activated-platelet (A and D); platelet contents, being vesicles, actin and microtubules are released and 
the plasma membrane has opened up and is often not present anymore. In citrated PRP (B and E) the 
platelet plasma membrane is clearly visible and around many platelets budding of small vesicles and 
lipid structures filled with actin is being observed. In EDTA PRP (C and F) platelets tend to be less 
flattened while the plasma membrane is clearly visible and usually devoid of budding vesicles or lipid 




The morphology of submicron particles 
 
Submicron particles in thrombin-activated platelets 
 
Many different vesicles with various sizes and shapes (Figure 4A-D) and also actin 
(Figure 4E and F) and microtubules filaments (Figure 4F and G) were observed in 
samples of thrombin-activated platelets. The vesicles included particles with an 
elongated tubular shape (Figure 4A and B) which in some instances were 
connected to a platelet. When platelets were not activated, their plasma membrane 
was smooth and their contents retained inside the plasma membrane. No vesicles 
were observed in the surrounding of resting platelets (data not shown). 
 
 
Figure 4. Cryo-EM images of structures/particles present in samples of thrombin-activated platelets. In 
samples of thrombin-activated platelets many different vesicles can be observed. (A and C) Dense 
vesicles with a rough surface and probably filled with actin (B and inset) are present around the 
platelets. Also spherical and less dense vesicles (D and inset), actin (E and F) and microtubules (F and 
G) are observed. Scale bars are 500 nm. 
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To obtain a three-dimensional image of the structure of activated platelets and the 
multitude of vesicles released by these platelets, we performed cryo-EM on 
activated platelets. The vesicles that are present in platelets, like mitochondria, 
alpha-granules and dense granules, could be easily observed in the tomograms 
(Figure 5B and C). These structures were morphologically similar to those reported 
in earlier morphological studies of platelets (23). Of interest, such vesicles seemed 
to originate from the outer membrane of the platelet (Figure 5B, D, E and G). 
Vesicles were also released from the platelet (Figure 5B, C and F), while actin and 
microtubules (Figure 5B and H) can be observed inside and outside the platelet. 
 
 
Figure 5. Cryo-EM of activated platelets in EDTA plasma. Cryo-EM shows several types of vesicular 
structures and cellular debris that can be found in the vicinity of activated platelets. In (A) a 175 nm thick 
tomographic slice of an activated platelet showing the debris that is released. Boxed show the positions 
of the enlarged images C to H. A surface rendered representation (B) shows dense granules (red), 
vesicles and lipid membrane structures (yellow), A-granules (blue), mitochondria (purple) and 
microtubules (green). Glycosomes and actin filaments are not included in the surface rendering. Small 
black dots in the background are fiducial gold used for tilt series alignment. The network like structure in 
the background is the lacey carbon film that is used as support film. Enlargements of several places 
surrounding the activated platelet show release of dense vesicles (C and F), round vesicles (C, E and F) 
and elongated lipid membrane structures (D), mixed actin/rough membranous structures (G), and 




Submicron particles in citrate and EDTA plasma 
 
The morphology of submicron particles in citrate and EDTA plasma was rather 
similar. In EDTA plasma (PRP, PPP, and PFP), there seemed to be less particles 
than in citrate plasma. Particles found in plasma have different shapes: some have 
a lipid membrane and are typically translucent with little material inside (lipid 
vesicles, Figure 6A-C) but most are typically round, electron dense without a clear 
visible lipid bilayer (Figure 6D-F). 
 
 
Figure 6. Cryo-EM images of structures/vesicles present in samples of EDTA plasma. The morphology 
of particles as observed by cryo-EM imaging in EDTA PRP (C and D) , PPP (E) and PFP (A,B and F) 
typically shows very few vesicles and only of two types. (A-C) Lipid structures (see arrows) are 
elongated and can be microns long. They also have a lipid membrane and are typically light of nature 
with little material inside. (C–F) Also lipoprotein-like particles can be observed (see arrows and arrow 
heads), which are typically round, electron dense, do not have a clear visible lipid bilayer and vary in 
size between 40 and 80 nm; these particles form the large majority in EDTA plasma. Scale bars are 500 
nm. 
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Previously we noticed that platelets appeared to be slightly activated in citrate 
PRP. In the medium surrounding these activated platelets we observed many 
particles (Figure 7), usually clusters of vesicles from opened platelets (Figure 7A 
and B). Also large single vesicles were observed (Figure 7C-F). Such large 
vesicles were not observed in EDTA PRP. 
 
Figure 7. Cryo-EM images of structures/particles present in samples of citrate PRP. The morphology of 
vesicles in citrated PRP as observed by cryo-EM imaging typically shows different kinds of structures. 
(A and B) Vesicles are in clusters and mitochondria are also present in these clusters which points 
towards opening and release of contents of the platelets. Arrows indicate vesicles (C-F) Vesicles have 




From their appearance it seemed that some electron dense particles observed in 
plasma (see Figures 2B, 6E and F) did not have an apparent lipid membrane. 
Given this absence of a clear lipid membrane, their high abundance, the electron 
dense appearance and the size distribution (from ~25 nm to a few hundred 
nanometers), these particles could be lipoproteins (VLDL, LDL, and HDL). To test 
this hypothesis, lipoproteins were isolated from EDTA PFP by density-gradient 
ultracentrifugation and cryo-EM was performed on the isolated fractions (Figure 8). 
Cryo-EM imaging of these lipoprotein fractions and also earlier published cryo-EM 
data of lipoproteins (24-27), confirmed that the electron dense particles without an 
apparent lipid membrane found in the plasma samples resembled lipoproteins in 
size and morphology. No particles were observed in the lipoprotein depleted 
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fraction. Interestingly, especially in the VLDL fraction we observed large dark spots 
without an apparent border (white arrow in Figure 8A) which were sometimes also 
observed in plasma fractions (Figure 2F). 
 
 
Figure 8. Cryo-EM of freshly isolated lipoprotein fractions. Overviews (A-C) and higher magnification (D-
F) images of VLDL (A and D), LDL (B and E) and HDL (C and F) fractions clearly show the different 
lipoprotein particles (denoted by black arrows). Scale bars are 500 nm (A), 200 nm (B and D) and 100 
nm (C, E and F). The white arrow in (A) points to a fuzzy round structure of unknown origin that was 
observed in several samples, but most common in purified VLDL. 
 
Quantitative analysis  
 
Number of platelets and submicron particles in EDTA plasma  
 
We counted all particles in 1,000 non-overlapping random images of 10 meshes in 
the cryo-EM samples of EDTA PRP, PPP and PFP of two healthy volunteers. 
Particles with an apparent lipid membrane were also counted separately. The 
results of these counts are summarized in Table 1A.  
 
We could detect platelets in EDTA PRP of the two volunteers (14 and 41 platelets 
per 1,000 images, respectively), but not in EDTA PPP and PFP (Table 1A).  
 
In agreement with our previous observations most particles in the PFP, PPP and 
PRP have a round shape and an electron dense appearance without a visible 
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membrane (Figure 6C-F), while a minority of the observed particles are lipid 
vesicles (Figure 6A and B). The number of electron dense particles was 2 to 3 
orders higher than the number of lipid vesicles and depended on the type of 
plasma and the individual. There seem to be relatively more lipid vesicles in PRP, 
where there were also more platelets, than in the PPP and PFP.  
 
Size distribution of MPs in EDTA plasma  
 
We analyzed the size of all particles with a size equal or above 25 nm. These 
particles have diameters ranging from 25 to 260 nm (Table 1B). Particles in PRP, 
PPP, and PFP have a median size of about 30 nm. Apparently the size of particles 
is not largely influenced by the procedure used to prepare the plasma, although 
particles in PRP seem to cover a wider range of sizes. 
 
Table 1. Particle counts in EDTA plasma of two healthy volunteers. 
A. 
Counts per ~3,000 micron2 
Volunteer EDTA plasma 















































Particles were counted in cryo-EM images of three types of plasma (PRP, PPP, and PFP) of two 
healthy volunteers. Also the size of these particles was determined. (A) The table gives the results of 
counting particles with a size equal or above 25 nm in 1000 images of 10 meshes. (B) The median and 




To our knowledge, in this study we used for the first time cryo-EM to visualize and 
characterize the morphology of submicron particles in fresh plasma as well as in 
isolated MP fractions. It was not possible to discriminate particles with a diameter 
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smaller than 25 nm due to the limited contrast of cryo-EM and the presence of 
many proteins in plasma.   
  
In isolated MP fractions we observed submicron particles with sizes ranging from 
25 to ~300nm. These particles had a lipid membrane and various shapes, sizes 
and morphologies. Most have vesicular structures with a round shape. Using 
conventional EM, Aras et al. (9) observed that MPs isolated from plasma had 
diameter sizes ranging from 100-500 nm. However, these MPs might be flattened 
during the preparation of the sample. In cryo-EM some flattening does only occur 
when particles are larger than the ice thickness. The observation of microtubules in 
the isolated MPs samples indicates the presence of platelet fragments in these 
preparations. Most likely this is due to the effect of high-speed centrifugation on 
residual platelets in the plasma.  
 
In plasma, only a few types of particles were observed. Most particles found in 
plasma resembled lipoproteins, whereas only a minor part was lipid vesicles (Table 
1). The nature of these lipid vesicles cannot be established without the use of 
specific labelling techniques. The lipid vesicles have a similar morphology as some 
of the vesicles observed close to activated platelets and to the lipid vesicles 
present in isolated MP preparations. A portion of the observed lipid vesicles could 
well be MPs, the small particles shed from the surface of many cells upon 
stimulation or apoptosis. Another portion might be exosomes, small membrane 
vesicles of endocytic origin that can be released by many different cells (28-30). At 
present there is no reliable estimate of the ratio in which MPs and exosomes occur 
in plasma.  
 
The presence of actin, microtubules and other cellular debris in MPs isolated from 
citrate and EDTA PPP indicates that PPP still contains cells that are damaged 
during the high-speed centrifugation used for MP isolation. It is not known to what 
extent these cellular fragments may influence measurements in these MP 
preparations.  
 
The morphology of platelets was studied in citrate and EDTA-anticoagulated PRP. 
We found that platelets tend to be slightly activated in citrate PRP. Platelets show 
membrane budding and the presence of surrounding vesicles while this occurs 
much less in EDTA PRP. Therefore, blood collection in EDTA might be preferred 
for the study of plasma MPs because it will help to reduce in vitro activation of 
platelets and platelet MP formation. 
 
Cryo-EM is a technique suited for the characterization of individual submicron 
particles, but less a technique for the quantification of the number of submicron 
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particles in large volume suspensions. The quantification with cryo-EM highly 
depends on the exact conditions of specimen preparation, and is susceptible for 
local variations in concentrations of particles on the EM support due to variations in 
hydrophobicity. Finally, quantification requires that a large number of images 
containing a large number of submicron particles at high resolution will need to be 
recorded, which is in most cases not possible using cryo-EM. Nevertheless, in this 
study a significant number of images were recorded that provides insights in the 
size distribution and morphology of submicron particles in plasma.  
 
In the EDTA PRP of two volunteers we counted 14 and 41 platelets per 1,000 
images, respectively. Assuming a vitreous water thickness of 150 nm, 1,000 
images would correspond to a volume of 450 micron3 or 0.45 pL. This would 
suggest that the platelet concentration in the PRP sample is 30-90 platelets/pL, 
about 100-fold higher than expected for PRP prepared from blood of a healthy 
donor (about 600,000 platelets/µL or 0.6 platelet/pL). Similarly, the concentration of 
lipid vesicles in PPP is about 5 particles/ pL, about 10-fold higher than for instance 
the number of PMPs detected by AFM in PPP of healthy donors (6). We can not 
explain these discrepancies. For instance, we cannot exactly determine the precise 
volume of sample that was attached to the EM grid. In addition, the measured 
concentrations of particles might be influenced preferential binding of platelets and 
vesicles to the EM grid.  
 
The diameters of particles found in the EDTA plasma samples of the two healthy 
volunteers ranged from 25-260 nm with a median of about 30 nm. Most of these 
particles resembled lipoprotein particles, while the minority of the observed 
particles is formed by lipid vesicles. Lipoprotein particles (e.g. VLDL, LDL) have 
reported sizes of 25 nm to 90 nm, which might explain why the median size of 
particles in plasma observed by cryo-EM (30 nm) is lower than that of the PMPs 
detected by AFM (67 nm) (6). 
 
Overall our data indicate that MPs constitute only a minority of all submicron 
particles in fresh PPP. This observation strongly indicates limitations on the variety 
of techniques that can be used for MP measurements directly in plasma. For future 
developments of methods to quantify plasma MPs it will be essential to find ways to 
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Use of immuno-magnetic beads for 
direct capture of nanosized blood 
microparticles from plasma 
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The mechanism of cancer-associated thrombosis is still unclear. Recent data 
indicate that blood microparticles (MPs) carrying active tissue factor (TF) may play 
a role in cancer-associated thrombosis. Methods such as flow cytometry and 
impedance based-flow cytometry allow the analysis of MP subsets but give no 
information on which MPs carry active TF. Conversely, the MP-TF activity itself 
provides no information, on the cellular origin of the MPs carrying the active TF. 
 
For this reason, we developed an immuno-magnetic beads method to capture 
subsets of MPs directly from plasma. The method was optimized for the capture of 
platelet-derived MPs (PMPs) from plasma. Only 100 µL platelet poor plasma (PPP) 
was needed in combination with 135 µL (27 µg) of biotinylated anti-human CD41 
monoclonal antibody (MoAb) and 200 µL of streptavidin beads to achieve complete 
separation of PMPs from plasma.  As a control biotinylated mouse IgG1 isotype 
control MoAb was used instead of the anti-CD41 MoAb. 
 
Using biotinylated anti-CD14 MoAb, CD14-positive MPs were captured from 
normal plasma spiked with MPs isolated from the supernatant of LPS-stimulated 
monocytes (MoMPs). TF activity was found both in the positive (selected) and 
negative (depleted) fractions indicating that both CD14-positive and -negative 
MoMPs have active TF.  
 
We propose that this method can be used in the future to investigate the source of 
MPs carrying active TF in plasma of patients with cancer and other diseases. 




There appears to be a two-way association between cancer and thrombosis. 
Cancer is associated with a 4-7 fold increased risk for venous thrombosis (VTE) 
(1;2), while on the other hand about 10% of patients with an episode of idiopathic 
VTE will develop cancer within 2 years after the event (3;4). Cancer patients who 
developed thrombosis also have a poor survival compared to those who did not 
develop thrombosis (5). Some studies indicate that in cancer patients blood 
microparticles (MPs) play a role both in the development of VTE and in the 
progression of disease. MPs, also named microvesicles, are nanosized vesicles 
which are released from virtually all cells of the body upon activation or apoptosis 
(6;7) and still express proteins derived from their parental cells (8;9). Some MPs 
also may carry active tissue factor (TF), a 47 kDa transmembrane glycoprotein, 
which is the main activator of blood coagulation (10-12). Tesselaar et al (11) 
reported that cancer patients with disseminated breast and pancreatic cancer, who 
presented with acute VTE, had higher levels of MP-associated TF activity (MP-TF 
activity) than healthy subjects, cancer patients without VTE and subjects with 
idiopathic VTE. Interestingly, in some of these patients a small fraction of their 
blood MP expressed MUC-1 antigen which raises the question whether a subset of 
MPs with TF activity is derived from tumour cells themselves. Increased MP 
procoagulant activity is not only found in cancer patients, but also in patients with 
cardiovascular and inflammatory diseases (7;13;14)  
  
Blood MPs used to be known as ‘platelet dust’ which was obtained after 
ultracentrifugation of platelet free plasma (15). Most MPs have sizes below 1 µm 
and the detection of MPs with sizes less than 0.5 µm is not sensitive when using a 
commonly applied method such as flow cytometry or bright field microscopy 
(16;17). Recently, our group reported the use of atomic force microscopy (AFM) 
operated in fluid-tapping mode to detect platelet-derived MPs (PMPs) and showed 
that AFM enables sensitive detection of MPs with diameter ranging from 10-475 
nm (mean: 67.5 ± 26.5 nm), far below the lower limit of what can be detected by 
conventional flow cytometry (18).  
  
However, up till now there is no method available to identify the origin of the 
subsets of plasma MPs carrying active TF. Current methods using flow cytometry 
(8) and impedance based-flow cytometry (19) only allow the identification of 
subsets of MPs carrying TF antigen in plasma but provide no information with 
regard to which MPs carry active TF. In this context it is important to mention that 




For the measurement of MP-TF activity MPs need to be separated from the plasma 
proteins (11;12;22;23), after which the TF activity of the isolated MPs is measured 
as the FVII-dependent factor Xa (FXa) generation. However, there is no easy way 
to measure TF activity in selected subsets of MPs. 
  
For this reason, we developed an immuno-magnetic beads method to directly 
capture a subset of plasma MPs. The method was optimized for the separation of 
PMPs, which form about 80% of the total blood MP population (7;9;11), and further 
tested for capturing monocyte-derived MPs (MoMPs). Biotinylated anti-human 
CD41 and CD14 monoclonal antibodies were coupled to streptavidin-magnetic 
beads to separate CD41- and CD14-positive MPs from plasma. Subsequently, the 
separated fractions were used to isolate and analyze MPs for specific antigens and 
TF activity.  
  
In this study we demonstrate that the use of immuno-magnetic beads can 
specifically and efficiently separate a subset of MPs from plasma. We propose to 
apply this method for further use in the identification of the MP subset(s) carrying 
active TF in patients. 
 




The µMACS streptavidin kit and CD14 MACS MicroBeads were purchased from 
Miltenyi Biotec Inc (CA, USA). Biotinylated anti-human CD41 monoclonal antibody 
(MoAb) clone P2 and biotinylated mouse IgG1 isotype control MoAb were from 
Beckman Coulter (Marseille, France). Biotinylated anti-human CD14 MoAb clone 
M5E2 and biotinylated mouse IgG2a, κ isotype control MoAb were from Biolegend 
(CA, USA). For PMP staining, anti-human CD41- phycoerythin (PE) MoAb clone 
P2 and anti-human CD61- fluorescein isothiocyanates (FITC) MoAb clone SZ21 
from Beckman Coulter were used. MoMPs were stained by anti-human CD14-PE 
MoAb clone M5E2 from BD Pharmingen (CA, USA) and anti-human tissue factor 
(TF)-FITC MoAb clone CLB/TF-5 from Sanquin (Amsterdam, The Netherlands). 
For controls, mouse IgG1 isotype control-PE and -FITC MoAbs clone X40 from 
Becton Dickinson (CA, USA) and mouse IgG2a, κ isotype control-PE MoAb clone 
G155-178 from BD Pharmingen were used. Recombinant human annexin V- 
allophycocyanin (APC) from Caltag Laboratories (CA, USA) was used to stain MPs 
bearing phosphatidylserine. Megamix beads were purchased from Biocytex 
(Marseille, France) to calibrate the FACS Calibur flow cytometer. For counting the 
absolute number of MPs in samples, flow cytometry absolute count standard beads 
from Bang Laboratories (IN, USA) were used. These beads have a mean diameter 
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of 7.58 µm per bead and a known concentration. Hepes buffer consists of 10 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes) (Merck, Darmstad, 
Germany), 137 mM NaCl (Merck), 4 mM KCl (Merck) and 0.1 mM Pefabloc SC 
(Fluka, Munich, Germany). Hepes-citrate buffer was prepared by adding 10.8 mM 
sodium citrate (Merck) to the Hepes buffer without Pefabloc. All buffers were set to 
pH 7.4. For the isolation of human monocytes, phosphate buffered saline (PBS) pH 
7.2 was used (LUMC Pharmacy, Leiden, The Netherlands). For some experiments 
PBS was supplemented with 0.5% bovine serum albumine (BSA) (Sigma-Aldrich, 
MO, USA) and 2 mM ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich) (pH 
7.2) (PBS-BE). Ficoll-amidotrizoate was from LUMC Pharmacy. 
Lipopolysaccharide (LPS) from Sigma-Aldrich was used to stimulate human 
monocytes. For monocyte culture, RPMI (Invitrogen, Breda, The Netherlands) was 
supplemented with 1% L-Glutamine (L-Glu) from Lonza (Cologne, Germany) and 
1% Penicillin/Streptomycin (Pen/Strep) from Invitrogen.   
 
Blood collection and plasma preparation 
 
After giving informed consent venous blood was collected from three healthy 
volunteers by using a 21-gauge needle (BD Vacutainer; Becton Dickinson) with 
minimal stasis. After discarding the first 4 mL of blood, blood was collected in 1/10 
volume of sodium citrate (3.2%, 0.105 M) using a 4.5-mL BD Vacutainer tube 
(Becton Dickinson). Within 10-15 minutes (min) of withdrawal, blood was 
centrifuged at 2,000g for 10 min at 20°C, without brake. Plasma was carefully 
collected and centrifuged again at 2,000g for 10 min at 20°C, without brake, to 
obtain platelet-poor plasma (PPP). PPP was aliquoted in 250-µL portions, snap 
frozen in liquid N2, and stored at -80°C. Before use, plasma was thawed quickly 
with a gentle swirl at 37°C.   
  
Eighteen mL of venous blood was collected in 4.5 ml K2 EDTA tubes (3.6 mg 
EDTA) (BD Vacutainer, Becton Dickinson). This blood was 3-fold diluted with PBS 
before use for monocyte isolation. 
 
Human monocyte isolation and stimulation 
 
 Fifteen mL of Ficoll-amidotrizoate was pipetted to a Leucosep tube (Greiner Bio-
One GmbH; Frickenhausen, Germany) and centrifuged in a swinging bucket rotor 
for 30 seconds (sec) at 1,000g, room temperature (RT), with brake. Diluted (3-fold) 
EDTA anticoagulated blood (15-30 mL) was carefully pipetted onto the filled 
Leucosep tube and centrifuged for 15 min at 800g, RT, without brake. The upper 
layer of plasma including the interphase (enriched in lymphocytes/mononuclear 
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cells) was harvested and placed into another centrifugation tube. PBS was added 
to a total volume of 50 mL and subsequently the cell suspension was centrifuged 
for 10 min at 300g, RT, with brake. The supernatant was removed and the cell 
pellet was resuspended in PBS and centrifuged for 10 min at 300g, RT, with brake. 
This washing step was repeated once. Finally, the cell pellet was resuspended in 5 
mL PBS-BE. Cells were stained with Trypan blue (Sigma-Aldrich) to exclude dead 
cells counted by using a Bürker haemacytometer (Superior, Marienfeld, Germany).  
  
CD14-positive cells were isolated using CD14 MicroBeads (Miltenyi Biotech) 
following the protocol of the manufacturer. Briefly, 80 µL of anti-human CD14 
MACS MicroBeads (diameter: ~50 nm) were mixed with 320 µL of cell suspension 
(4x107 cells) and incubated for 15 min in the refrigerator (2-8°C). In the meantime, 
the MS column was placed on the miniMACS separator (both from Miltenyi 
Biotech). The column was rinsed with 500 µL of PBS-BE buffer. Then, the cell 
suspension was applied to the column and the flow through was collected. This 
flow through was applied again to the column and then discarded. The column was 
removed from the separator and placed on a collection tube. One mL of PBS-BE 
was pipetted into the column and immediately a plunger was applied to flush out 
the magnetically labelled cells.  
  
For monocyte culture, cells were centrifuged for 10 min at 300g, RT, with brake. 
The cell pellet was resuspendend, counted, and distributed into a 6-wells plate at a 
concentration of 2x106 cells per well in RPMI medium containing 1% L-Glu and 1% 
Pen/Strep, and 10 µg/mL LPS. After incubation for 0, 6, 18, and 24 hours (h), the 
cell supernatant was collected and centrifuged for 20 min at 2000g at RT, with 
brake to remove cell debris. The supernatant was aliquotted in 500-µL portions, 
snap frozen in liquid N2, and stored at -80°C.  
 
Immuno-magnetic beads capture 
 
Hundred µL of PPP was mixed with 135 µL (27 µg) of biotinylated anti-human 
CD41-/CD14 MoAb and gently rotated for 30 min at RT, shielded from light. As 
negative controls, PPP was mixed with 135 µL (27 µg) of biotinylated mouse 
IgG1/IgG2a, κ isotype control MoAb. Next, 200 µL of streptavidin beads were 
added to the mixture and rotated for 5 min at RT, shielded from light. In the 
meantime, the µ Column was placed on the µMACS magnet separator (both from 
Miltenyi Biotech) and rinsed with 100 µL of the equilibration buffer included in the 
µMACS streptavidin kit. Afterwards, the µ Column was rinsed twice with 250 µL 
Hepes-citrate buffer. The mixture of PPP with antibody and beads was added to 
the µ Column and the flow through was collected. This flow through was added 
again into the µ Column to ensure that all the captured MPs were bound to the 
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magnet and then the flow through was collected (negative fraction). The µ Column 
was rinsed twice with 500 µL Hepes-citrate buffer. To collect the bound MPs, the µ 
Column was detached from the magnet after which quickly 75 µL Hepes-citrate 
buffer was added to the µ Column. The first eluate was collected. The µ Column 
was rinsed again with 75 µL Hepes-citrate buffer and a syringe plunger (5 mL) was 
applied to the µ Column to increase elution efficiency. Finally, the second eluate 




To isolate MoMPs, frozen supernatant of LPS stimulated-monocytes was thawed 
quickly with a gentle swirl at 37°C. The supernatant (500 µL) was centrifuged for 30 
min at 18,890g, 20°C, with minimum brake, to isolate MPs and the supernatant 
was carefully removed, leaving a volume of 50 µL containing the MP pellet. To 
wash the MPs, 450 µL of Hepes buffer was added, and this mixture was then 
centrifuged again for 30 min at 18,890g, 20°C, with minimum brake. The 
supernatant was removed and the residual 50 µL was diluted to 200 µL with Hepes 
buffer. This MP fraction was directly used for the measurements. 
  
MPs were isolated from plasma as previously described (22;24). Frozen PPP 
samples (250 µL) were thawed quickly with a gentle swirl at 37°C. Then, they were 
centrifuged three times at 18,890g for 30 min at 20°C with minimum brake, to pellet 
the MPs. MPs were extensively washed between the centrifugation steps with 
Hepes-citrate buffer to reduce the concentration of plasma proteins to less than 
0.5%. To isolate MPs from positive and negative fractions obtained from immuno-
magnetic beads capture, the procedure (centrifugation and washing steps) was the 
same as the procedure to isolate MPs from plasma. At the third centrifugation step, 
the supernatant was carefully removed, leaving 25 µL of MP suspension. The MP 
suspensions obtained from plasma and positive/negative fractions were diluted to 
100 µL before used for measurement.  
     
Flow cytometry analysis 
  
Flow cytometry analysis was performed using a FACS Calibur flow cytometer with 
CELLQUEST PRO software (Becton Dickinson). Before measurement the FACS 
Calibur was calibrated by using Megamix beads (25). Staining plasma MPs for 
CD41/CD61 after beads separation was done by adding 10 µL of anti-human 
CD41-PE MoAb and 10 µL of anti-human CD61-FITC MoAb into 15 µL of the MP 
fraction, and then diluting up to a volume of 50 µL with Hepes-citrate buffer. This 
mixture is incubated for 30 min at RT in the dark. As negative controls, mouse IgG1 
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isotype control-PE MoAb and mouse IgG1 isotype control-FITC MoAb were used at 
the same concentration as the antibodies.  
  
When staining plasma MPs after beads isolation for CD14, 10 µL of anti-human 
CD14-PE MoAb was added into 15 µL of the MP fraction and diluted with Hepes-
citrate buffer up to a volume of 50 µL. This mixture was incubated for 30 min at RT 
in the dark. As negative controls, mouse IgG2a, κ isotype control-PE MoAb was 
used at the same concentration as the antibody.  
  
For staining MoMPs isolated from supernatant, 10 µL MPs was mixed with 5 µL 
anti-human CD14-PE MoAb, 5 µL anti-human TF-FITC MoAb, 5 µL annexin V-
APC, and 25 µL Hepes buffer containing 2.5 mM CaCl2. Anti-human CD14-PE 
MoAb and anti-human TF-FITC MoAb were 20 times diluted, whereas annexin V-
APC was 300 times diluted in the final mixture. This mixture was incubated for 30 
min, in the dark, at RT. As negative controls, mouse IgG2a, κ isotype control-PE 
MoAb and mouse IgG1-FITC MoAb were used at the same concentration as the 
antibodies. As a control of annexin V staining, Hepes buffer without CaCl2 was 
used. 
  
Before flow cytometry, 500 µL of Hepes-citrate buffer was added to the mixture 
containing labelled MPs. For counting absolute numbers of MPs per µL plasma or 
MoMPs per 500 µL supernatant, 200 µL of flow cytometry absolute count standard 
beads was mixed with Hepes buffer to a volume of 600 µL and then measured in 
triplicate. For measurement of counting beads as well as MPs, the flow cytometer 
was programmed to count events in 1 min. 
 
MP-TF activity assay 
  
Freshly isolated MPs were directly used for the measurement of MP-TF activity as 
previously described (22). In this assay the factor VII (FVII)-dependent factor Xa 
(FXa) generation was measured. MP-TF activity is expressed as fM FXa/min. The 
FXa generation was measured in the presence and absence of excess (33 µg/mL) 
polyclonal sheep anti-human TF IgG (Affinity Biologicals INC, Canada) and (1 nM) 
human FVII (Kordia, Leiden, The Netherlands). Human factor X (50 nM) (Kordia) 
was added to start FXa formation. The MP-TF activity (TF-activity in isolated MPs) 




The beads separation method was based on the capture of a specific subset of 
MPs from plasma by using biotinylated antibody and streptavidin magnetic beads. 
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We first tested the procedure to capture PMPs. The biotinylated anti-human CD41 
MoAb was incubated with the plasma before the streptavidin magnetic beads were 
added. After application of this mixture to the column, positive and negative 
fractions were collected (Figure 1). Subsequently, the separated fractions were 




Figure 1. Scheme for the immuno-magnetic beads capture procedure using biotinylated anti-human 
CD41 MoAb and biotinylated mouse IgG1 isotype control MoAb. After beads separation using 
biotinylated anti-human CD41 MoAb, MPs in positive and negative fractions were collected. 
 
 
Optimizing of the concentrations of anti-CD41 antibody and streptavidin 
magnetic beads 
  
For PMP capture from plasma by antibody-coated magnetic beads both the 
concentration of antibodies and of streptavidin magnetic beads need to be 
optimized. To check whether the antibody saturated the surface antigen CD41 of 
PMPs, PPP (100 µL) was first reacted with different concentrations of biotinylated 
anti-human CD41 MoAb. Subsequently MPs were labelled by fluorescent 
antibodies, anti-human CD41-PE MoAb and anti-human CD61-FITC MoAb or the 
fluorescently labelled isotype controls, and analysed by flow cytometry. These 
experiments showed that 135 µL (27 µg) biotinylated anti-human CD41 MoAb 
specifically binds and saturates the surface antigen CD41 of PMPs in 100 µL 
plasma. Figure 2A and B show flow cytometry analysis of plasma MPs without 
biotinylated anti-human CD41 MoAb. The PMPs express both CD41 and CD61 
(Figure 1A). When biotinylated anti-human CD41 MoAb (27 µg/135 µL) was added, 
plasma PMPs show only CD61 and no CD41 expression (Figure 2C). Figure 2E 
shows that when using biotinylated mouse IgG1 isotype control MoAb instead of 
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biotinylated anti-human CD41 MoAb, the surface antigens CD41 and CD61 could 
still be detected on PMPs by anti-CD41 and anti-CD61 antibodies.  
 
Streptavidin magnetic beads should be added in excess to bind all biotinylated 
antibodies present in the plasma. We found that 200 µL streptavidin magnetic 
beads were needed and that the streptavidin magnetic beads did not interfere with 
the binding of anti-CD41 and anti-CD61 antibodies to PMPs (Figure 2G). 
Fluorescently labelled IgG1 were used as controls at the same concentrations as 
the staining antibodies (Figure 2 B, D, F, and H).  
  
 
Figure 2. Optimizing the concentration of antibodies, streptavidin magnetic beads, and plasma for the 
immuno-magnetic beads method. Stainings of samples were performed by using anti-human CD41-PE 
and anti-human CD61-FITC MoAbs (A, C, E, G). As controls, mouse IgG1-PE and mouse IgG1-FITC 
MoAbs were used at the same concentrations (B, D, F, H). After staining, PPP (A, B) and PPP 
incubated with biotinylated anti-human CD41 MoAb (C, D), biotinylated mouse IgG1 isotype control 
MoAb (E, F), or streptavidin beads (G, H) were measured by flow cytometry. Experiments were done in 
duplicate. 
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In conclusion, 135 µL (27 µg) biotinylated anti-human CD41 MoAb and 200 µL 
streptavidin magnetic beads can be used for optimal capturing of CD41-positive 
MPs from 100 µL PPP. As PMPs bearing CD41/CD61 are the most abundant MPs 
in plasma, these optimized conditions can also be applied to capture other subsets 
of MPs from plasma. 
 
Use of immuno-magnetic beads to capture PMPs from plasma. 
  
After beads separation for PMPs bearing CD41, positive and negative fractions 
were collected (Figure 1) and stained by using fluorescently labelled anti-human 
CD41 and anti-human CD61 MoAbs or their isotype controls as described in the 
methods section. Flow cytometry analysis (Figure 3A) showed that there is no 
fluorescence signal of the anti-human CD41 MoAb, but only of the anti-human 
CD61 MoAb on MPs in the positive fraction. This indicated that the surface antigen 
CD41 of PMPs in this positive fraction still was saturated by the biotinylated anti-
human CD41 MoAb. In the negative fraction no CD41- and CD61-positive MPs 
were detected (Figure 3C). Figure 3B and D show fluorescently labelled isotype 
controls staining of these fractions.  
 
To check for non-specific binding of biotinylated anti-human CD41 MoAb, 
biotinylated mouse IgG1 isotype control MoAb was used (Figure 3E-H). In the 
positive fraction no CD41- and CD61-positive MPs were detected (Figure 3E). 
These were only present in the negative fraction (Figure 3G) indicating that CD41-
positive MPs are specifically captured from plasma by using this procedure. Figure 
3F and H show fluorescently labelled isotype controls staining of these fractions. 
 
Flow cytometry quantification of CD41 and CD61-positive MPs  
 
Frozen-thawed PPP from three healthy volunteers was used to perform the 
immuno-magnetic beads capture of PMP by using biotinylated anti-human CD41 
MoAb.  Figure 4 shows that no CD41-positive MPs were detected in the negative 
fractions. In these fractions about 1, 0, and 6% of CD61-positive MPs were found in 
volunteer 1, 2, and 3 respectively. This indicated that almost all PMPs (CD41-
positive MPs) were captured. As the anti-CD41 coated-beads saturated the surface 
antigen CD41 of MPs, there were no CD41-positive MPs detected in the positive 
fraction. However, there were also few CD61-positive MPs present in this positive 
fraction. Possibly the magnetic beads which still present on the surface of MPs in 
the positive fraction interfere with the fluorescence staining with anti-CD61 antibody 




When biotinylated mouse IgG1 isotype control MoAb was used instead of 
biotinylated anti-human CD41 MoAb, we found that about 5% and 80% of 
CD41/CD61-positive MPs were recovered in the positive and negative fractions of 




Figure 3. Flow cytometry analysis of positive and negative fractions after beads separation for PMPs 
bearing CD41. After beads separation using biotinylated anti-human CD41 MoAb, MPs in positive (A, B) 
and negative fractions (C, D) were collected, stained by anti-human CD41-PE and anti-human CD61-
FITC MoAbs (A, C) or isotype controls (B, D), and measured by flow cytometry. Staining was also done 
for MPs in the positive (E, F) and negative (G, H) fractions collected from beads separation using 
biotinylated mouse IgG1 isotype control MoAb by using anti-human CD41-PE and anti-human CD61-
FITC MoAbs (E, G) or isotype controls (F, H). All measurements were performed in duplicate. 
 
Flow cytometry and MP-TF activity measurements of in vitro generated 
MoMPs 
  
Monocytes were isolated from human blood and stimulated with LPS for 0, 6, 18, 
and 24 h to produce MoMPs. MoMPs were isolated from the supernatant, stained 
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with fluorescently labelled annexin V, anti-human CD14 and anti-human TF MoAbs 
and analysed by flow cytometry. Figure 5A shows that MoMPs expressed annexin 
V, CD14 antigen, and TF antigen. However, not all MoMPs were CD14 positive as 
measured by flow cytometry. After 6, 18 and 24 h stimulation with LPS, there were 
more TF- and annexin V-positive MoMPs than without LPS stimulation.  
 
MP-TF activity measurements were performed to investigate whether MoMPs 
derived from LPS-stimulated monocytes carry active TF. The results are 
summarized in Figure 5B and show that MoMPs isolated from the supernatant of 
monocytes stimulated with LPS for 6, 18, and 24 h carried active TF and this TF 





Figure 4. Flow cytometry quantification of CD41/CD61-positive MPs in the positive and negative 
fractions obtained from immuno-magnetic beads separation using biotinylated anti-human CD41 or 
mouse IgG1 isotype control MoAb. PPP used in these experiments was prepared from blood of 3 
healthy volunteers (white bar: volunteer 1, black bar: volunteer 2, hatched bar: volunteer 3). 
Measurements were performed in duplicate. 
 
Use of immuno-magnetic beads to capture MoMPs from plasma spiked with 
in vitro generated MoMP 
  
We added MoMPs carrying active TF (isolated from the supernatant of monocytes 
stimulated with LPS for 0, 6, 18, or 24 h) to frozen-thawed PPP of a healthy 
volunteer in a 1:1 ratio (v/v); no visible clot was formed after 30 and 60 minutes at 
RT. The procedure of immuno-magnetic beads to capture MoMPs was the same 
as the procedure used to capture PMPs from plasma. Plasma spiked with MoMPs 
(100 µL) were incubated with biotinylated anti-human CD14 MoAb and streptavidin 




Figure 5. Flow cytometry analysis and MP-TF activity measurements of MoMPs. MoMPs isolated from 
the supernatant of monocytes stimulated with LPS for 0, 6, 18, and 24 h were stained by using annexin 
V APC, anti-TF FITC, and anti-CD14 PE antibodies and quantified by flow cytometry (A). The same 
batch of MoMPs was used for the measurement of TF activity (B) in the presence (○) or absence (●) of 
an anti-TF antibody.  
 
The concentration of biotinylated anti-human CD14 MoAb used was the same as 
that of biotinylated anti-human CD41 MoAb in the PMP separations. The positive 
and negative fractions were collected and subjected to MP-TF activity analysis. For 
baseline measurements, PPP, MoMPs, and PPP spiked with MoMPs before beads 
separation were used. 
 
The results of the MP-TF activity measurements are shown in Figure 6 and Table 
1. In Figure 6 it is shown that MPs isolated from PPP have no active TF, while as 
expected MoMPs isolated from supernatant of monocytes stimulated with LPS for 
6, 18, and 24 h have active TF, which is completely inhibited by an anti-TF 
antibody. TF activity was also present in the MPs isolated from PPP spiked with 
MoMPs; however, the TF activity was 2-fold lower than expected on the basis of 
the TF activity of the isolated MoMPs added, which might be due to loss of MPs 
during the isolation of MPs from PPP. After the column separation we found TF 
activity both in the positive and negative fractions of PPP spiked with MoMPs 
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isolated from the supernatant of monocytes stimulated with LPS for 0, 6, 18, and 
24h. This indicated that both CD14-positive and negative MoMPs have active TF. 
When the MP-TF activities (fM FXa/min) of PPP spiked with MoMPs before and 
after beads separation were compared, we found that after beads separation the 
combined MP-TF activities of the positive and negative fractions were about 1.2-




Figure 6. MP-TF activity of PPP spiked with MoMPs before and after beads separation. PPP spiked with 
MoMPs were incubated with biotinylated anti-human CD14 MoAb and streptavidin magnetic beads. This 
mixture was subjected to a column for magnetic beads separation. Positive and negative fractions from 
this beads separation were collected and measured by MP-TF activity assay in the presence (hatched 
bar) or absence (black bar) of an anti-TF antibody. PPP without MoMPs, MoMPs alone, and PPP spiked 
with MoMPs before beads separation were used as baseline measurements. 
 
Table 1. TF activity levels (expressed as fM FXa/min) of PPP spiked with MoMPs before and after 












Samples fM FXa/min 
Before beads separation 
MoMPs (0h) + PPP 
MoMPs (6h) + PPP 
MoMPs (18h) + PPP 






After beads separation 
Positive + negative fractions (0h) 
Positive + negative fractions (6h) 
Positive + negative fractions (18h) 










In this study we present a method to use a combination of a biotinylated antibody 
and streptavidin magnetic beads to capture a specific subset of MPs from plasma. 
A positive fraction (containing selected subset of MPs) bound to the beads was 
separated from the negative fraction (containing the depleted plasma) and these 
fractions can be analysed for specific markers like for instance TF activity.  
 
This immuno-magnetic beads method was optimized to capture PMPs. We used 
biotinylated anti-human CD41 MoAb at a concentration that saturated the surface 
antigen CD41 of MPs. The streptavidin beads were added in excess to bind all 
biotinylated antibodies present in the plasma. To obtain a specific interaction 
between the antibody and the surface antigen of MPs, it is important to first 
incubate plasma with the biotinylated antibody before the streptavidin magnetic 
beads are added. The biotin-streptavidin interaction was chosen for this procedure 
because the non-covalent interaction between biotin and streptavidin is the 
strongest interaction known with a dissociation constant, K(d), in the order of 4x10-
14 M (26). The bond also forms very rapidly and is stable over a wide range of pH 
and temperature (27).  
 
The capture of the CD41-positive MP subset from plasma was successful as flow 
cytometry analysis demonstrated that these MPs were barely found in the negative 
(depleted) fraction obtained after column separation (Figure 3). The recovery of the 
CD41-positive MPs in the positive fraction could not accurately be quantified by 
flow cytometry. The magnetic beads (diameter: ~50 nm) which were still attached 
to CD41-positive MPs after the column separation apparently hindered the 
detection of MPs by using fluorescently labelled anti-human CD61 MoAb and flow 
cytometry. To capture CD41-positive PMPs, PPP of healthy volunteers were used. 
As these plasma contained very low MP-TF activity (~20 fM Xa/min), it was not 
possible to obtain accurate results for the MP-TF activity measurements in the 
positive and negative fractions. 
 
We also tested the immuno-magnetic beads method to capture CD14-positive MPs 
from plasma and analysed the positive and negative fractions for MP-TF activity. 
However, the concentration of MoMPs in plasma of healthy individuals is low 
(about 2% of the total blood MP population) (8;11). Thus, MoMPs isolated from 
LPS-stimulated monocytes were used as a model of monocyte derived active TF 
bearing MPs and spiked to plasma of a healthy volunteer. We found TF activity 
both in the positive (CD14-positive) and negative (CD14-negative) fractions of 
plasma spiked with these MoMPs. This is in agreement with our finding that not all 
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active TF carrying MoMPs isolated from the supernatant of LPS stimulated 
monocytes were CD14 positive.   
  
In conclusion, the immuno-magnetic beads method can be used for capture 
specific subsets of MPs directly from plasma. For future application, other specific 
biotinylated antibodies can be used to capture different subsets of MP from 
plasma. Ultimately this approach will help us to identify the cellular sources of MP 
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Multiple myeloma (MM) is associated with an increased risk of venous 
thromboembolic (VTE) complications. Aim of this study was to measure 
microparticle-associated tissue factor (MP-TF) activity in patients with newly 
diagnosed MM before and after chemotherapy and to investigate whether MP-TF 
activity is associated with VTE. MP-TF activity was assessed in 122 newly 
diagnosed MM patients who were eligible for combination chemotherapy. MP-TF 
activity levels (17.6 fM Xa/min [8.6-33.2] (median [IQR]) were higher in untreated 
MM patients compared to normal healthy volunteers (4.1 fM Xa/min [2.3-6.6], p 
<0.001). MP-TF activity prior to the start of treatment was not different between 
patients who developed a VTE during follow-up (n=15) and those who did not 
(n=107). In 75 patients in whom plasma was obtained before and after 
chemotherapy, MP-TF activity decreased significantly (from 17.4 [10.2-32.8] to 
12.0 [7.0-18.5] fM Xa/min, P=0.006). MP-TF activity remained, however, elevated 
in patients who developed VTE (15.1 [10.3-25.2]), in contrast to patients not 
developing VTE (11.4 [7.0-25.2], P<0.001). In conclusion, MP-TF activity is 
increased in patients with MM. Whether MP-TF activity has a pathogenetic role in 
VTE in MM patients remains to be established in future studies.  




An increased risk of venous thrombo-embolism (VTE) is observed in multiple 
myeloma (MM), especially when these patients are treated with combination 
treatment including high dose dexamethasone, doxorubicin or multi-agent 
chemotherapy in combination with thalidomide or lenalidomide (1-2). The exact 
mechanism of the increased risk of VTE is not yet fully understood, but a number of 
mechanisms have been proposed to contribute to the development of the 
hypercoagulable state in these patients. These include increased levels of factor 
VIII or von Willebrand factor and hypofibrinolysis (3-6). Furthermore, an association 
between acquired APC resistance and the occurrence of VTE in MM has also been 
reported (5, 7).  
 
Tissue factor is the principal initiator of the coagulation cascade and can be 
demonstrated on circulating microparticles that are released from cells following 
activation or during apoptosis (8-9). In addition tissue factor is expressed on the 
surface of cells in many tumour types and the expression appears to correlate with 
grade of malignancy and with tumour progression (10-12) TF expression of various 
tumour types has been associated with the risk of development of VTE 
complications (13). Tesselaar et al. observed an association of microparticle 
associated-tissue factor (MP-TF) activity and VTE using a functional assay to 
measure TF activity in the MP fraction of plasma (MP-TF activity) in patients with 
disseminated mucinous adenocarcinoma (14). More recent studies have shown 
similar results for other types of cancer (15-17). Zwicker et al showed that elevated 
levels of TF-MP were associated with an increased cumulative incidence of VTE 
(16, 18). Also Khorana et al. found an association between TF antigen levels, TF 
MP procoagulant activity and development of VTE (19). Some of these studies 
indicate that at least part of the TF+ MP is derived from tumour cells, but also 
platelet-derived and monocyte-derived MPs are increased (16, 20-21). Despite the 
fact that several patient groups with different types of cancer have been studied, no 
data are available on MP-TF activity in MM patients, who have a very high risk of 
developing VTE. 
 
Therefore the aim of the current study was to investigate MP-TF activity in MM 








A total of 122 patients with newly diagnosed MM according to the Mayo Clinic 
criteria who were eligible for chemotherapy followed by autologous stem cell 
transplantation were included in the study (22). The patients were admitted to the 
department of Haematology of the Erasmus MC Rotterdam, an academic tertiary 
referral hospital in the Netherlands. These patients were recruited from the 
HOVON-50 MM (METC no 01/080) and HOVON-65 MM/GMMG-HD4 (EUDRACT 
no 2004-000944-26) studies. Only patients who were eligible for intensive 
chemotherapy with high dose melphalan and autologous stem cell support were 
included. The Central Medical Ethical Committee of the Erasmus MC approved the 
study and written informed consent was obtained from all patients before 
performing the investigation. Patients were randomized to  received either 3 
courses of VAD (doxorubicin [9 mg/m2 i.v., day 1-4], dexamethasone [40mg orally, 
day 1-4, 9-12, 17-20] and vincristine [0.4 mg i.v., day 1-4]), or TAD (thalidomide 
200 mg orally daily, doxorubicin [9 mg/m2 i.v., day 1-4], dexamethasone [40 mg 
orally, day 1-4, 9-12, 17-20] or PAD (bortezomib [1.3 mg/m2 i.v., days 1,4,8,11], 
doxorubicin [9 mg/m2 i.v., day 1], dexamethasone [40 mg orally day 1-4, 9-12, 17-
20]). During thalidomide treatment, patients received a prophylactic dose of LMWH 
(nadroparin 2850 IE anti-Xa (body weight < 90kg) or 5700 IE anti-Xa (body weight 
≥ 90kg) subcutaneously. At entry in the study the patients were staged according to 
the criteria of Salmon and Durie, as well as to the recently introduced prognostic 
International Staging System (ISS) (23-24). Plasma levels of MP-TF activity were 
also determined in twenty healthy volunteers (median age 48 years [range 31-69], 
45% males). 
 
In case patients had complaints suggestive of pulmonary embolism, standardized 
diagnostic strategies were used, including computed tomography of the chest and 
compression ultrasonography in case of complaints suggestive for deep venous 
thrombosis of the leg or arm in order to confirm or exclude the VTE. When a VTE 
was confirmed oral anticoagulant (coumarin) was initiated in therapeutic dose (INR 
2.5-3.5). 
  
Materials & methods 
 
Venous blood was collected using a vacutainer system in citrate (0.105 M, Becton-
Dickinson, Plymouth, UK). The first five mL of blood were discarded. Platelet-free 
plasma (PFP) was prepared by double centrifugation (4°C at 2,000g for 10 minutes 
[min] followed by 10 min at 4°C at 21,475g) and sto red in small aliquots at –70°C 
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until use. The blood samples were collected at time of diagnosis (time point 1) and 
after three courses of multi-agent chemotherapy (time point 2). Plasma was 
immediately snap frozen in liquid nitrogen and stored at –70oC until use. The same 
procedure was used for the preparation of plasma of patients and of healthy 
volunteers. Plasma was obtained at entry of the study of 122 patients, and plasma 
was collected at the second time point (after induction chemotherapy) in 75 of the 
122 patients. Of the 122 patients 15 developed a VTE during follow-up, of whom 
plasma samples were available of 11 patients at the second time point. 
 
Dioleoylphosphatidlyserine (DOPS) and Dioleoylphosphatidylcholine (DOPC) were 
purchased from Avanti Polar Lipids (Alabaster, AL). Hirudin was from Sigma 
(Germany). The human Factor VII (FVII) and Factor X (FX) were obtained from 
Kordia Life Sciences (Leiden, NL). Sheep anti-human Tissue Factor IgG1 (TF) was 
from Affinity Biologicals (Ancaster, Canada). Chromogenic substrate S-2765 was 
from Instrumentation Laboratory Company (Milano, Italy). Innovin was obtained 




The isolation of MP was performed as previously described (25). In order to reduce 
the contamination with plasma proteins MPs were washed extensively (<0.5% in 
the final MP preparation). In brief, two vials (each 250 µL) of frozen plasma were 
thawed at 37°C and then vortexed thoroughly. The vi als were centrifuged at 
18,890g, 20°C for 30 min. The supernatants were rem oved carefully except for 25 
µL containing the MP pellet. Subsequently, each pellet was washed with 475 µL 
PBS containing 0.32% citrate (pH 7.45) and centrifuged (18,890g, 20°C, 30 min). 
This wash and centrifugation step was repeated once with 225 µL PBS-citrate. The 
supernatants were removed carefully except for the 25 µL containing the MP pellet. 
Finally, the two MP pellets were resuspended, pooled, and directly assayed for TF 
activity. The number of platelets in platelet-free plasma (PFP) is 1.72x106/L 
plasma, which is 16-fold lower than in platelet-poor plasma (PPP) prepared by a 
single centrifugation of 1,550g for 20 min. The MP fraction isolated form 
frozen/thawed PFP contains 10-fold less MPs when compared to MP fraction 
isolated from frozen/thawed PPP (1.3 x 108/L and 1.4x109/L, respectively). This 
conclusion is based on the results of flow cytometry measurements (scatter) on 





Figure 1: FACS analysis of MPs isolated from PFP (B) and PPP (C). The MP gate (R1) was defined 
using Hepes buffer (pH 7.45) containing 137 mM NaCl, 4 mM KCl (A.). MPs were isolated from 250 µL 
plasma and resuspended in 100 µL Hepes buffer; 5 µL of this suspension was diluted to 350 µL for 
FACS analysis; the Figures show duplicates of the scatter events in 74 µL of the measured suspension. 
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Tissue factor activity assay 
 
MP-associated TF activity was measured at room temperature by determining the 
FVII-dependent factor Xa (FXa) generation in the presence of excess negatively 
charged phospholipids. MP-TF activity is expressed as fM FXa/min. This relates to 
the activity of the TF-VIIa complex when all TF has been saturated with FVIIa. In all 
samples, FXa generation was measured both in the presence and absence of FVII 
and in the presence and absence of sheep anti-human TF IgG1 to confirm the FVII-
and TF-dependence of the FXa generation. Twenty five µM DOPS: DOPC (10:90) 
were incubated for 15 min in 10 mM Hepes buffer (pH 7.45) containing 137 mM 
NaCl, 4 mM KCl, 5 mg/mL Ovalbumine, 6 mM CaCl2, and 50 nM Hirudin. In 100 µL 
of this solution, 20 µL of MP-suspension was added and incubated for 15 min 
before 40 µL of 1.1 nM FVII (or buffer) was added. After 10 min, 25 µL S2765 was 
added and the reaction was started by adding 40 µL of 250 nM FX. The rate of p-
Nitroaniline (pNA) formation as a product of the reaction was measured at 405 nm 
(expressed in mAbs) for 90 min, plotted as a function of time (t) and, after 
correction for the absorbance in the absence of FVII, as a function of t2. The slope 
of the latter curve is a measure for the rate of FXa generation and expressed as 
mAbs/min2 or as fM FXa/min. The MP-associated TF activity was calculated from 
the difference in the rate of Xa generation in the absence and presence of 11.1 
µg/mL anti-TF antibody and reported as fM Xa/min in the assay. Dilutions of a 
recombinant full length TF (Innovin, 750 pg/mL and 150 pg/mL) were used as 
positive controls and to monitor interassay variation of the TF activity assay. 
Plasma of a patient with elevated MP-TF activity was used for the measurement of 
the interassay variation of the complete procedure, including the isolation of MP 
from plasma and the measurement of TF activity. Both CVs were <10% (N=9). This 
variation includes the MP isolation from plasma and the MP-TF activity 




Since the levels of MP-TF activity are not normally distributed, also not after 
transformation, the basic descriptive statistics are presented as median and 
interquartile range for continuous variables and as count (percentages) for 
categorical variables. Differences between two groups were tested with the Mann-
Whitney test. Comparisons over time were evaluated with a paired analysis using 
the Wilcoxon signed rank test. The association between VTE risk and MP-TF 
activity was assessed by logistic regression analysis. All statistical analyses were 








A total of 122 patients with MM were included in this prospective study, of whom 39 
(32%) had stage I, 66 (54%) stage II and 16 (13%) had stage III disease according 
to the ISS criteria (23). The median age was 55 years (range 29-71) and 58% were 
males. Seventy patients received VAD, thirty-six TAD and fifteen PAD induction 
chemotherapy. The baseline patient characteristics are summarized in Table 1. Of 
the 122 included patients a post-treatment blood sample was obtained of 75 
patients. The baseline characteristics were not different between these 75 patients 
and the 47 of whom only a pre-treatment plasma sample was obtained, with the 
exception of a slightly lower hemoglobin level at diagnosis (7.1 [6.4-7.9] vs 6.5 [5.7-
7.2], p=0.01 (Table 2).  
 




MP-TF activity at baseline and after induction chemotherapy 
 
The results of the MP-associated tissue factor activity levels are summarized in 
Table 3. The median MP-TF activity of the total group of patients with MM was 17.6 
fM Xa/min (IQR 8.6-33.2), which was significantly higher than that in healthy 
volunteers (4.1 fM Xa/min (IQR 2.3-6.6); P<0.001, range 0-11.8) (Figure 2).  
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Figure 2: MP-Tissue factor activity in fM Xa/min in MM patients, before (n=122) and after induction 
chemotherapy (n=75) and in healthy subjects (n=20). The horizontal line indicates the median level. P-
value denotes the difference between both before and after treatment versus healthy subjects. The p-
values of paired analysis between before and after treatment are given in Table 3. 
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We observed significantly lower MP-TF activity levels in MM patients with light 
chain lambda (12.1 fM Xa/min [IQR 5.7-18.4] than in MM patients with light chain 
kappa (24.0 fM Xa/min [11.8-37.9]; p<0.05). None of the clinical patient 
characteristics (sex, beta-2 microglobulin, albumin, calcium, hemoglobin, platelets 
or disease stage) correlated with the MP-TF activity levels. MP-TF levels were not 
associated with age (r2 =0.102). There was no significant difference in TF-MP 
activity at baseline between the 47 patients of whom no second blood sample was 
obtained (17.8 fM Xa/min [6.7-36.1]) and the 75 patients of whom also blood was 
drawn after chemotherapy (17.4 fM Xa/min [10.2-32.8], p=0.45). 
 




Paired analysis in 75 patients of whom plasma was obtained at two time points, 
before and after chemotherapy, of MP-TF activity revealed a significant reduction 
of MP-TF activity following induction treatment (from 17.4 fM Xa/min [10.2-32.8] to 
12.0 fM Xa/min [7.0-18.5], P=0.006, Table 3). This reduction was observed in all 
ISS stages of disease. Subgroup analysis for the different induction treatments 
revealed that VAD, TAD and PAD induced similar decrease of MP-TF activity 
levels (data not shown). When comparing MP-TF activity at the moment of 
response evaluation after the induction chemotherapy, no relationship between the 
change in MP-TF activity and the remission status (CR versus PR versus SD/PD) 
could be observed (data not shown). In addition the MP-TF activity levels were 
independent from the absolute or relative M-protein levels before and after 
induction therapy. 
  
MP-TF activity and venous thrombosis 
 
Fifteen of the 122 patients (12%) developed a VTE complication during the 
induction treatment (n=13) or high dose melphalan treatment and autologous stem 
cell transplantation (n=2). The baseline characteristics were similar for patients 
who did and did not develop VTE (Table 1). The incidence of VTE was 10% in the 
VAD treated patients, 16.7% in patients treated with thalidomide (TAD) and 13% in 
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patients who received Bortezomib (PAD).  The MP-TF activity prior to the start of 
treatment was not different between patients who developed VTE (16.8 [11.4-36.1]; 
n= 15), and those who did not (17.8 [8.1-32.5]; n=107). In the 75 patients of whom 
plasma was obtained before and after chemotherapy we found that in the patients 
who did not develop VTE (n=64) during the course of treatment, the MP-TF activity 
levels decreased significantly (from 18.3 [IQR 9.8-32.6]) to 11.4 [IQR 7.0-25.2]; 
P<0.001). In contrast, in patients who did develop VTE (n=11) the MP-TF activity 
levels remained unchanged after induction chemotherapy (from 16.8 [IQR 11.4-
34.6]) to 15.1 [IQR 10.3-25.2]; P=0.71, Figure 3). We calculated the risk of VTE in 
MM patients based on MP-TF activity levels below (n=40) and above (n=82) the 
upper limit in the healthy volunteers (11.8 fM Xa/min). The calculated risk for VTE 
in individuals with high MP-TF levels was 1.4 (0.4-4.7) [OR (95% CI)], for TF levels 
measured before start of induction and 3.0 (0.7-12.4) for MP-TF levels measured 




Figure 3: MP-Tissue factor activity in fM/Xa/min before and after induction chemotherapy in 75 MM 
patients, of whom plasma was available for two time points who did (VTE, n=11) and who did not (no 





In this study we have shown that MP-TF activity levels are increased in patients 
with MM. The MP-TF activity levels in these patients decrease after induction 
chemotherapy. In patients experiencing VTE during or following treatment of MM, 
MP-TF activity levels did not decrease in contrast to the non-VTE patients in whom 
MP-TF activity decreased significantly compared to baseline.  
 
Tissue factor is commonly regarded as the main determinant of a hypercoagulable 
state in patients with cancer (26). We measured tissue factor activity on circulating 
microparticles, small membrane vesicles derived from different cell types, including 
monocytes, platelets and tumour cells (14). In patients with untreated MM we 
observed increased MP-TF activity levels compared to healthy controls. From 
previous studies it is well known that several tumour types express high levels of 
tissue factor on their surface (13, 27). In addition, Kakkar et al. have shown that 
plasma tissue factor levels are increased in patients with malignancy (28). Also in 
patients with haematological disease, including acute myeloid leukaemia and 
malignant lymphoma, high plasma tissue factor antigen levels have been observed 
(29). Tissue factor messenger RNA levels in leukocytes from patients with 
hematopoietic tumours are increased compared to healthy controls (30). More 
recently plasma levels of tissue factor antigen were not found to be elevated in a 
small number of MM patients and also tissue factor mRNA levels measured in 
peripheral blood mononuclear cells were not elevated in these patients (31).  In a 
recent study Shimizu described tissue factor production by clonal plasma cells in a 
patient with MM. In these plasma cells the cytoplasm stained positive for TF, which 
disappeared after chemotherapy (32).  Since membrane-bound tissue factor exists 
both in an encrypted, inactive form as in an active form, tissue factor plasma 
antigen levels may not be representative of tissue factor activity in plasma, and 
therefore measurement of plasma tissue factor activity levels is preferred. We 
measured increased MP-TF levels in myeloma patients compared to healthy 
individuals. The levels of MP-TF activity in our study are lower in patients and 
control subjects than those reported previously by Tesselaar et al. (14). 
Centrifugation speed during plasma preparation has an effect on the number MPs 
in the final preparation. In the present study we used platelet-free plasma for the 
MP isolation (10 min at 2,000g followed by 10 min at 21,475g), while Tesselaar et 
al. used platelet-poor plasma (single centrifugation, at 1,550g for 20 min). This 
double centrifugation resulted in an about tenfold reduction of MP numbers in the 
isolated MP preparation as measured by FACS analysis (see methods section and 
Figure 1).  
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At present we do not know the cellular source of the MPs carrying active TF. 
Previously it has been shown that TF bearing MPs may be derived form cancer 
cells, platelets and leucocytes (14, 21, 33). Information on the cellular source of the 
MPs that carry TF activity would be extremely helpful to determine the 
pathogenetic role of these MPs in the development of thrombosis.  
 
The stage of disease according to Salmon-Durie or the prognostic ISS stages were 
not correlated with the levels of MP-TF activity, suggesting that the tumour load is 
not associated with MP-TF activity levels.  Remarkably, patients with a lambda type 
M-component exhibited significantly lower MP-TF activity compared to the kappa 
type M-component. The clinical significance of this observation is not yet clear 
since there are no data in the literature, which indicate a different incidence of 
thrombo-embolic complications.  
 
Thrombo-embolic complications were observed in 15 patients (12%) and occurred 
with a similar frequency during all three chemotherapeutic regimens. It should be 
noted that patients, who were treated with chemotherapy in combination with the 
anti-angiogenic drug thalidomide, also received thromboprophylaxis with LMWH. 
Despite this thromboprophylaxis, 17% of patients treated with TAD experienced a 
thrombo-embolic complication. Interestingly, in patients who developed VTE, MP-
TF activity levels remained elevated after induction treatment, while in patients who 
did not develop VTE the levels decreased significantly.  
 
The high levels of MP-TF activity measured after induction treatment may suggest 
a pathogenetic role of MP-TF in the development of VTE in patients with MM. 
However the persistent high MP-TF levels may also be a result of thrombus 
formation. Because we measured MP-TF activity only twice it is difficult to establish 
that the highest levels of MP TF activity were observed at a time associated with 
thrombosis. It is known from previous studies that VTE in MM patients is most 
frequently observed during the first months of treatment (3, 34-35). This coincides 
with the highest MP-TF activity levels in plasma, as found in our study. It is also 
possible that MP-TF activity levels remained high as a consequence of the 
development of VTE. A causative role of MP-TF activity in the development of VTE 
can therefore not be established from our study. This should be assessed in larger 
studies, in which MP-TF activity is measured more frequently during induction 
treatment of MM. 
 
The results of our study may have implications for prophylactic antithrombotic 
treatment of MM patients to prevent VTE during chemotherapy. So far no 
consensus on the optimal prophylactic antithrombotic regimen has been reached 
(2). Nowadays MM patients receive no prophylaxis, LMWH, fixed low-dose warfarin 
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or aspirin as prophylaxis (2, 35-36).  The observation that MM patients have 
increased levels of MP-TF activity may suggest that antithrombotic agents targeted 
at inhibition of TF-initiated secondary hemostasis by LMWH or vitamin K 
antagonists is preferable to aspirin. 
  
Our patients were treated with multi-agent chemotherapy and after three courses 
the MP-TF activity levels decreased irrespective of the therapeutic regimen (VAD 
or TAD or PAD). Chemotherapy in combination with anti-angiogenic drugs in MM is 
associated with the highest risk of thrombo-embolic complications. Our results 
indicate that this high risk in the TAD treated patients cannot be attributed to an 
increase of MP-TF activity (37).  
 
In conclusion, MP-TF activity levels are increased in patients with MM and 
decrease significantly after induction chemotherapy. MP-TF activity levels after 
chemotherapy remained high in patients developing VTE. Whether MP-TF activity 








(1)  Zangari M, Elice F, Fink L, Tricot G. Thrombosis in multiple myeloma. Expert Rev Anticancer 
Ther. 2007 Mar;7(3):307-315. 
(2)  Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. 
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 
2008 Feb;22(2):414-423. 
(3)  Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW. Prothrombotic coagulation abnormalities 
in patients with newly diagnosed multiple myeloma. Haematologica. 2007 Feb;92(2):279-280.  
(4)  Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM. Extremely high levels of von Willebrand 
factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated 
with activity status but not with thalidomide treatment. J Thromb Haemost. 2003 Mar;1(3):445-
449. 
(5)  Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C 
(aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of 
venous thromboembolism. Br J Haematol. 2006 Aug;134(4):399-405. 
(6)  van Marion AM, Auwerda JJ, Minnema MC, van Oosterom R, Adelmeijer J, de Groot PG, et al. 
Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous 
thrombosis. Thromb Haemost. 2005 Dec;94(6):1341-1343. 
(7)  Jimenez VHs, Dominguez VJs. Acquired activated protein C resistance and thrombosis in 
multiple myeloma patients. Thromb J. 2006 Aug 21;4(1):11. 
(8)  Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, et al. Blood-borne tissue factor: 
another view of thrombosis. Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2311-2315. 
(9)  Morel O, Toti F, Hugel B, Freyssinet JM. Cellular microparticles: a disseminated storage pool of 
bioactive vascular effectors. Curr Opin Hematol. 2004 May;11(3):156-164. 
Microparticle-associated tissue factor activity 
 153 
(10)  Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RC. Tissue factor expression 
correlates with histological grade in human pancreatic cancer. Br J Surg. 1995 Aug;82(8):1101-
1104. 
(11)  Uno K, Homma S, Satoh T, Nakanishi K, Abe D, Matsumoto K, et al. Tissue factor expression as 
a possible determinant of thromboembolism in ovarian cancer. Br J Cancer. 2007 Jan 
29;96(2):290-295. 
(12)  Wojtukiewicz MZ, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in 
malignancy. Neoplasia. 2001 Sep-Oct;3(5):371-384. 
(13)  Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, et al. Tissue factor 
expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007 May 
15;13(10):2870-2875. 
(14)  Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-
associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost. 
2007 Mar;5(3):520-527. 
(15)  Manly DA, Wang J, Glover SL, Kasthuri R, Liebman HA, Key NS, et al. Increased microparticle 
tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res. 2010 
Jun;125(6):511-512. 
(16)  Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, et al. Tumor-derived tissue 
factor-bearing microparticles are associated with venous thromboembolic events in malignancy. 
Clin Cancer Res. 2009 Nov 15;15(22):6830-6840. 
(17)  Toth B, Liebhardt S, Steinig K, Ditsch N, Rank A, Bauerfeind I, et al. Platelet-derived 
microparticles and coagulation activation in breast cancer patients. Thromb Haemost. 2008 
Oct;100(4):663-669. 
(18)  Zwicker JI. Predictive value of tissue factor bearing microparticles in cancer associated 
thrombosis. Thromb Res. 2010 Apr;125 Suppl 2:S89-91. 
(19)  Khorana AA, Francis CW, Menzies KE, Wang JG, Hyrien O, Hathcock J, et al. Plasma tissue 
factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost. 
2008 Nov;6(11):1983-1985. 
(20)  Tesselaar ME, Osanto S. Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med. 
2007 Sep;13(5):362-367. 
(21)  Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S, et al. Tissue factor-
positive microparticles: cellular origin and association with coagulation activation in patients with 
colorectal cancer. Thromb Haemost. 2007 Jan;97(1):119-123. 
(22)  Kyle RA. Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am. 1992 
Apr;6(2):347-358. 
(23)  Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging 
system for multiple myeloma. J Clin Oncol. 2005 May 20;23(15):3412-3420. 
(24)  Durie BG, Salmon SE. Cellular kinetics staging, and immunoglobulin synthesis in multiple 
myeloma. Annu Rev Med. 1975;26:283-288. 
(25)  Vanwijk MJ, Svedas E, Boer K, Nieuwland R, Vanbavel E, Kublickiene KR. Isolated 
microparticles, but not whole plasma, from women with preeclampsia impair endothelium-
dependent relaxation in isolated myometrial arteries from healthy pregnant women. Am J Obstet 
Gynecol. 2002 Dec;187(6):1686-1693. 
(26)  Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest. 2003 
Sep;124(3 Suppl):58S-68S. 
(27)  Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells 
promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A. 1992 Dec 
15;89(24):11832-11836. 
(28)  Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RC. Extrinsic-pathway 




(29)  Sase T, Wada H, Yamaguchi M, Ogawa S, Kamikura Y, Nishikawa M, et al. Haemostatic 
abnormalities and thrombotic disorders in malignant lymphoma. Thromb Haemost. 2005 
Jan;93(1):153-159. 
(30)  Sase T, Wada H, Kamikura Y, Kaneko T, Abe Y, Nishioka J, et al. Tissue factor messenger RNA 
levels in leukocytes compared with tissue factor antigens in plasma from patients in 
hypercoagulable state caused by various diseases. Thromb Haemost. 2004 Jul;92(1):132-139. 
(31)  Negaard HF, Iversen PO, Ostenstad B, Iversen N, Holme PA, Sandset PM. Hypercoagulability 
in patients with haematological neoplasia: No apparent initiation by tissue factor. Thromb 
Haemost. 2008 Jun;99(6):1040-1048. 
(32)  Shimizu K, Itoh J. A possible link between Trousseau's syndrome and tissue factor producing 
plasma cells. Am J Hematol. 2009 Jun;84(6):382-385. 
(33)  Key NS, Chantrathammachart P, Moody PW, Chang JY. Membrane microparticles in VTE and 
cancer. Thromb Res. 2010 Apr;125 Suppl 2:S80-83. 
(34)  Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and 
prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in 
elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006 Mar 
11;367(9513):825-831. 
(35)  Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, et al. Deep vein 
thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: 
effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004 Sep;126(5):715-
721. 
(36)  Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated with 
immunomodulatory drug combinations. Thromb Haemost. 2006 Jun;95(6):924-930. 
(37)  Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, et al. Thalidomide and 
















Although the intriguing association between cancer and thrombosis has been 
recognized since the 19th century, the mechanism(s) underlying this association 
have not been revealed yet. In the past years it has been suggested that 
microparticles (MPs; also known as microvesicles) derived from various types of 
cells and formed by budding of cell membranes upon activation and apoptosis may 
play a role in cancer-associated thrombosis. These MPs still bear antigens from 
their parental cells (blood cells, endothelial cells, and most likely also tumour cells). 
In addition they carry the negatively charged phosphatidylserine (PS) on their 
membrane surface as the result of membrane remodelling during their formation 
(1;2). Interestingly, MPs bearing tissue factor (TF), the major initiator of blood 
coagulation, are increased in plasma of patients with certain types of cancer (3-6). 
Unfortunately, the growing interest to study the role of MPs in health and disease is 
limited by the lack of well standardized pre-analytical and analytical procedures 
resulting in a wide variation in the results reported by different research groups 
(1;2).  
 
The aim of the studies described in this thesis was to develop novel methodology 
for the sensitive detection and accurate quantification of (subsets of) MPs in their 
native state and for the analysis of the cellular origin of MPs bearing active TF. In 
addition, a possible association between MPs bearing active TF and the 
development of venous thrombosis (VTE) was investigated in patients with multiple 
myeloma. 
 
Measurement of microparticles 
 
Important factors  
 
Several pre-analytical conditions such as blood collection, centrifugation used to 
prepare plasma/MPs, and storage (including freezing-thawing) of plasma may 
influence the outcome of the measurement of MPs. In Chapter 2 of this thesis we 
discussed that during blood collection, it is necessary to prevent ex vivo activation 
of blood which may lead to inadvertent production of erythrocyte MPs (ErMPs) or 
platelet MPs (PMPs). We recommend that blood should be drawn by using a large 
diameter needle, for example a 21-G needle, and that prolonged placement of a 
tourniquet during venepuncture should be avoided.  
 
Plasma for MP measurements is usually prepared from blood collected in 1/10 
volume of sodium citrate (0.105 or 0.129 mol/L). The choice of this anticoagulant is 
based on international guidelines for routine haematology testing but might be less 
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optimal for MP measurements. Therefore, more information is needed on the 
stability of MPs in blood collected in other anticoagulants such as 
ethylenediaminetetraacetic acid (EDTA) and citrate theophylline adenosine 
dipyridamole (CTAD) in comparison to that in citrate.  Furthermore, the entire 
process from blood collection until plasma preparation should be rapid and gentle 
to avoid ex vivo activation of blood cells in the collection tube. The removal of 
platelets from plasma by centrifugation is crucial, but at the same time the 
centrifugal force used should not trigger inadvertent formation of PMPs.  
 
Preferably, MP measurements should be performed directly in fresh plasma to 
reduce MP loss and to preserve MP characteristics. However, in multi-centre 
studies and prospective trials it is often inevitable to freeze and store the plasma 
samples before performing the analysis. Unfortunately, validated protocols are not 
yet available for freezing and thawing of plasma to be used for MP analysis. In 
Chapter 2 we recommend that when frozen-thawed plasma is used for MP 
measurements, especially PMP and annexin V-positive MP counts should be 
interpreted with caution. 
 
As mentioned in the general introduction of this thesis, MPs vary in size in the 
submicron range. Therefore, a method which enables the detection of MPs within 
this size range is needed to provide an accurate measurement of total MPs in the 
sample. Current flow cytometers are not able to sensitively detect MPs smaller 
than 0.5 µm (7). Although there are advances made in developing new generation 
flow cytometers (5;8), they have not been tested extensively for routine 
measurements of MPs. Nevertheless, when flow cytometry is chosen as a method 
for quantification of MPs, some analytical conditions should be standardized. 
Recently, the Vascular Biology group of the Scientific and Standardization 
Committee (SSC) of the International Society on Thrombosis and Haemostasis 
(ISTH) proposed to standardize the enumeration of PMPs larger than 0.5 µm by 
using calibrated size standard beads (Megamix beads) to adjust the instrument 
setting and increase the resolution of the flow cytometer (9). 
 
Other methods used to study plasma MPs are electron microscopy, capture-based 
assays and functional assays of isolated MPs. In Chapter 2 we discussed the 
advantages and disadvantages of these methods. In general, they can be used to 
study plasma MPs as long as there is standardization of protocols, including the 
use of appropriate reagents and reference materials, to improve intra- and inter-
laboratory reproducibility. We also discussed some novel methods to measure MPs 
including proteomic analysis, impedance-based flow cytometry, atomic force 
microscopy (AFM), nanoparticle tracking analysis (NTA), and dynamic light 
scattering (DLS). At this moment, these methods are not easily applicable in the 
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clinic since they are time-consuming and labour-intensive. In addition, none of 
these methods gives information on the functional properties of MPs. 
 
Atomic force microscopy 
 
In Chapter 3 we report the development of a novel method to measure MPs by 
using AFM. This method is based on the capture of MPs by anti-human CD41 
monoclonal antibody (MoAb) coated on a modified mica surface. AFM operated in 
fluid/liquid tapping mode is used to detect MPs attached to the anti-CD41-coated 
surface. The advantages of this method are that forces as small as a few 
picoNewton can be sensitively detected and that sample properties are preserved. 
In this study, we observed that the binding of MPs to anti-CD41-coated mica 
seemed to be specific, as a markedly lower number of MPs bound to IgG1 isotype 
control-coated mica. Also, a linear relationship was obtained between the number 
of CD41-positive MPs per 100 µm2 surface and the MP concentration which 
saturated at a concentration of ~500 MPs per 100 µm2 surface. We quantified the 
number of CD41-positive MPs isolated from double-centrifuged fresh platelet-poor 
plasma (PPP) of 7 blood donors and 3 cancer patients both by AFM and flow 
cytometry. We found that the numbers of CD41-positive MPs measured by AFM 
were 1,000-fold higher than those measured by flow cytometry (3-702 x 109/L 
plasma vs. 11-626 x 106/L plasma). The MPs detected by AFM have diameters 
(dsph) ranging from 10-475 nm with a peak at 67.5 nm, which is clearly far below the 
detection limit of conventional flow cytometry. 
 
We also investigated whether the AFM method can be used to detect TF-bearing 
MPs (Chapter 4). To this purpose, we coated modified mica with FITC-labelled 
anti-human TF MoAb to capture MPs isolated from the supernatant of cultured 
MDA-MB231 cells stimulated with calcium ionophore. TF-positive MPs with 
diameters (dsph) ranging from 6-296 nm (median: 40.4 nm; mean: 46.4 ± 26.0 nm) 
were successfully captured on FITC-labelled anti-TF-coated surface. Only few MPs 
were captured on the mica surface coated with FITC-labelled mouse IgG1 isotype 
control MoAb. We also found that the numbers of TF-positive MPs measured by 
AFM were 2,000-fold higher than those measured by flow cytometry in the same 
sample (8 x 106 per µL supernatant vs. 4 x 103 per µL supernatant). 
 
To allow the detection of MPs directly in plasma, the use of a combination of 
microfluidics and AFM was investigated (Chapter 5). Tenfold-diluted EDTA PPP 
was flown through a microfluidic channel with a controlled pressure driven laminar 
flow to allow direct contact with anti-human CD41 antibody-coated mica. MPs 
bearing CD41 antigen were captured on this surface and subsequently detected by 
AFM operated in fluid tapping mode. The majority of the captured MPs have 
Summary and General Discussion 
 159 
diameters (dsph) of 45 nm (range: 30-90 nm), similar to prior results obtained with 
MPs immediately isolated from fresh PPP. Apparently, the high-speed 
centrifugation needed to isolate MPs did not influence the size distribution of MPs. 
Use of the microfluidic system also increased the efficiency of capturing MPs. We 
applied this microfluidic system to count PMPs in plasma from healthy donors and 
compared it with a drop method. We detected considerably more CD41-positive 
MPs per 100 µm2 surface when plasma was run through the microfludic system 
than when measured by the drop method. Our preliminary data also showed that 
there was a linear dose-response curve between the number of CD41-positive MPs 
per 100 µm2 surface and the MP concentration. 
 
In conclusion, AFM operated in fluid tapping mode can sensitively detect and 
accurately quantify subsets of MPs by using specific MoAbs. In combination with 
microfluidics MPs can be directly measured in plasma, thus, reducing time between 
venepuncture and MP measurement and also preventing MP loss because of 
washing steps in the isolation procedure. Importantly, as this method relies on the 
use of an antibody for the detection of MPs, a specific and high-affinity antibody is 
required to capture a specific MP subset on the mica surface.  Furthermore, to 
assess the precise number of MPs in a given sample, the availability of an external 




Conventional electron microscopy (EM) has been used to study the morphology of 
isolated MPs. However, the sample preparation and imaging techniques in 
conventional EM require dehydration, chemical fixation, and staining of specimens 
and are, therefore, less suitable to study the morphology of MPs directly in plasma. 
We investigated whether cyro-EM can be used to study the size and morphology of 
submicron particles (MPs and exosomes), and also to estimate the number of 
these particles in a fresh plasma sample without the use of staining or chemical 
fixation procedures. We used fresh plasma (platelet-rich plasma/PRP, PPP, 
platelet-free plasma/PFP), isolated MPs, and also (thrombin activated-) isolated 
platelets. These samples were directly applied onto an EM grid and vitrified for 
cyro-EM measurement (Chapter 6). 
 
In Chapter 6 we observed that platelets were more activated in fresh citrate PRP 
than in EDTA PRP, although clearly less than in samples of thrombin-activated 
platelets. Therefore, to reduce in vitro activation of platelets and PMP formation, 
blood collection in EDTA is recommended for the study of plasma MPs. Most of the 
submicron particles found in plasma of healthy volunteers were spherical electron 
dense particles resembling lipoprotein particles. Low numbers of electron lucent 
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particles with a discernable lipid bilayer (lipid vesicles) were also found. These 
could be MPs, exosomes or both. Similar lipid vesicles were found in samples of 
thrombin-activated isolated platelets and isolated MPs. All types of particles have 
about the same size distribution (median: 30 nm; range: 25-260 nm). Because MPs 
form only a minority of all submicron particles present in fresh plasma, we have to 
consider the limitations of techniques used to measure MPs directly in plasma. 
Finding ways to label MPs and/or exosomes directly in plasma will be essential for 
further studies of these particles by for instance NTA and cryo-EM. 
 
Immuno-magnetic beads capture 
 
There is not yet a method which provides information on the cellular origin of the 
plasma MPs carrying active TF. In Chapter 7 we report on the development of an 
immuno-magnetic beads method to capture a defined subset of MPs from plasma 
by using a specific biotinylated antibody and streptavidin magnetic beads.  
 
This method was optimized for the capture of PMPs from plasma of healthy 
volunteers. Plasma was incubated with biotinylated anti-human CD41 MoAb before 
streptavidin magnetic beads were added. After application of this mixture to the 
column, positive (containing the selected subset of MPs) and negative (containing 
the depleted plasma) fractions were collected and used directly for the isolation 
and analysis of MPs for specific antigens and TF activity.  
 
By using flow cytometry we showed that biotinylated anti-human CD41 MoAb 
specifically binds and saturates the surface antigen CD41 of PMPs. The 
streptavidin magnetic beads did not interfere with the binding of anti-CD41 and 
anti-CD61 antibodies to PMPs. After separation, there were no CD41-positive MPs 
and only few CD61-positive MPs in the negative fraction, indicating that almost all 
PMPs (CD41-positive MPs) were captured. This capture was CD41-specific as 
most of CD41/CD61-positive MPs were recovered in the negative fraction of the 
biotinylated IgG1-beads separation.  
 
Using biotinylated anti-CD14 MoAb at the same concentration as anti-CD41 MoAb, 
CD14-positive MPs were captured from normal plasma spiked with MPs isolated 
from the supernatant of LPS-stimulated isolated monocytes (MoMPs). TF activity 
was found both in the positive and negative fractions indicating that both CD14-
positive and -negative MoMPs have active TF. This seems in agreement with our 
finding that not all active TF carrying MoMPs isolated from the supernatant of LPS 
stimulated monocytes were CD14-positive.  
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In the future the beads capture method can be used to investigate the source of 
MPs carrying active TF in plasma of patients with cancer by using cell- or other 
tumour-specific antibodies such as  anti-MUC1 (breast and pancreatic cancer cells) 
(4;5), anti-FasL (melanoma cells) (10), anti-EGFRvIII (glioblastoma cells) (11), and 
anti-CXCR-4 (leukaemic cells) (12). 
 
MP-associated TF activity in patients with multiple myeloma 
 
For the measurement of MP associated tissue factor activity (MP-TF activity) 
freshly isolated MPs are supplemented with excess FVII(a) and FX in the presence 
of calcium, after which the formation of FXa is measured with a specific 
chromogenic substrate using either a one-stage (4;6;13) or two-stage approach 
(14;15). These two different approaches were discussed in detail in Chapter 2 of 
this thesis. To asses MP-TF activity in multiple myeloma (MM) patients, we used 
the one-stage approach (Chapter 8).  
 
Chemotherapy in combination with anti-angiogenic drugs in multiple myeloma is 
associated with a high risk of thrombo-embolic complications (16;17). We 
measured MP-TF activity in MPs isolated from PFP of 122 patients with newly 
diagnosed MM before and after chemotherapy to investigate whether MP-TF 
activity is associated with VTE. MP-TF activity levels of untreated patients were 
significantly higher than those in healthy volunteers [17.6 fM FXa/min (IQR 8.6-
33.2) versus 4.1 fM FXa/min (IQR 2.3-6.6), P<0.001]. None of the patient 
characteristics or laboratory measurements (sex, age, disease stage, beta-2 
microglobulin, albumin, calcium, haemoglobin, platelets) correlated with the MP-TF 
activity levels.  
 
MP-TF activity prior to the start of treatment was not different between patients who 
developed a VTE during follow-up (n=15) and those who did not (n=107). In 75 
patients in whom plasma was obtained before and after chemotherapy, MP-TF 
activity decreased significantly (from 17.4 [10.2-32.8] to 12.0 [7.0-18.5] fM Xa/min, 
P=0.006). This reduction was observed in all ISS stages of disease suggesting that 
the tumour load is not associated with MP-TF activity levels. The MP-TF activity 
levels also decreased irrespective of the therapeutic regimen [vincristine, 
adriamycin, and dexamethasone (VAD), thalidomide, adriamycin, and 
dexamethasone (TAD), or bortezomib, adriamycin, and dexamethasone (PAD)]. 
MP-TF activity remained, however, elevated in patients who developed VTE (15.1 




In future studies MP-TF activity should be assessed more frequently during 
induction treatment of MM to investigate whether MP-TF activity has a 




Thus far there is no general consensus on the size and number of MPs due to 
discrepancies between the results of MP measurements reported in the literature. 
We are aware that these discrepancies are not only caused by differences between 
the methods used to measure MPs. Pre-analytical procedures such as blood 
collection, plasma/MPs preparation, and storage are some of the important factors 
which might influence the number, morphology and characteristics of MPs. The use 
of EDTA instead of citrate as anticoagulant for blood collection to reduce in vitro 
activation of platelets and PMP formation (Chapter 6) is preferred for the study of 
plasma MPs. We also have an indication that the high-speed centrifugation used to 
isolate MPs has no effect on the size distribution of MPs (Chapter 5). Eventually, it 
is essential to set up guidelines for these pre-analytical procedures to improve 
intra- and inter-laboratory reproducibility.   
 
In the past, MPs were defined by having a size distribution in the micrometer 
range, whereas now we found them to be in the nanometer range (Chapter 3, 4, 5, 
and 6). This is explained by the technical limitations of the methods previously 
used to characterize MPs. For example, methods such as flow cytometry with a 
detection threshold of 0.5 µm and conventional EM for which dehydration, chemical 
fixation, and staining of specimens are needed for sample preparation, are less 
suitable for detection and characterization of MPs. Furthermore, there are no 
suitable reference materials (standards) to calibrate and adjust the settings of the 
methods for MP analysis (18). Currently, new methods such as AFM, NTA, and 
cryo-EM allow detection and characterization of MPs in the nanometer range and 
in their physiological state. However, these methods are not yet suitable for use in 
the clinic as they are low throughput, labour-intensive and still need to be optimized 
and validated (e.g. accuracy, precision, specificity, detection limit and 
quantification, linearity and range, robustness). Therefore, improvements are 
needed, for example by using automated sample handling systems, standardized 
reagents, reference materials for calibration and settings, and an external standard 
to obtain absolute numbers of MPs. Ultimately, a small MP measurement device 
which uses just a pinprick of blood and provides results in less than 30 minutes 
(lab-on-a-chip) would be desirable for a routine test.  
 
There is evidence that MP-TF activity is increased in cancer patients who develop 
(cancer-associated) VTE (4;6). Further investigations are needed to learn whether 
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MPs bearing active TF in cancer patients are indeed the cause of thrombosis. 
Furthermore, to understand the mechanism(s) of the association between cancer 
and thrombosis, it is important to identify whether MPs bearing active TF come 
from the cancer cell itself or not; in the latter case it is important to identify the cell 
of origin (monocytes, endothelial cells, platelets) and the mechanism by which the 
active TF is produced. 
 
Finally, further research is needed to investigate how MPs are precisely formed. 
According to a widely accepted hypothesis MPs are shed by cells as a result of 
loss of membrane phospholipid asymmetry during processes such as activation 
and apoptosis, exposing PS on the outer cell surface. This hypothesis is supported 
by the rare bleeding disorder, Scott syndrome. This syndrome is characterized by a 
decreased scramblase activity which results in reduced expression of PS and 
reduced MPs shedding (1;2). Interestingly, the existence of MPs that do not expose 
PS challenges the hypothesis of MP formation (19-22). It remains a matter of 
debate whether the existence of PS-negative MPs is the result of the limitations of 
the current methodology. Annexin V is widely used as a probe of PS exposure in 
methods to detect and quantify MPs such as flow cytometry and annexin V 
capture-based assays. However, the binding of annexin V to MPs depends on the 
calcium concentration and the membrane PS content (23;24). Another possible 
explanation for the finding of PS negative MPs might be that they are formed by 
multiple fusion events between plasma membrane components with cell debris or 
small endosomal secreted vesicles (exosomes) (25). Alternatively, MPs might be 
released from the plasma membrane as a result of destabilization of the actin 
cytoskeleton via αIIbβ3 signalling which does not require rearrangement of 
phospholipids distribution (26). 
 
In conclusion, MPs are no longer regarded as cellular debris or experimental 
artefacts, but in fact MPs may participate in processes of coagulation, inflammation 
and tumorigenesis. It is of interest to investigate from which cells MPs are formed, 
why they are formed and how they interact with other cells in the body. Therefore, 
standardisation of pre-analytical and analytical procedures for the measurement of 
MPs is urgently needed to understand their presence and to elucidate their 
physiological function and role in diseases. In the future the measurement of MPs 
will contribute to the development of MPs as diagnostic and perhaps predictive 
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Hoewel het intrigerende verband tussen kanker en trombose sinds de 19de eeuw 
bekend is, is het mechanisme dat deze samenhang verklaart  nog niet duidelijk. 
Micropartikels (MPs; ook wel microvesicles genoemd) kunnen ontstaan na 
activering van de cel  door afsnoering van de celmembraan of na apoptosis 
(geprogrammeerde zelfdood van de cel) en kunnen afkomstig zijn van diverse 
soorten cellen. Sinds enige jaren denkt men dat MPs een rol zouden kunnen 
spelen bij het ontstaan van kanker-geassociëerde trombose.  
 
MPs dragen nog kenmerken (antigenen) van de cellen waaruit ze gevormd 
werden, bloedcellen, vaatendotheelcellen, en vermoedelijk  ook tumorcellen. 
Daarnaast bevatten ze op hun buitenmembraan negatief geladen fosfolipiden 
(fosfatidylserine, PS) ten gevolge van membraan remodelling  tijdens hun vorming. 
Interessant is dat in plasma van patiënten met bepaalde soorten kanker het aantal 
MPs, dat actief tissue factor (TF, de belangrijkste initiator van de bloedstolling) 
bevat, sterk verhoogd blijkt te zijn. Helaas wordt de studie van de rol van MPs bij 
ontstaan en progressie van ziekte ernstig gehinderd door het ontbreken van 
gestandaardiseerde pre-analytische en analytische procedures voor het meten van 
MPs, hetgeen resulteert in een grote variatie in de resultaten die door verschillende 
onderzoeksteams worden gerapporteerd. 
 
Het doel van het onderzoek dat in dit proefschrift wordt beschreven, was om 
nieuwe methoden te ontwikkelen voor het nauwkeurig kwantificeren en 
karakteriseren van MPs en hun deelpopulaties, en wel zoveel mogelijk in hun 
oorspronkelijke staat. De tot voor kort gebruikte technieken, waarmee de 
concentratie van MPs werd gemeten, zijn geen van alle geschikt om deeltjes met 
afmetingen in het nanometer gebied te meten. Daarnaast hebben we geprobeerd 
een methode te ontwikkelen om de cellulaire oorsprong van MPs met op hun 
membraan functioneel TF, vast te stellen. Tenslotte  werd een mogelijk verband 
onderzocht tussen MPs die funtioneel TF op het oppervlak hebben en het optreden 
van veneuze trombo-embolie (VTE) in patiënten die behandeld worden voor de 
kwaadaardige ziekte multipel myeloom. 
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Verschillende pre-analytische omstandigheden zoals bloedafname, centrifugeren 
tijdens de bereiding van plasma en MPs, en opslag van plasma (inclusief invriezen-
ontdooien), kunnen het resultaat van de MP metingen beïnvloeden. In Hoofdstuk 2 
van dit proefschrift wordt besproken dat het noodzakelijk is om ex vivo-activering 
van bloedcellen te verhinderen tijdens afname en opwerken van bloed. Dit zou 
namelijk kunnen leiden tot de ongewenste vorming van MPs uit bloedcellen, met 
name uit bloedplaatjes (PMPs), maar wellicht ook uit andere bloedcellen zoals de 
erytrocyt (ErMPs). Om activatie van bloedcellen buiten het lichaam zoveel mogelijk 
tegen te gaan, is het van belang bloed af te nemen met een naald met een grote 
diameter, bijvoorbeeld een 21-G naald, en tijdens de venapunctie langdurig stuwen 
met een tourniquet te vermijden.  
 
Plasma voor MP metingen wordt gewoonlijk bereid door bloed tijdens afname te 
verzamelen in, en te mengen met, 1/10 volume natriumcitraat (0.105 of 0.129 
mol/L). De keuze van dit antistollingsmiddel is gebaseerd op internationale 
richtlijnen voor routine bepalingen in de hematologie, maar dit kan voor MP 
metingen minder optimaal zijn. Daarom is het nodig de stabiliteit van MPs in bloed 
verzameld in andere antistollingsmiddelen zoals ethylenediaminetetra-azijn zuur 
(EDTA) en citraat theofylline adenosine dipyridamole (CTAD) te vergelijken met de 
stabiliteit van MPs in bloed afgenomen op natriumcitraat. Voorts moet het volledige 
proces van bloedafname tot plasmabereiding snel plaatsvinden om ex vivo-
activering van bloedcellen in de verzamelbuis te voorkomen. De verwijdering van 
bloedplaatjes uit plasma door centrifugatie is essentieel, maar tegelijkertijd kan het 
centrifugeren tot ongewenste vorming van MPs uit bloedplaatjes (PMPs) aanleiding 
geven. 
 
Om MP kenmerken zo goed mogelijk te behouden zouden de MP metingen bij 
voorkeur direct in vers bereid plasma moeten worden uitgevoerd. Het is echter 
vaak niet praktisch uitvoerbaar om een meting direct uit te voeren na afname van 
het bloed. Plasmamonsters moeten dan worden ingevroren en bewaard. Dit 
teneinde in een later stadium plasmamonsters van verschillende individuen, 
afgenomen op verschillende tijdstippen, tegelijk te meten, zodat monsters 
onderling vergeleken kunnen worden. Helaas zijn er nog geen gestandaardiseerde 
protocollen beschikbaar voor het invriezen en ontdooien van plasma voor het 
meten van MPs. In Hoofdstuk 2 adviseren wij, dat wanneer MP metingen worden 
gedaan in ingevroren en vervolgens ontdooid plasma, vooral de aantallen PMPs 
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en annexin V positieve MPs met terughoudendheid moeten worden 
geïnterpreteerd. 
 
Zoals vermeld in de introductie van dit proefschrift, variëren MPs in grootte in het 
submicrongebied. Daarom is een methode nodig, die MPs met nanometer 
afmetingen nauwkeurig kan meten. De huidige flowcytometers kunnen echter MPs 
kleiner dan 0.5 µm niet nauwkeurig detecteren. Er zijn wel nieuwe typen 
flowcytometers in ontwikkeling, die ook deeltjes die iets kleiner zijn dan 0.5 micron 
nauwkeurig kunnen meten, maar het betrouwbare meetgebied zal niet liggen onder 
de 0.3 µm. Ook zijn deze nieuwere flowcytometers nog niet uitgebreid getest voor 
het routinematig meten van aantallen MPs. Wanneer desalniettemin flowcytometrie 
gebruikt blijft worden voor MP tellingen, zullen een aantal analytische 
omstandigheden moeten worden gestandaardiseerd. Onlangs stelde de Vascular 
Biology groep van de Scientific and Standardization Committee (SSC) van de 
International Society on Thrombosis and Haemostasis (ISTH) voor om het meten 
van PMPs groter dan 0.5 µm te standaardiseren door bolletjes met een 
gekalibreerde grootte (Megamix) te gebruiken om de instelling van de 
flowcytometer aan te passen en de resolutie te verhogen.  
 
Andere methoden, die gebruikt worden om plasma MPs te bestuderen, zijn 
elektronenmicroscopie, capture-based analyses en functionele analyses van 
geïsoleerde MPs. In Hoofdstuk 2 bespreken wij de voor- en nadelen van deze 
methoden. In het algemeen kunnen ze gebruikt worden om metingen aan plasma 
MPs te doen mits ze gebruik maken van gestandaardiseerde protocollen, inclusief 
het gebruik van geschikte reagentia en referentiematerialen. Deze zijn nodig om de 
reproduceerbaarheid van de bepaling zoals verricht in verschillende laboratoria te 
vergroten. Wij bespreken in Hoofdstuk 2 ook enkele nieuwe methoden om MPs te 
meten zoals proteoom analyse, impedance-based flowcytometrie, 
atoomkrachtmicroscopie (AFM), nanoparticle tracking analysis (NTA), en dynamic 
light scattering (DLS). Op dit ogenblik zijn deze methoden niet eenvoudig 
toepasbaar in het laboratorium omdat ze tijdrovend en arbeidsintensief zijn. Ook 





In Hoofdstuk 3 beschrijven wij de ontwikkeling van een geheel nieuwe methode om 
MPs afkomstig uit bloed te meten door gebruik te maken van een 
atoomkrachtmicroscoop (AFM) of tastmicroscoop. Eerst hebben we een methode 
ontwikkeld om MPs met een specifiek antilichaam te binden aan een zeer zuiver en 
glad mica-oppervlak. De AFM werd vervolgens gebruikt om met de zogenaamde 
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vloeistof tapping mode de MPs te detecteren die specifiek aan anti-CD41-gecoat 
mica waren gebonden. We meten met deze techniek dus alleen MPs die zelf het 
antigeen CD41 (een bloedplaatjes antigeen) bevatten. Voordelen van deze 
methode zijn dat zelfs krachten van een paar picoNewton zeer gevoelig kunnen 
worden gedetecteerd en dat de eigenschappen van de micropartikels worden 
behouden. In Hoofdstuk 3 toonden we aan dat de binding van MPs aan anti-CD41-
gecoat mica specifiek was. Er werden duidelijk geringere aantallen MPs gemeten 
op mica gecoat met een IgG1 isotype controle. Ook werd een lineair verband 
gevonden tussen het aantal CD41-positieve MPs, dat per 100 µm2 mica gebonden 
werd, en de MP concentratie in het monster. Wij maten het aantal CD41-positieve 
MPs in uit vers, dubbel-gecentrifugeerd plaatjes-arm plasma (PPP) geïsoleerde 
MPs van 7 bloeddonoren en 3 kankerpatiënten met zowel AFM als flowcytometrie. 
Wij vonden dat de aantallen CD41-positieve MPs, die met AFM worden gemeten, 
1.000-maal hoger waren dan de aantallen gemeten met flowcytometrie (3-702 x 
109/L plasma versus 11-626 x 106/L plasma). De MPs die met AFM werden 
gedetecteerd hebben diameters (dsph) van 10-475 nm met een piek bij 67.5 nm, die 
duidelijk ver onder de detectiegrens van conventionele flowcytometrie ligt. 
 
We hebben ook onderzocht of de AFM kon worden gebruikt voor de detectie van 
TF-positieve MPs (Hoofdstuk 4). Daartoe werd gemodificeerd mica met FITC-
gelabeld anti-humaan TF MoAb gecoat. TF-positieve MPs werden geïsoleerd uit 
het supernatant van gekweekte  MDA-MB231 borstkankercellen, die met calcium 
ionofore waren gestimuleerd. TF-positieve MPs met diameters (dsph) van 6 tot 296 
nm (mediaan: 40,4 nm met een gemiddelde van 46,4 ± 26,0 nm) werden met 
succes gebonden en gedetecteerd op een FITC-gelabeld anti-TF-gecoat 
oppervlak. Slechts enkele MPs werden gebonden op een mica oppervlak, dat was 
gecoat met FITC-gelabeld muis lgG1 isotypecontrole. We vonden ook dat het 
aantal TF-positieve MPs gemeten met de AFM 2.000-maal hoger was dan dat 
gemeten met flowcytometrie in hetzelfde monster (8 x 106 per µL supernatant vs 4 
x 103 per µL supernatant). 
 
Om MPs direct in plasma te kunnen detecteren is een geheel nieuwe 
meetopstelling gemaakt, waarbij we gebruik hebben gemaakt van een combinatie 
van microfluidics en AFM (Hoofdstuk 5). Tienvoudig verdund-EDTA PPP werd door 
een capillair (een heel dun kanaal) van een microfluïdic chip geinjecteerd onder 
een gecontroleerde constante druk. Deze veroorzaakt een laminaire stroming die 
nodig is om direct contact tussen het anti-humaan CD41 antilichaam-gecoate mica 
en MPs te bewerkstelligen. MPs met CD41 antigeen werden gebonden op dit 
oppervlak en vervolgens gedetecteerd door middel van AFM in vloeistof tapping 
mode. De meerderheid van de gebonden MPs bleken een  diameter (dsph) van 45 
nm (bereik: 30-90 nm) te hebben, hetgeen goed overeenkomt met wat wij eerder 
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vonden met MPs onmiddellijk geïsoleerd uit vers PPP. Blijkbaar heeft de hoge-
snelheid centrifugatie, die nodig is om MPs te isoleren, geen invloed op de 
grootteverdeling van de MPs. Gebruik van microfluidics bleek ook de efficiëntie 
waarmee MPs op het mica oppervlak werden gebonden, te verhogen. We 
gebruikten de microfluidics om PMPs aanwezig in het plasma van gezonde 
donoren te tellen en we vergeleken de resultaten met die verkregen met de 
zogenaamde druppelmethode. We constateerden dat aanzienlijk meer CD41-
positieve MPs per 100 µm2 oppervlak gebonden werden, wanneer het plasma werd 
gemeten met microfluidics dan wanneer deze gemeten werd met een 
druppelmethode. Uit onze voorlopige gegevens bleek ook dat er een lineair 
verband bestond tussen het aantal CD41-positieve MPs per 100 µm2 oppervlak en 
de MP concentratie in het monster. 
  
Tot slot, door gebruik te maken van een specifiek MoAb en AFM  in vloeistof 
tapping mode zijn wij in staat om een deelpopulatie van MPs met grote 
gevoeligheid te detecteren en nauwkeurig te kwantificeren. In combinatie met 
microfluidics kunnen MPs ook direct worden gemeten in plasma. Dit verkort de tijd 
tussen venapunctie en MP meting en het voorkomt ook verlies van MPs in de 
wasstappen, die nodig zijn tijdens de isolatie van MPs. Omdat deze methode 
afhankelijk is van het gebruik van antilichamen, die een specifieke subpopulatie 
van MPs kunnen binden, zijn specifieke antilichamen nodig met een hoge affiniteit 
voor het geselecteerde antigeen. Bovendien, om in de toekomst het precieze 
aantal MPs te kunnen bepalen in een monster, zal de beschikbaarheid van een 





Conventionele elektronenmicroscopie (EM) werd eerder gebruikt om de morfologie 
van geïsoleerde MPs te bestuderen. In de conventionele EM is voor de 
monstervoorbereiding en beeldvormende technieken uitdroging, chemische fixatie 
en kleuring van het preparaat nodig. Daarom is conventionele EM minder geschikt 
om de morfologie van MPs direct in plasma te bestuderen. We hebben in 
Hoofdstuk 6 onderzocht of Cyro-EM kan worden gebruikt om de grootte en de 
morfologie van submicrondeeltjes (MPs en exosomen) in plasma te bestuderen, en 
ook om het aantal van deze deeltjes in een vers plasmamonster te schatten zonder 
gebruik te maken van kleuringen of chemische fixatie procedures. We gebruikten 
vers plasma (bloedplaatjes-rijk plasma/PRP, bloedplaatjes arm plasma/PPP, 
bloedplaatjes-vrij plasma/PFP), geïsoleerde MPs, en ook (trombine geactiveerde-) 
geïsoleerde bloedplaatjes. Deze monsters werden direct op een EM grid 




In Hoofdstuk 6 hebben we vastgesteld, dat bloedplaatjes in vers citraat PRP meer 
geactiveerd waren dan in EDTA PRP, maar duidelijk minder dan in monsters van 
trombine-geactiveerde bloedplaatjes. Om in vitro-activatie van bloedplaatjes en 
vorming van PMP te verminderen wordt daarom voor de studie van plasma MPs 
bloedafname in EDTA aanbevolen. Het merendeel van de submicrondeeltjes 
aangetroffen in plasma van gezonde vrijwilligers bestond uit bolvormige 
elektronen-dichte deeltjes, die op lipoproteïne deeltjes lijken. Lage aantallen van 
elektronen-arme deeltjes met een waarneembare lipide dubbellaag (lipide vesikels) 
werden ook gevonden. De laatste kunnen MPs zijn, exosomen of beide. 
Soortgelijke lipide vesikels werden gevonden in monsters van trombine-
geactiveerde geïsoleerde bloedplaatjes en geïsoleerde MPs. Alle soorten deeltjes 
hebben ongeveer dezelfde grootteverdeling (mediaan: 30 nm, bereik: 25-260 nm). 
Omdat MPs slechts een minderheid vormen van alle submicrondeeltjes, die in vers 
plasma aanwezig zijn, moeten we de beperkingen overwegen van de technieken 
die gebruikt worden om MPs direct in plasma te meten. Het vinden van manieren 
om MPs en / of exosomen direct in plasma te kleuren met behulp van specifieke 
gelabelde antilichamen is van essentieel belang voor de verdere studies van deze 
deeltjes met technieken als NTA en cryo-EM. 
 
Immuno-magnetische beads  
 
Er is nog geen methode, die informatie geeft over de cellulaire oorsprong van de  
MPs met actief TF, die uit plasma geïsoleerd kunnen worden. In Hoofdstuk 7 
hebben we gerapporteerd over de ontwikkeling van een methode die gebruik 
maakt van een specifiek gebiotinyleerd antilichaam en magnetische streptavidine 
beads om een bepaalde populatie van MPs uit het plasma te isoleren.  
 
Deze methode werd geoptimaliseerd voor het isoleren van PMPs uit plasma van 
gezonde vrijwilligers. Plasma werd met gebiotinyleerd anti-humaan CD41 MoAb 
geïncubeerd voordat streptavidine magnetische beads werden toegevoegd. Na het 
aanbrengen van dit mengsel op een kolom van magnetische streptavidine beads, 
werden positieve (met daarin de geselecteerde subset van MPs) en negatieve (met 
daarin het gedepleteerde plasma) fracties verzameld en direct gebruikt voor de 
isolatie en analyse van MPs voor specifieke antigenen en TF activiteit. 
 
Met behulp van flowcytometrie laten we zien dat gebiotinyleerd anti-humaan CD41 
MoAb specifiek het antigeen CD41 van PMPs verzadigt. De magnetische 
streptavidine beads interfereren niet met de binding van anti-CD41 en anti-CD61 
antilichamen aan PMPs. Na de scheiding waren er geen CD41-positieve MPs en 
slechts enkele CD61-positieve MPs in de negatieve fractie, waaruit blijkt dat bijna 
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alle PMPs (CD41-positieve MPs) werden gebonden door de beads. De binding 
was CD41-specifiek, want de meeste CD41/CD61-positive MPs werden in de 
negatieve fractie gevonden, indien gebiotinyleerd IgG1 MoAb werd gebruikt in 
plaats van gebiotinyleerd anti-CD41 MoAb. 
 
Met behulp van gebiotinyleerd anti-CD14 MoAb en magnetische streptavidine 
beads werden CD14-positieve MPs gevangen uit normaal plasma, dat verrijkt was 
met MPs geïsoleerd uit het supernatant van LPS-gestimuleerde geïsoleerde 
monocyten (MoMPs). TF-activiteit werd zowel in de positieve als negatieve fracties 
gevonden. Dit geeft aan dat zowel de CD14-positieve als negatieve MoMPs actief 
TF hebben. Dit lijkt in overeenstemming met onze bevinding dat niet alle MoMPs 
met actief TF, die geïsoleerd werden uit het supernatant van LPS gestimuleerde 
monocyten, CD14-positief waren. 
 
In de toekomst zal de beads capture methode gebruikt kunnen worden om de 
oorsprong van MPs met actief TF in het plasma van patiënten met kanker te 
onderzoeken. Hierbij zal gebruik gemaakt moeten worden van celspecifieke of 
tumorspecifieke antilichamen, zoals anti-MUC1 (borst-en pancreaskanker cellen), 
anti-FasL (melanoom cellen), anti-EGFRvIII (glioblastoma cellen) en anti-CXCR-4 
(leukemische cellen). 
 
MP-geassocieerde TF activiteit in patiënten met mul tipel myeloom 
 
Voor het meten van MP-geassocieerde tissue factor activiteit (MP-TF activiteit) 
werden vers geïsoleerde MPs geïncubeerd met een overmaat FVII(a) en FX in de 
aanwezigheid van calcium, waarna de vorming van FXa met een specifiek 
chromogeen substraat kon worden gemeten in een eenstaps of tweestaps 
bepaling. Deze bepalingen werden in detail in Hoofdstuk 2 van dit proefschrift 
besproken. Voor de meting van MP-TF activiteit in multipel myeloom (MM) 
patiënten hebben we de eenstaps bepaling gebruikt. (Hoofdstuk 8). 
 
Chemotherapie in combinatie met anti-angiogene geneesmiddelen bij multipel 
myeloom is geassocieerd met een hoog risico op trombo-embolische complicaties. 
We hebben MP-TF activiteit gemeten in MPs geïsoleerd uit PFP van 122 patiënten 
met MM voor en na de chemotherapie en onderzochten of de MP-TF activiteit 
geassocieerd is met VTE. MP-TF activiteit van niet-behandelde patiënten was 
significant hoger dan die van gezonde vrijwilligers [17,6 fM FXa / min (IQR 8,6-
33,2) versus 4,1 fM FXa / min (IQR 2,3 tot 6,6), P <0,001]. Geen van de 
patiëntkenmerken (geslacht, leeftijd, ziekte stadium) of laboratoriummetingen 
(beta-2 microglobuline, albumine, calcium, hemoglobine, bloedplaatjes) bleek 
gecorreleerd met de MP-TF activiteit. 
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Voor de start van de behandeling was er geen verschil in MP-TF-activiteit tussen 
patiënten die tijdens de follow-up wel een VTE ontwikkelden (n = 15) en degenen 
die geen VTE ontwikkelden (n = 107). Bij 75 patiënten van wie plasma beschikbaar 
was van voor en na de chemotherapie, daalde de MP-TF-activiteit aanzienlijk na 
chemotherapie (van 17,4 [10,2-32,8] tot 12,0 [7,0-18,5] fM Xa / min, P = 0,006). 
Deze daling werd in alle ISS stadia van de ziekte waargenomen. Dit suggereert dat 
de tumormassa niet met MP-TF activiteit is geassocieerd. De MP-TF activiteit 
verminderde ook onafhankelijk van het therapeutische regime [vincristine, 
adriamycine en dexamethason (VAD); thalidomide, adriamycine en dexamethason 
(TAD); of bortezomib, adriamycine en dexamethason (PAD)]. MP-TF activiteit bleef 
echter na chemotherapie verhoogd bij patiënten die VTE hadden ontwikkeld (15,1 
[10,3-25,2]), in tegenstelling tot patiënten die geen VTE hadden ontwikkeld (11,4 
[7,0-25,2], p <0,001). 
 
In toekomstige studies moet MP-TF activiteit vaker gemeten worden tijdens de 
inductietherapie van MM om te leren of MP-TF activiteit een pathogenetische rol 




Tot nu toe is er geen consensus over de grootte en het aantal MPs in plasma. Dit 
komt doordat de in de literatuur gerapporteerde resultaten van MP metingen sterk 
verschillen. Wij zijn ons ervan bewust dat deze verschillen niet alleen veroorzaakt 
worden door verschillen tussen de tot dusver gebruikte methoden om MPs te 
meten. Pre-analytische procedures zoals bloedafname, plasma/MP bereidingen en 
de opslag van plasma zijn ook belangrijke factoren, die het aantal, de morfologie 
en andere kenmerken van MPs, zouden kunnen beïnvloeden. Het gebruik van 
EDTA in plaats van citraat voor de bloedafname kan in vitro-activatie van 
bloedplaatjes en vorming van PMP verminderen (Hoofdstuk 6) en heeft daarom de 
voorkeur voor de studie van plasma MPs. We hebben ook een aanwijzing dat de 
hoge-snelheid centrifugatie die gebruikt wordt om de MPs te isoleren geen 
belangrijk effect heeft op de grootteverdeling van de MPs (Hoofdstuk 5). 
Uiteindelijk is het belangrijk richtlijnen voor de pre-analytische procedures op te 
stellen om de intra- en inter-laboratorium reproduceerbaarheid te verbeteren. 
 
In het verleden werden MPs gevonden in het micrometergebied, terwijl we ze nu 
vinden in het nanometergebied (Hoofdstuk 3, 4, 5 en 6). Dit wordt verklaard door 
de technische beperkingen van de methoden, die eerder gebruikt werden om MPs 
te karakteriseren. Bijvoorbeeld, methoden zoals flowcytometrie met een 
detectiegrens van 0,5 micrometer en conventionele EM waarvoor uitdroging, 
chemische fixatie en kleuring van monsters nodig is, zijn minder geschikt voor de 
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detectie en karakterisering van MPs. Verder zijn er geen geschikte 
referentiematerialen (standaarden) om de instellingen van de verschillende 
methoden voor de analyse van MPs te kalibreren. Op dit moment maken nieuwe 
methoden, zoals AFM, NTA, en cryo-EM het mogelijk MPs in het nanometergebied 
in hun fysiologische toestand te detecteren en te karakteriseren. Maar deze 
methoden zijn nog niet geschikt voor gebruik in de kliniek omdat ze tijdrovend en 
arbeidsintensief zijn en nog moeten worden geoptimaliseerd en gevalideerd met 
betrekking tot hun nauwkeurigheid, specificiteit, detectielimiet en kwantificering, 
lineariteit en bereik, en robuustheid. Daarvoor zijn verbeteringen nodig zoals 
bijvoorbeeld geautomatiseerde monsterbehandelingsystemen, gestandaardiseerde 
reagentia, referentiematerialen voor de kalibratie van apparatuur instellingen en 
een externe standaard om absolute aantallen MPs te kunnen rapporteren. 
Uiteindelijk zou een klein MP meetapparaat wenselijk zijn dat slechts gebruik 
maakt van een speldenprik bloed en voor een routine test resultaten levert in 
minder dan 30 minuten (lab-on-a-chip). 
 
Er is bewijs dat MP-TF-activiteit is verhoogd bij patiënten met kanker die VTE 
ontwikkelen (kanker-geassocieerde VTE). Verder onderzoek is nodig om te leren of 
een verhoogde MP-TF-activiteit bij patiënten met kanker daadwerkelijk de oorzaak 
is van trombose. Om het onderliggend mechanisme van het verband tussen kanker 
en trombose te begrijpen, is het bovendien belangrijk om vast te stellen of TF-
dragende MPs afkomstig zijn uit de kankercel zelf of niet. In het laatste geval is het 
belangrijk om de cel van oorsprong (monocyten, endotheelcellen, bloedplaatjes) en 
het mechanisme waarmee de actieve TF wordt geproduceerd te onderzoeken. 
 
Uiteindelijk is nader onderzoek nodig om te onderzoeken hoe MPs precies worden 
gevormd. Volgens een algemeen aanvaarde hypothese vormen cellen MPs ten 
gevolge van het verlies van membraanfosfolipiden-asymmetrie tijdens processen 
als activering en apoptose, waarbij PS beschikbaar komt op de buitenkant van het 
celoppervlak. Deze hypothese wordt ondersteund door de zeldzame 
bloedaandoening, Scott syndroom. Dit syndroom wordt gekenmerkt door een 
verminderde activiteit van het enzym scramblase hetgeen resulteert in een 
verminderde expressie van PS en verminderde vorming van MPs. Interessant is 
dat de aanwezigheid van MPs die geen PS-expressie hebben de hypothese van 
MP vorming lijkt tegen te spreken. De vraag blijft of het bestaan van PS-negatieve 
MPs het gevolg is van de beperkingen van de huidige meetmethoden. Annexine V 
wordt op grote schaal gebruikt voor de meting van PS-expressie in flowcytometrie 
en capture-gebaseerde testen. Echter, de binding van annexine V aan MPs is 
afhankelijk van de calciumconcentratie en de PS dichtheid op de membraam. Een 
andere mogelijke verklaring voor het vinden van PS-negatieve MPs zou kunnen 
zijn dat ze gevormd worden door fusies van plasmamembraancomponenten met 
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celresten of kleine uitgescheiden endosomale blaasjes (exosomen). Ook is het 
mogelijk, dat MPs worden afgestoten door de plasmamembraan ten gevolge van 
destabilisatie van het actine-cytoskelet via αIIbβ3 signalering, waarvoor geen 
verlies van membraamfosfolipiden-assymmetrie nodig is. 
 
Tot slot, MPs worden niet langer beschouwd als cellulaire brokstukken of 
experimentele artefacten. In feite kunnen MPs deelnemen aan processen van 
stolling, ontstekingen en tumorvorming. Het is van belang om te onderzoeken uit 
welke cellen MPs worden gevormd, waarom ze worden gevormd en hoe ze met 
andere cellen in het lichaam communiceren. Standaardisering van pre-analytische 
en analytische procedures voor de meting van MPs is dringend nodig om hun 
aanwezigheid in bloed te begrijpen en om hun fysiologische functie en rol in 
ziektes toe te lichten. De toekomst zal leren of MP metingen gebruikt kunnen 
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